Aspirin-Exacerbated Respiratory Disease

Complex MONDO:0008834 Pathograph 47 Show in embeddings browser Asthma

A chronic inflammatory respiratory disorder classically comprising asthma, chronic rhinosinusitis with nasal polyps and acute respiratory reactions to aspirin or other strong COX-1 inhibitors. Components can emerge over months to years, and partial presentations occur. Dysregulated lipid mediators, impaired protective PGE2 signaling and a heterogeneous type 2 inflammatory network contribute. Cross-reactive NSAID reactions are pharmacologic rather than drug-specific IgE allergy; IgE-associated airway inflammation can still coexist. Avoiding triggers prevents exposure-related reactions but does not remove the underlying airway disease.

Ask OpenScientist

Ask a research question about Aspirin-Exacerbated Respiratory Disease. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part

👪

Inheritance

Multifactorial

AERD is generally an acquired complex disorder with minimal reported heritability. Candidate genetic and epigenetic associations do not establish a monogenic cause, and no clinically diagnostic genotype is defined by these sources.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"The adult onset of AERD, along with its minimal heritability, and intransient nature are consistent with a contribution from epigenetic changes, perhaps as a result of a prior insult."

Minimal heritability and proposed epigenetic contributions are distinct from a demonstrated inherited causal allele.

◈

Mechanistic Hypotheses

Leukotriene-dependent IL-33 amplification in the PGE2-deficient airway

leukotriene_il33_amplification EMERGING

Evidence balance 1 support

Human polyp IL-33 abundance and activation signatures are consistent with this route, but causal dependency is established chiefly in dust-mite-primed Ptges-null mice. Global Ltc4s deletion and IL-33/ST2 blockade do not identify a direct epithelial receptor mechanism or prove necessity in all human AERD.

Pathograph links

Enhanced Cysteinyl Leukotriene Receptor Signaling -> Increased Airway IL-33 Availability INDIRECT UNKNOWN INTERMEDIATES A leukotriene-dependent increase in airway IL-33 is supported in dust-mite-primed Ptges-null mice. The human route, cellular receptor and intervening inflammatory effects are not established by this experiment.

Increased Airway IL-33 Availability -> Enhanced IL-33-ST2 Signaling INDIRECT UNKNOWN INTERMEDIATES Available extracellular IL-33 can engage ST2. Translation from greater tissue abundance to increased released, active ligand remains inferred in human AERD.

Enhanced IL-33-ST2 Signaling -> Mast Cell Activation INDIRECT UNKNOWN INTERMEDIATES IL-33 blockade and soluble ST2-Fc reduce mast-cell-associated mediator release in the mouse model. Human cellular mediation remains an extrapolation.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"The lungs of the ptges−/−/ltc4s−/− mice also contained substantially less IL-33 protein than did the lungs of the ptges−/− controls"

Genetic dependency in a conditioned mouse model supports the proposed amplification route.

Discussions and Knowledge Gaps

What initiates the acquired chronic airway phenotype and determines which mediator abnormalities are causal?

KNOWLEDGE GAP aerd_initiating_lesion

Attached to

pathophysiology#Reduced Respiratory PGE2 Availability pathophysiology#Increased Bronchial LTC4 Synthase-Positive Cells pathophysiology#Reduced Inflammatory-Cell EP2 Abundance

Cell counts, receptor abundance, urinary mediators and tissue transcriptional programs are measured in established disease. They do not identify a single first lesion or explain every clinical presentation. Genetic susceptibility and epigenetic observations do not establish a diagnostic monogenic cause.

Which mechanisms and patient characteristics determine benefit from maintenance aspirin?

KNOWLEDGE GAP aerd_desensitization_mechanism

Attached to

treatments#Aspirin desensitization followed by maintenance aspirin

Clinical effects vary between regimens and trials. Aspirin maintenance does not consistently suppress cysteinyl leukotriene production; lack of changes in three serum cytokines does not exclude local or unmeasured immune effects. Safe patient selection and maintained tolerance are separate from proving disease modification.

Show evidence (1 reference)

PMID:26083948 SUPPORT PRIMARY RESULT Human Clinical

"no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study"

Limits the measured systemic cytokine response without excluding other mechanisms.

Which inflammatory cells and remodeling processes are necessary for persistent polyp disease?

KNOWLEDGE GAP aerd_eosinophil_mediation

Attached to

pathophysiology#Eosinophilic Airway Infiltration phenotypes#Nasal polyposis

Tissue eosinophilia is prominent, but depletion need not improve polyps. Likewise, mediator biology and receptor activation do not guarantee efficacy of a proposed blocking drug.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"In an open-label study of 16 patients with CRSwNP, several of whom had AERD, dexpramipexole induced a 97% reduction from baseline in nasal polyp tissue eosinophilia. Nonetheless, there was no significant reduction in nasal polyp score, nor any significant improvement in measures of olfaction or..."

The small mixed CRSwNP study limits an eosinophil-only explanation.

Can a reproducible biomarker predict aspirin tolerance during biologic therapy?

KNOWLEDGE GAP aerd_tolerance_biomarkers

Attached to

treatments#Dupilumab biochemical#Urinary leukotriene E4

In the 2026 nested challenge study, ten NSAID-tolerant CRSwNP controls lacked asthma and disease controls were younger. N-ERD kinetics were aligned to reaction onset while controls were aligned to dosing; repeat challenge was only in the 11 N-ERD patients. Clinical and type 2 mediator improvement did not uniquely distinguish the five complete/partial tolerance responders from six remaining intolerant participants. Bulk nasal transcripts cannot establish protein flux, pathway mediation or a clinical decision threshold.

Show evidence (1 reference)

PMID:41309110 SUPPORT PRIMARY RESULT Human Clinical

"Interestingly, the development of tolerance was not associated with specific cytokine patterns."

A small exploratory study does not validate a tolerance predictor.

Can GLP-1 receptor agonism improve clinical AERD outcomes independently of metabolic indications?

KNOWLEDGE GAP aerd_glp1_translation

Attached to

pathophysiology#Enhanced Transcellular Cysteinyl Leukotriene Synthesis

The recovered primary study combines mouse pretreatment and human ex-vivo platelet assays. Platelet-leukocyte aggregates were not significantly reduced, and no human aspirin-challenge or clinical efficacy study was performed. GLP-1 agonism remains a translational lead rather than an established AERD treatment.

Show evidence (2 references)

PMID:37870292 SUPPORT PRIMARY RESULT In Vitro

"Pretreatment with GLP-1R agonist liraglutide at doses comparable to the serum concentrations achieved in vivo during active clinical treatment (50nM) attenuated TP-induced CD62P expression on CD41+ platelets in both groups"

Describes the measured platelet-activation response in human blood preparations.

PMID:37870292 SUPPORT PRIMARY RESULT In Vitro

"Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population"

The negative aggregate result limits inference from the positive free-platelet activation readout.

What can the Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD) study establish?

KNOWLEDGE GAP aerd_registry_04261582

Attached to

pathophysiology#Reduced Respiratory PGE2 Availability

Suspended observational genetics/epithelial transcriptomics study, planned enrollment 245. No results are posted; proposed EGR/ERBB2 mechanisms are hypotheses rather than confirmed AERD causal genes.

Show evidence (1 reference)

clinicaltrials:NCT04261582 SUPPORT PRIMARY RESULT Other

"the objective of the proposed study is to determine whether EGR gene are also down-regulated in AERD"

The registry defines an exploratory observational question or sample-analyzability endpoint.

What can the A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only study establish?

KNOWLEDGE GAP aerd_registry_01631773

Attached to

pathophysiology#Reduced Respiratory PGE2 Availability

Completed observational nasal microRNA comparison, actual enrollment 26. No results are posted; the registry does not validate a diagnostic microRNA signature.

Show evidence (1 reference)

clinicaltrials:NCT01631773 SUPPORT PRIMARY RESULT Other

"We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)."

The registry defines an exploratory observational question or sample-analyzability endpoint.

What can the Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP study establish?

KNOWLEDGE GAP aerd_registry_05672030

Attached to

pathophysiology#Enhanced IL-5 Signaling

Completed 30-participant observational tissue study with 10 AERD, 10 aspirin-tolerant CRSwNP and 10 controls. Posted outcomes count analyzable specimens for transcriptomic/IL-5R assays, not effect sizes demonstrating a receptor-mediated disease mechanism.

Show evidence (1 reference)

clinicaltrials:NCT05672030 SUPPORT PRIMARY RESULT Other

"The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit."

This registered hypothesis motivates the observational study; it is not evidence that the proposed non-eosinophil mechanism or clinical benefit has been established.

⚙

Pathophysiology

Pharmacological COX-1 Inhibition

Aspirin and other strong COX-1 inhibitors suppress cyclooxygenase activity. This acute pharmacologic exposure triggers reactions in a susceptible airway; it does not explain the acquired chronic asthma and sinonasal disease.

Downstream

Reduced Respiratory PGE2 Availability COX-1 inhibition reduces the residual COX-1-dependent prostaglandin supply during an acute reaction.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Inhibition of COX-1 activity in patients with N-ERD further reduces the “braking” effects of PGE2/EP2 on mast cells and 5-LO activity, which increases the release of cysLTs in urine and airway fluids, precipitating respiratory symptoms."

The statement describes the acute pharmacologic trigger in a susceptible airway; it does not identify the cause of the chronic disease.

Reduced Respiratory PGE2 Availability

Reduced production and/or increased catabolism lowers protective PGE2 availability in respiratory tissues. Chronic COX-2/mPGES-1 abnormalities and acute COX-1 inhibition are distinct contributors; neither complete PGE2 absence nor a single initiating lesion is established.

Animal models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations Mouse perturbs Loss of mPGES-1 impairs inducible PGE2 synthesis.

Downstream

Reduced PGE2-Mediated Restraint Lower ligand availability can reduce the protective PGE2 signal. The magnitude depends on cell type and receptor function.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"Several studies link AERD to diminished production (or increased catabolism) of PGE2 in the respiratory tract"

Reduced respiratory PGE2 availability is supported by several studies, with heterogeneous synthesis and degradation contributions.

Reduced Inflammatory-Cell EP2 Abundance

A study of 12 aspirin-sensitive and 10 non-sensitive rhinosinusitis polyps found a lower fraction of inflammatory cells expressing EP2. Global mucosal EP2 staining was increased, largely in epithelial/goblet cells. Abundance is distinguished from a direct functional-response assay.

mast cell CL:0000097 eosinophil CL:0000771 neutrophil CL:0000775

Downstream

Reduced PGE2-Mediated Restraint Reduced inflammatory-cell EP2 abundance may weaken the protective PGE2 response, but staining alone does not establish universal PGE2 resistance.

Show evidence (1 reference)

PMID:16461132 SUPPORT PRIMARY RESULT Human Clinical

"the percentages of neutrophils, mast cells, eosinophils, and T cells expressing EP(2), but not EP(1), EP(3), or EP(4), were significantly reduced (P < or = .04) in the aspirin-sensitive compared with nonaspirin-sensitive patients"

Nasal-polyp immunohistochemistry identifies a lower EP2-positive fraction of inflammatory cells, not global receptor absence.

Reduced PGE2-Mediated Restraint

Loss of some PGE2-mediated inhibition permits greater mediator synthesis and cellular activation. This is a context-dependent signaling defect: PGE2 still suppressed anti-IgE-induced cysteinyl leukotriene release in cultured blood-progenitor-derived mast cells from AERD donors. Inhaled PGE2 also protected against aspirin challenge in a small crossover study.

Experimental models

AERD blood-progenitor-derived mast-cell culture PRIMARY CELL CULTURE PGE2 inhibits stimulated cysteinyl leukotriene output in AERD cultures.

Downstream

Increased Cysteinyl Leukotriene Availability Reduced PGE2-dependent inhibition permits 5-lipoxygenase-dependent leukotriene synthesis during the reaction.

Mast Cell Activation Weakened PGE2 stabilization permits mast-cell activation; other activating signals remain relevant.

Show evidence (3 references)

PMID:36184313 SUPPORT REVIEW SYNTHESIS In Vitro

"PGE2 stabilizes and prevents the activation of mast cells (2) and group 2 innate lymphoid cells (ILC2s)(3), and prevents the formation of cysLTs by inhibiting the translocation of 5-lipoxygenase (5-LO) (4)."

Reviews functional inhibition of mast cells, ILC2s and 5-lipoxygenase by PGE2.

PMID:17508965 SUPPORT PRIMARY RESULT In Vitro

"In contrast, PGE(2) suppressed only anti-IgE induced cys-LTs release from mast cells of AERD patients."

The cultured-cell study tests a retained PGE2 response; its stimulus and differentiation conditions differ from airway tissue.

PMID:8564100 SUPPORT PRIMARY RESULT Human Clinical

"Inhaled PGE2 provided almost complete protection in all patients."

Seven aspirin-sensitive participants underwent placebo/PGE2 crossover challenges; this is mechanistic protection, not an established long-term treatment.

Increased Bronchial LTC4 Synthase-Positive Cells

Bronchial biopsies in a small selected cohort contained more LTC4-synthase-positive cells. This is a tissue cell-count observation, not quantified per-cell enzyme expression or the proven initiating defect. Baseline BAL leukotrienes correlated with these counts; the post-challenge increment did not.

leukotriene biosynthetic process GO:0019370 ↑ INCREASED

Downstream

Increased Cysteinyl Leukotriene Availability A larger population capable of terminal leukotriene synthesis may contribute to baseline mediator excess; the human evidence is correlational.

Show evidence (2 references)

url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf SUPPORT PRIMARY RESULT Human Clinical

"Counts of cells expressing the terminal enzyme for cys-LT synthesis, LTC4 synthase, were fivefold higher in AIA biopsies"

The study counted LTC4-synthase-positive cells in 10 AIA, 10 ATA and 9 normal bronchial biopsies; staining intensity per cell was not quantified.

url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf SUPPORT PRIMARY RESULT Human Clinical

"no attempt was made to quantify the intensity of staining within each cell."

The full Methods limits the interpretation to numbers of positively stained cells.

Increased Platelet-Leukocyte Adherence

Increased platelet attachment to circulating myeloid leukocytes and colocalization in nasal polyps are observed in AERD. The platelet-intrinsic LTC4 synthase activity was not higher than in aspirin-tolerant controls. Enhanced adhesion-receptor expression on platelet-associated cells occurred across groups, not uniquely in AERD.

platelet CL:0000233

Experimental models

Liraglutide perturbation of human platelet activation CO CULTURE TP stimulation and liraglutide pretreatment test platelet-leukocyte aggregate formation.

Downstream

Enhanced Transcellular Cysteinyl Leukotriene Synthesis Attachment brings platelet terminal synthase together with leukocyte-derived precursor; removal and add-back experiments support a contribution in isolated cell preparations.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml SUPPORT PRIMARY RESULT Human Clinical

"the percentages of platelet-adherent eosinophils, neutrophils, and monocytes in the blood of subjects with AERD were much higher than in either the ATA or the nonasthmatic controls"

The blood study compared 15 AERD, 13 aspirin-tolerant asthma and 9 nonasthmatic participants; tissue comparisons were smaller.

Enhanced Transcellular Cysteinyl Leukotriene Synthesis

Adherent platelets provide LTC4 synthase activity and augment stimulated leukotriene generation by isolated granulocytes. Trypsin removal reduced output and platelet add-back restored robust synthesis. This ex vivo contribution does not prove that adhesion is the sole source of systemic leukotriene excess or that antiplatelet therapy is effective.

Experimental models

AERD granulocyte-platelet ex vivo preparations CO CULTURE Platelet removal lowers fMLP-stimulated cysteinyl leukotriene release.

Downstream

Increased Cysteinyl Leukotriene Availability Increased transcellular synthesis contributes to the available cysteinyl leukotriene pool; its quantitative contribution in vivo remains uncertain.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml SUPPORT PRIMARY RESULT In Vitro

"Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%"

Platelet removal reduces stimulated cysteinyl leukotriene output in AERD preparations.

Increased Cysteinyl Leukotriene Availability

Airway cysteinyl leukotrienes and urinary LTE4 are increased at baseline and can rise further during COX-1-inhibitor reactions. Multiple cellular sources and altered synthesis/regulation contribute. Urinary LTE4 is a systemic readout, not a specific measure of one cell type or a stand-alone diagnostic test.

Downstream

Enhanced Cysteinyl Leukotriene Receptor Signaling Increased ligands engage cysteinyl leukotriene receptors, whose ligand preferences and tissue distribution differ.

Show evidence (2 references)

url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf SUPPORT PRIMARY RESULT Human Clinical

"Lysine-aspirin challenge released additional cys-LTs into BAL fluid in AIA patients"

BAL assays document an additional mediator rise after challenge in the selected cohort.

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"N-ERD patients have elevated levels of cysLTs"

Summarizes the mediator excess in human N-ERD.

Enhanced Cysteinyl Leukotriene Receptor Signaling

Cysteinyl leukotrienes activate CysLT1, CysLT2 and CysLT3/GPR99 pathways with differing ligand preferences. These receptors support bronchomotor, vascular and inflammatory responses. A CysLT1 antagonist does not block every leukotriene receptor or suppress synthesis.

Leukotriene-dependent IL-33 amplification in the PGE2-deficient airway

Downstream

Airway Smooth Muscle Contraction Receptor signaling promotes contraction of bronchial smooth muscle.

Increased Airway Vascular Permeability Receptor signaling increases vascular permeability in the airway.

Increased Airway IL-33 Availability A leukotriene-dependent increase in airway IL-33 is supported in dust-mite-primed Ptges-null mice. The human route, cellular receptor and intervening inflammatory effects are not established by this experiment.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Other

"Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx."

Distinguishes CysLT receptor activation from mediator production.

Increased Airway IL-33 Availability

Full-length and smaller IL-33 protein forms are increased in AERD nasal polyps. Epithelial staining is prominent, but sorted fibroblast and endothelial preparations also contain transcript. Protein abundance and cleavage-band size do not directly measure release or biologic activity.

Leukotriene-dependent IL-33 amplification in the PGE2-deficient airway

Animal models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations Mouse measures Lung IL-33 abundance decreases with additional Ltc4s deletion.

Downstream

Enhanced IL-33-ST2 Signaling Available extracellular IL-33 can engage ST2. Translation from greater tissue abundance to increased released, active ligand remains inferred in human AERD.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Human Clinical

"Both the full-length form and the 18–21 kDa forms were more abundant in polyps from subjects with AERD than from controls"

Human polyp lysates show greater IL-33 protein abundance. All surgical subjects received preoperative prednisone.

Enhanced IL-33-ST2 Signaling

IL-33/ST2 signaling is implicated by human polyp activation signatures and by blockade of aspirin- and LTE4-associated responses in Ptges-null mice. The experiments do not identify a necessary epithelial source or establish a mast-cell-specific ST2 requirement in patients.

Leukotriene-dependent IL-33 amplification in the PGE2-deficient airway

Animal models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations Mouse perturbs IL-33 antibody or soluble ST2-Fc blocks signaling before challenge.

Downstream

Mast Cell Activation IL-33 blockade and soluble ST2-Fc reduce mast-cell-associated mediator release in the mouse model. Human cellular mediation remains an extrapolation.

Type 2 Lymphoid Cell Activation IL-33 can activate type 2 innate lymphoid and T-helper cells; its necessary contribution in individual human AERD patients is unresolved.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2"

Anti-IL-33 and soluble ST2-Fc pretreatment inhibit mediator responses in the dust-mite-primed mouse model.

Enhanced TSLP Signaling

Increased sinonasal TSLP expression and cultured mast-cell responses implicate TSLP signaling in the inflammatory network. Human correlations do not establish that TSLP is the initiating lesion or that every patient has the same dependence.

Downstream

Mast Cell Activation TSLP stimulation promotes a mediator-producing mast-cell state in human culture experiments.

Type 2 Lymphoid Cell Activation TSLP can stimulate type 2 lymphoid cells in the broader alarmin network.

Show evidence (2 references)

PMID:36184313 SUPPORT REVIEW SYNTHESIS In Vitro

"Nasal polyp levels of TSLP mRNA correlate with mast cell-related transcripts and with urinary PGD2 metabolites, and TSLP stimulates human mast cells to generate PGD2 ex vivo"

Separates human tissue correlations from the ex vivo mast-cell perturbation.

PMID:41309110 SUPPORT PRIMARY RESULT Human Clinical

"The epithelial alarmin TSLP was markedly elevated in N‐ERD patients as compared to CRSwNP and DC already after 60 min of symptom onset"

In the small challenge substudy, a nasal mediator increase was measured; no lineage-specific source or necessity was tested.

Mast Cell Activation

Airway mast-cell activation releases lipid and granule mediators. Both innate and IgE-associated activation programs may contribute; this does not make cross-reactive COX-1-inhibitor reactions a drug-specific IgE allergy.

mast cell CL:0000097

Experimental models

AERD blood-progenitor-derived mast-cell culture PRIMARY CELL CULTURE Anti-IgE activates cultured mast cells for mediator-release measurement.

Animal models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations Mouse measures BAL histamine, mMCP1 and PGD2 responses are reduced by IL-33/ST2 blockade.

Downstream

Increased PGD2 Production Activated mast cells contribute PGD2, although they are not its exclusive source.

Increased Cysteinyl Leukotriene Availability Activated mast cells contribute cysteinyl leukotrienes; anti-IgE stimulation of cultured AERD donor cells increases their release.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"a high degree of activation in nasal polyp mast cells, with enrichment for both IgE- and IL-33-driven transcriptional signatures."

Human single-cell transcriptional observations support mast-cell activation, not one exclusive upstream trigger.

Increased PGD2 Production

PGD2 output is increased in AERD and can rise during aspirin reactions despite COX-1 inhibition. It contributes bronchoconstrictor and inflammatory actions. Negative CRTH2-antagonist trials caution against equating receptor biology with established clinical benefit.

Downstream

Airway Smooth Muscle Contraction PGD2 promotes bronchoconstriction, including through thromboxane-prostanoid receptor signaling; model antagonist data do not establish PGD2 as the sole ligand.

Type 2 Lymphoid Cell Activation PGD2 can recruit and activate type 2 lymphoid cells through CRTH2; this route is not proven to dominate chronic polyp disease.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls, and often paradoxically increase in parallel with LTE4 during reactions to aspirin"

Human metabolite observations support enhanced prostanoid output; urinary metabolites do not uniquely identify source cells.

Type 2 Lymphoid Cell Activation

Type 2 lymphoid cells, including ILC2s and Th2 cells, contribute cytokines to the airway network. Challenge-associated redistribution of ILC2s is observed in humans, whereas depletion-based necessity was tested in mice.

group 2 innate lymphoid cell CL:0001069

Downstream

Enhanced IL-5 Signaling Type 2 lymphoid cytokine production supplies IL-5.

Enhanced IL-4R-Alpha Signaling Type 2 lymphoid cytokines supply IL-13 and related IL-4R-alpha ligands; mast cells are an additional IL-13 source.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS In Vitro

"large quantities of IL-5, IL-13 and other cytokines in response to both innate cytokines (IL-33, thymic stromal lymphopoietin (TSLP), IL-25) and lipid mediators."

The reviewed ILC2 biology supports cytokine production after innate stimulation.

Enhanced IL-5 Signaling

IL-5 signaling contributes to eosinophil development and survival in type 2 airway inflammation. IL5RA transcripts on additional polyp cell types do not by themselves demonstrate functional IL-5 responses in those cells.

Downstream

Eosinophilic Airway Infiltration IL-5 supports the eosinophilic compartment through production and survival pathways; recruitment also depends on chemotactic signals.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"IL-5, produced by activated Th2 cells, ILCs, and mast cells, is elevated in the respiratory tissues of patients with AERD relative to controls and is required for the development of tissue eosinophilia."

The review links elevated tissue IL-5 with tissue eosinophilia.

Enhanced IL-4R-Alpha Signaling

IL-4 and IL-13 signal through receptors containing IL-4R-alpha. Elevated nasal cytokines and epithelial response signatures support this pathway in AERD. Its pleiotropic effects are not reduced to a single established epithelial-to-polyp sequence.

Downstream

Nasal polyposis IL-4R-alpha signaling contributes to the inflammatory process sustaining polyps; receptor blockade improves polyp burden, but the necessary intermediate cells and remodeling steps are incompletely resolved.

Asthma Blocking this receptor pathway improves lower-airway disease in selected AERD cohorts; multiple cellular intermediates may contribute.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"IL-4 and IL-13 are critical to the pathogenesis of T2I, signal through a shared common receptor subunit, IL-4Rα, and are elevated in the nasal fluid of AERD patients compared to controls"

Connects elevated airway cytokines with the common receptor pathway targeted by dupilumab.

Eosinophilic Airway Infiltration

Eosinophils accumulate in airway tissue and provide mediator-producing cells. Their presence does not establish that eosinophils alone cause polyps: marked depletion in a small CRSwNP study, including AERD, did not improve polyp size or smell.

eosinophil CL:0000771

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"Eosinophilia is a prominent histologic feature of CRSwNP and asthma, especially in AERD"

Histologic eosinophilia is distinct from a universal elevated blood count.

Airway Smooth Muscle Contraction

Contraction of bronchial smooth muscle narrows the airways during acute mediator-driven reactions. Chronic asthma has additional inflammatory and structural components.

Animal models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations Mouse partially recapitulates Challenge produces increased airway resistance that is inhibited by upstream blockade.

Liraglutide pretreatment in allergen-primed Ptges-null mice Mouse perturbs Pretreatment blunts challenge-associated airway resistance.

Downstream

Aspirin-induced respiratory reaction Smooth-muscle contraction contributes to the bronchospastic component of the exposure-related reaction; upper-airway reactions can occur without bronchospasm.

Wheezing Airway narrowing can produce expiratory wheeze.

Dyspnea Bronchomotor narrowing contributes to breathlessness during lower-airway reactions.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Other

Reviews bronchial smooth-muscle contraction after cysteinyl leukotriene receptor stimulation.

Increased Airway Vascular Permeability

Cysteinyl leukotriene signaling increases vascular permeability, contributing to airway edema and upper-airway symptoms. Nasal obstruction also reflects fixed polyp burden and other inflammatory effects.

Downstream

Nasal obstruction Mediator-associated edema contributes to congestion during acute reactions; chronic obstruction has additional causes.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Other

Reviews vascular permeability effects of cysteinyl leukotriene receptors.

⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.

●

Phenotypes

Blood 1

Eosinophilia Increased total eosinophil count HP:0001880

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD."

The clinical statement identifies eosinophilia in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Cardiovascular 2

Urticaria HP:0001025

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies urticaria in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Angioedema HP:0100665

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies angioedema in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Digestive 3

Nausea HP:0002018

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies nausea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Vomiting HP:0002013

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies vomiting in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Diarrhea HP:0002014

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies diarrhea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Head and Neck 5

Nasal polyposis HP:0100582

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors."

The clinical statement identifies nasal polyposis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Chronic rhinosinusitis Chronic sinusitis HP:0011109

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors."

The clinical statement identifies chronic rhinosinusitis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Nasal obstruction Nasal congestion HP:0001742

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure."

The clinical statement identifies nasal obstruction in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Chemosis HP:0012375

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies chemosis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Anosmia HP:0000458

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"CRSwNP – The diagnosis requires a history of symptoms including persistent nasal obstruction, anosmia, and anterior or posterior discharge."

The clinical statement identifies anosmia in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Immune 2

Asthma HP:0002099

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors."

The clinical statement identifies asthma in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Aspirin-induced respiratory reaction Aspirin-induced asthma HP:0012042

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies aspirin-induced respiratory reaction in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Integument 1

Pruritus HP:0000989

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies pruritus in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Respiratory 4

Rhinorrhea HP:0031417

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies rhinorrhea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Wheezing HP:0030828

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Asthma – The diagnosis requires a history of symptoms including cough, shortness of breath, wheeze, and/or chest tightness and evidence of variable airflow obstruction and/or airway hyperresponsiveness."

The clinical statement identifies wheezing in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Dyspnea HP:0002094

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies dyspnea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Cough HP:0012735

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies cough in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Constitutional 2

Sneezing Sneeze HP:0025095

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

The clinical statement identifies sneezing in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

Abdominal pain HP:0002027

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea."

The clinical statement identifies abdominal pain in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.

💊

Medical Actions

Inhaled corticosteroid-based asthma therapy

Category: Therapeutic

Platform: Small molecule

Treat the asthma component with an inhaled corticosteroid-based regimen, adding a long-acting bronchodilator according to severity and control. Continue necessary controller therapy through specialist desensitization. This controls airway disease but does not establish unrestricted NSAID tolerance.

Mechanism Target:

MODULATES Asthma — Controller therapy treats the lower-airway disease.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Inhaled corticosteroids (ICSs) and ICSs combined with long-acting β2-agonists for asthma should be continued during aspirin desensitization."

The work-group guidance preserves controller treatment during desensitization.

Show evidence (2 references)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Inhaled corticosteroids (ICSs) and ICSs combined with long-acting β2-agonists for asthma should be continued during aspirin desensitization."

The work-group guidance preserves controller treatment during desensitization.

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Standard medical treatment for AERD focuses on managing the upper and lower respiratory tract symptoms and can include the use of corticosteroids, leukotriene-modifying drugs (LTMDs), and biologics that target type 2 inflammatory cytokines."

Identifies corticosteroids as part of routine upper/lower airway management.

Topical sinonasal corticosteroids and saline irrigation

Category: Therapeutic

Platform: Small molecule

Use topical anti-inflammatory sinonasal therapy and saline irrigation as part of chronic rhinosinusitis care, including after surgery when appropriate. Delivery and adherence matter; extensive polyps may limit topical penetration.

Mechanism Target:

MODULATES Chronic rhinosinusitis — Topical therapy treats sinonasal inflammatory symptoms; saline also clears secretions.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids."

The guidance identifies saline and corticosteroids as topical sinonasal treatments.

Show evidence (2 references)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids."

The guidance identifies saline and corticosteroids as topical sinonasal treatments.

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

Corticosteroids are part of standard upper-airway management.

Montelukast

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: montelukast CHEBI:50730

Platform: Small molecule

A CysLT1 receptor antagonist used as an adjunct to airway controller treatment. It can reduce leukotriene-mediated symptoms and blunt reactions during supervised challenge/desensitization, but it does not inhibit leukotriene synthesis or block all CysLT receptors.

Mechanism Target:

INHIBITS Enhanced Cysteinyl Leukotriene Receptor Signaling — Blocks the CysLT1 component of the receptor network.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Other

"zafirlukast and montelukast, which only block CysLT1R."

Identifies receptor specificity rather than inhibition of leukotriene synthesis.

Show evidence (2 references)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Other

"zafirlukast and montelukast, which only block CysLT1R."

Identifies receptor specificity rather than inhibition of leukotriene synthesis.

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"The use of the leukotriene receptor antagonist montelukast, or the 5-lipooxygenase inhibitor zileuton, can in some instances pharmacologically blunt or sufficiently prevent the clinical manifestations of NSAID-induced reactions so that the reactions are not noticed by the patient."

Explains both clinical utility and potential masking of reactions.

Zileuton

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: zileuton CHEBI:10112

Platform: Small molecule

A 5-lipoxygenase inhibitor that reduces leukotriene production. It is a selected adjunct for persistent airway symptoms and can attenuate reactions; its use requires attention to drug-specific contraindications, interactions and monitoring.

Mechanism Target:

INHIBITS Increased Cysteinyl Leukotriene Availability — Reduces leukotriene synthesis upstream of LTC4 synthase.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"Treatment with zileuton, which inhibits 5-LO and decreases production of leukotrienes, attenuates the sinonasal symptoms (16), lung function changes (17), and gastrointestinal and cutaneous symptoms that occur during aspirin-induced reactions in AERD."

Identifies the synthetic target and reported clinical effects.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

Identifies the synthetic target and reported clinical effects.

Endoscopic sinus surgery

Category: Therapeutic Action: Endoscopic Sinus Surgery NCIT:C157836

Platform: Surgery

Consider surgery for substantial or refractory polyp/sinus disease. It removes polyp burden and improves access for topical treatment; recurrence remains possible. It may precede aspirin therapy after desensitization in suitable patients, but every patient does not require the same surgery-plus-aspirin sequence.

Mechanism Target:

MODULATES Nasal polyposis — Surgery removes polyps directly; it does not bypass a single established molecular pathway.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids."

Supports mechanical debulking and improved topical access.

Show evidence (2 references)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids."

Supports mechanical debulking and improved topical access.

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/ SUPPORT REVIEW SYNTHESIS Other

"From an economic and efficacy perspective, ESS and/or ATAD as initial treatment for patients with NSAID‐ERD should be performed in experienced centres if there are no contraindications"

The 2026 consensus presents selection-dependent options rather than a mandatory combined regimen.

Aspirin desensitization followed by maintenance aspirin

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: acetylsalicylic acid CHEBI:15365

Platform: Small molecule

A specialist option for confirmed AERD with persistent symptoms, recurrent polyps or a separate need for aspirin. Benefits vary by patient and regimen: one 34-person randomized trial reported symptom/medication benefit, whereas a 2025 trial randomizing 26 successfully desensitized participants found no significant between-group difference in SNOT-22, asthma-control or polyp scores over 11 months. That trial used 125 mg daily initially then 250 mg and does not exclude benefit from other regimens. Screen for uncontrolled asthma, ulcer/bleeding risk, pregnancy and ability to adhere. Daily maintenance is needed; more than two missed days requires reassessment before unsupervised resumption.

Mechanism Target:

MODULATES Aspirin-induced respiratory reaction — Desensitization establishes a temporary tolerant state that requires ongoing dosing.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"After patients have been desensitized to aspirin, they should continue taking aspirin daily."

Supports maintenance of the desensitized state, with interruption limits stated separately.

Show evidence (4 references)

PMID:26083948 SUPPORT PRIMARY RESULT Human Clinical

"Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months"

The small randomized study reported benefit under its maintenance regimen.

PMID:40726272 SUPPORT PRIMARY RESULT Human Clinical

"In the linear mixed effects model, p-values for the combined effect of group and time showed no difference between placebo and ATAD for SNOT-22, ACT, and NPS, with p-values 0.17, 0.45, and 0.18, respectively."

A later small randomized trial did not show between-group benefit under its 125-to-250-mg daily protocol.

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"if a desensitized patient misses more than 2 days of aspirin it is strongly recommended they be evaluated for repeat desensitization before resuming therapy."

The tolerant state may be lost after interruption.

+ 1 more reference

Dupilumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: Dupilumab NCIT:C162455

Platform: Monoclonal antibody

An IL-4R-alpha blocker used in eligible uncontrolled asthma/CRSwNP. In an open-label AERD cohort, 7 of 30 tolerated the highest aspirin challenge dose after six months and another 10 tolerated higher doses; this was not universal tolerance or a placebo-controlled comparison. Average polyp, asthma and smell outcomes improved. A nested 11-person 2026 mechanistic analysis found reduced nasal type 2 responses without a cytokine pattern reliably distinguishing tolerance; transcriptional associations do not establish mediation. NSAID use still requires individual specialist assessment.

Mechanism Target:

INHIBITS Enhanced IL-4R-Alpha Signaling — Blocks IL-4R-alpha-mediated IL-4/IL-13 signaling.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"Treatment with dupilumab, a humanized antibody against IL-4Rα, leads to robust improvements in upper and lower respiratory tract symptoms in AERD patients, including improved sense of smell, reduced nasal polyp size, and improved lung function"

Supports the target and reported clinical response.

Show evidence (3 references)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

Supports the target and reported clinical response.

PMID:36549708 SUPPORT PRIMARY RESULT Human Clinical

"After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses."

Complete tolerance refers to the tested cumulative dose, not all possible exposures.

PMID:41309110 SUPPORT PRIMARY RESULT Human Clinical

"Interestingly, the development of tolerance was not associated with specific cytokine patterns."

The small nested analysis does not validate a type 2 cytokine predictor or mediator of tolerance.

Omalizumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: Omalizumab NCIT:C29299

Platform: Monoclonal antibody

Anti-IgE treatment may be selected under the applicable asthma/CRSwNP indication. A 16-person atopic AERD crossover trial reduced challenge-associated urinary LTE4 and allowed 10 participants to tolerate the highest tested aspirin dose after three months. Six still reacted; generalization to nonatopic or uncontrolled severe disease is limited. Biomarker reductions imply reduced mediator activity but do not directly identify the responsible airway cell population.

Mechanism Target:

INHIBITS Mast Cell Activation — Neutralizing IgE can reduce the IgE-associated component of mast-cell activation; this is indirect and does not block all innate triggers.

Show evidence (1 reference)

PMID:36184313 SUPPORT INDIRECT REVIEW SYNTHESIS Human Clinical

"These findings support a role for IgE, likely derived locally from plasma cells in the respiratory tract (56), in driving both the steady-state eicosanoid formation and the mast cell-dependent clinical reactions to aspirin"

The reviewed treatment response supports an IgE contribution with unresolved cellular mediation.

Show evidence (2 references)

PMID:32142372 SUPPORT PRIMARY RESULT Human Clinical

"Ten of 16 patients (62.5%) developed oral aspirin tolerance up to cumulative doses of 930 mg in the omalizumab phase"

This was a randomized double-blind crossover study in selected atopic, stable Japanese adults; the primary endpoint was urinary LTE4 log-AUC.

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"The mechanisms by which IgE can induce a chronically activated mast cell population, and the antigen specificity of the locally produced IgE remain to be determined."

The upstream IgE mechanism and antigen specificity remain unresolved.

Mepolizumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: Mepolizumab NCIT:C157376

Platform: Monoclonal antibody

An anti-IL-5 option for appropriately selected eosinophilic asthma/CRSwNP. AERD-specific studies report symptomatic benefit, but aspirin reactions can persist. IL5RA expression on non-eosinophil cells does not itself prove a functional therapeutic mechanism in those cells.

Mechanism Target:

INHIBITS Enhanced IL-5 Signaling — Neutralizes IL-5 and reduces downstream eosinophilic signaling.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Other

"Neutralization of IL-5 with the humanized antibody mepolizumab reduces blood and tissue eosinophilia in patients with severe asthma and CRSwNP and improves symptomatic control over placebo."

Distinguishes the broader asthma/CRSwNP trial evidence from AERD-specific cohorts.

Show evidence (2 references)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"Open label studies reveal that mepolizumab provides moderate symptomatic benefit for patients with AERD (64, 65), but does not consistently block NSAID-induced reactions (66)."

The AERD-specific evidence does not guarantee NSAID tolerance.

PMID:36184313 SUPPORT REVIEW SYNTHESIS Other

"Neutralization of IL-5 with the humanized antibody mepolizumab reduces blood and tissue eosinophilia in patients with severe asthma and CRSwNP and improves symptomatic control over placebo."

Distinguishes the broader asthma/CRSwNP trial evidence from AERD-specific cohorts.

Acute bronchospasm treatment

Category: Therapeutic

Platform: Small molecule

Promptly treat acute lower-airway reactions with inhaled short-acting bronchodilators and clinical monitoring in an appropriately equipped setting. Severity determines additional emergency treatment; chronic controller therapy is separate.

Mechanism Target:

INHIBITS Airway Smooth Muscle Contraction — Bronchodilator rescue opposes acute bronchomotor narrowing.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Respiratory reactions with shortness of breath and wheezing can be treated with nebulized or meter-dose inhaled short-acting beta agonists, short-acting anticholinergics, short-acting beta-agonist/anticholinergic combination therapy, or intramuscular epinephrine."

Provides rescue treatment in the supervised reaction setting.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

Provides rescue treatment in the supervised reaction setting.

Emergency treatment of systemic reactions

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: (R)-adrenaline CHEBI:28918

Platform: Small molecule

Use intramuscular epinephrine for anaphylactic/systemic reactions, with emergency support according to severity. Isolated upper-airway symptoms are assessed and treated according to their actual presentation.

Show evidence (1 reference)

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

"Systemic reactions should be treated with intramuscular epinephrine, and very occasionally intravenous fluids are needed."

The work group specifies systemic-reaction rescue, not routine epinephrine for every nasal symptom.

NSAID avoidance and assessment of alternatives

Category: Counseling / Informational

Platform: Other

Counsel patients about strong COX-1 inhibitors and accidental exposure. Selective COX-2 agents are usually tolerated, but tolerance is not guaranteed; high-dose acetaminophen can trigger reactions in a minority. Select an alternative and supervised challenge according to the reaction history and clinical need. Avoidance does not replace asthma and sinonasal care.

Show evidence (2 references)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"patients with N-ERD almost always tolerate selective COX-2 inhibitors during observed drug challenges"

Observed tolerance is common rather than absolute.

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"The inhibition of COX-1 by NSAIDs, and high-dose paracetamol (acetaminophen) in a minority of patients, precipitates respiratory tract reactions."

High-dose acetaminophen is not uniformly safe.

Shared treatment selection and longitudinal monitoring

Category: Monitoring

Platform: Other

Coordinate allergy, respiratory and rhinology care. Reassess asthma control, exacerbations, smell, polyp burden, quality of life, treatment adverse effects and adherence. Select surgery, aspirin maintenance or biologics using disease burden, contraindications, comorbid indications, patient preferences and access; comparative superiority is not established by uncontrolled cohorts or indirect network comparisons.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/ SUPPORT REVIEW SYNTHESIS Other

"The treatment approach thus should be based on shared decision‐making, considering the patient's clinical characteristics, the likelihood of patient adherence, the availability of endoscopic sinus surgery options, the cost of the medications, and access to biologic therapies"

The 2026 consensus supports individualized treatment selection.

Tezepelumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: Tezepelumab NCIT:C152582

Platform: Monoclonal antibody

A TSLP-blocking option for patients meeting a relevant severe-asthma indication. In the 52-week NAVIGATOR analysis, the post hoc subgroup with a history of aspirin or NSAID sensitivity had an estimated 83% lower annualized exacerbation rate than placebo (95% CI 66–91). This subgroup is distinct from the smaller recorded AERD/N-ERD/Samter triad subgroup. No formal hypothesis testing or between-biologic comparison was performed; the result does not establish aspirin tolerance or superiority for challenge-confirmed AERD.

Mechanism Target:

INHIBITS Enhanced TSLP Signaling — Neutralizes TSLP signaling; this target is broader than the source or trigger of airway TSLP production.

Show evidence (1 reference)

PMID:38802635 SUPPORT BACKGROUND Other

"Tezepelumab binds specifically to thymic stromal lymphopoietin (TSLP)"

The article describes the established pharmacological target.

Show evidence (2 references)

PMID:38802635 SUPPORT PRIMARY RESULT Human Clinical

"Reductions with tezepelumab compared with placebo in patients with asthma‑related comorbidities ranged from 58% (95% CI: 47, 67) in patients with rhinitis to 83% (95% CI: 66, 91) in patients with aspirin or NSAID sensitivity"

The reported NSAID-sensitivity subgroup result is exploratory, distinct from a prospectively powered challenge-confirmed AERD trial.

PMID:38802635 SUPPORT PRIMARY RESULT Human Clinical

"No formal hypothesis testing was performed to compare tezepelumab with placebo or to compare effects between the subgroups investigated."

Limits the exploratory subgroup comparisons.

Benralizumab

Category: Therapeutic Action: Pharmacotherapy NCIT:C15986

Agent: Benralizumab NCIT:C88594

Platform: Monoclonal antibody

An IL-5R-alpha-directed antibody that can be selected for a qualifying eosinophilic-asthma indication. Eosinophil depletion and asthma benefit do not establish universal control of polyp disease or aspirin tolerance. A small retrospective NSAID-ERD series mixing benralizumab, mepolizumab and reslizumab reported substantial nonresponse; those pooled observations do not provide a drug-specific response rate or a head-to-head comparison.

Mechanism Target:

INHIBITS Enhanced IL-5 Signaling — Blocks IL-5 receptor signaling and supports depletion of receptor-bearing eosinophils.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/ SUPPORT REVIEW SYNTHESIS Other

"Benralizumab is a humanized IgG1κ antibody that binds to and inhibits extracellular IL‐5Rα, preventing IL‐5 signaling"

Identifies the receptor-directed action, distinct from ligand neutralization by mepolizumab.

Show evidence (2 references)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/ SUPPORT REVIEW SYNTHESIS Other

"Benralizumab is a humanized IgG1κ antibody that binds to and inhibits extracellular IL‐5Rα, preventing IL‐5 signaling"

Identifies the receptor-directed action, distinct from ligand neutralization by mepolizumab.

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"the modest therapeutic efficacy of anti-IL-5 treatments, such as benralizumab, mepolizumab, or reslizumab"

The review describes limited clinical efficacy and cautions against an eosinophil-only account of disease.

Selected short-course systemic corticosteroids

Category: Therapeutic

Platform: Small molecule

Systemic corticosteroids may be needed for severe airway exacerbations or reactions, selected according to presentation. They are an adjunct to immediate rescue when indicated; cumulative exposure and adverse effects should inform long-term steroid-sparing treatment decisions.

Show evidence (2 references)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/ SUPPORT REVIEW SYNTHESIS Other

"Consider systemic corticosteroids for severe reactions"

The consensus desensitization protocol identifies systemic steroids as a severity-dependent adjunct.

PMID:33307116 SUPPORT REVIEW SYNTHESIS Other

Corticosteroids remain among the medical options for upper and lower airway disease.

🌍

Environmental Factors

Aspirin and other strong COX-1 inhibitors

Exposure can trigger an acute reaction in susceptible patients. This is distinct from causing the underlying chronic airway disease.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors."

Defines the characteristic triggering drug class.

Mechanism Target:

TRIGGERS Pharmacological COX-1 Inhibition — The drug inhibits COX-1 activity, initiating the acute pharmacologic perturbation.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"The inhibition of COX-1 by NSAIDs, and high-dose paracetamol (acetaminophen) in a minority of patients, precipitates respiratory tract reactions."

Identifies the exposure and target-linked acute response.

🔬

Biochemical Markers

Urinary leukotriene E4 (INCREASED)

Context: A stable excreted cysteinyl leukotriene product that can be elevated at baseline and rise during reactions. It is an adjunctive systemic pathway readout, not a specific cell-source assay or stand-alone diagnostic/predictive test. Treatment-associated changes do not establish causal mediation of tolerance.

Pathograph Readouts

Readout Of Increased Cysteinyl Leukotriene Availability Positive Diagnostic

Urinary LTE4 reflects systemic cysteinyl leukotriene generation with assay and clinical-context limitations.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Additional measurement of urinary LTE4 levels is useful, but not sufficient, for the diagnosis of N-ERD."

Supports an adjunctive pathway biomarker rather than a definitive threshold.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Additional measurement of urinary LTE4 levels is useful, but not sufficient, for the diagnosis of N-ERD."

The guideline explicitly limits diagnostic sufficiency.

Urinary PGD2 metabolites (INCREASED)

Context: Elevated metabolites can indicate increased prostanoid production at baseline or during reactions, but do not uniquely identify mast cells or establish a diagnostic threshold.

Pathograph Readouts

Readout Of Increased PGD2 Production Positive Diagnostic

Systemic PGD2 metabolite output is a research/adjunctive readout of production, not a validated stand-alone diagnostic test.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls"

Supports the biochemical association.

Show evidence (1 reference)

PMID:36184313 SUPPORT REVIEW SYNTHESIS Human Clinical

"The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls, and often paradoxically increase in parallel with LTE4 during reactions to aspirin"

Documents the human mediator pattern.

Exhaled nitric oxide (INCREASED)

Context: FeNO can be elevated in the type 2 airway phenotype, but is neither sensitive nor specific for N-ERD.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD."

The threshold is a supportive observation, not a diagnostic criterion.

🔬

Diagnosis

Clinical history and respiratory assessment

Document asthma, sinonasal disease and the timing/reproducibility of reactions to COX-1 inhibitors. A convincing history can establish the diagnosis; partial presentations occur and IgE-mediated single-drug allergy, NSAID-induced urticaria/anaphylaxis and other airway disorders require distinction.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"A clinical diagnosis of N-ERD can often be established by history and physical exam alone."

Avoids requiring provocation in every clinically clear case.

Supervised aspirin provocation when indicated

Graded oral aspirin challenge is the reference test when the history is unclear. It requires specialist supervision, stable airway disease and rescue capability. Recent polyp surgery, leukotriene modifiers, systemic corticosteroids or biologics can attenuate reactions; a negative test in these settings needs contextual interpretation. The WAO diagnostic-challenge guidance requires stable patients with FEV1 at least 70% predicted and identifies current beta-blocker treatment as a contraindication.

Show evidence (4 references)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Oral ASA challenge testing is the gold standard for diagnosing hypersensitivity to NSAIDs, and sensitive and specific for N-ERD."

Supports the reference-test role.

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"a negative DC does not fully exclude hypersensitivity, especially if the patient has well-controlled asthma, underwent recent surgical excision of nasal polyps, or is taking leukotriene (LT) receptor antagonists or high-dose systemic corticosteroids"

Identifies circumstances that can reduce reaction severity.

PMID:40837856 SUPPORT REVIEW SYNTHESIS Other

"Patients undergoing oral or inhaled DC should be in a stable condition, with an FEV1 ≥ 70% of predicted value."

Specifies the diagnostic-challenge respiratory safety criterion.

+ 1 more reference

Spirometry and assessment of variable airflow obstruction

Use bronchodilator-response spirometry or serial peak flow to establish and monitor the asthma component; these tests do not independently distinguish AERD from other asthma.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Spirometry with bronchodilator response testing or peak flow monitoring to capture variable airflow obstruction should be the first step."

Guideline assessment of the lower-airway component.

Sinonasal endoscopy and selected CT imaging

Endoscopy documents polyps and sinonasal disease. CT is useful when surgery is being considered; routine diagnostic polyp biopsy is not required.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Sinus computed tomography (CT) scans may be reserved for those requiring surgery. Other imaging modalities are not recommended. A diagnosis of nasal polyposis is best established on nasal endoscopy."

Defines the roles of endoscopy and surgical-planning imaging.

Adjunctive inflammatory biomarkers

Blood eosinophils, FeNO and urinary LTE4 can support phenotyping but cannot establish or exclude N-ERD alone. No reliable in-vitro diagnostic test replaces clinical evaluation and, when appropriate, challenge.

Show evidence (2 references)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"No in vitro tests are sensitive or reliable to be recommended in the diagnosis of N-ERD."

Limits biomarker and laboratory-test interpretation.

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD."

Directly supports the limited sensitivity and specificity of the named laboratory findings.

📈

Progression

Variable emergence of chronic airway disease

Age: Peak incidence in the third and fourth decades; wider ages occur

Sinonasal symptoms and smell loss often precede asthma. Components develop over months to many years, rather than following a mandatory two-year/five-year sequence.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

"Each component of the triad can develop over a span of months to many years. Peak incidence is in the third and fourth decade of life, with cases reported as early as puberty onset and as late as the eighth decade of life."

Describes both the broad onset range and variable temporal sequence.

Acute COX-1-inhibitor reaction

Upper and/or lower respiratory symptoms typically begin 30 minutes to 3 hours after exposure. Mixed presentations can include skin or gastrointestinal symptoms; ongoing asthma and CRSwNP require treatment between reactions.

Show evidence (1 reference)

PMID:40837856 SUPPORT REVIEW SYNTHESIS Human Clinical

Provides the acute exposure-to-reaction time window.

📊

Prevalence

Adults with asthma

Point Prevalence 7150.0 per 100,000 >1 in 1,000

Pooled prevalence across all study designs in asthmatic populations, 7.15% (95% CI 5.26-9.03%), from a meta-analysis of 27 studies. This is a pooled estimate from selected studies with differing ascertainment methods, searched through June 2013, not a contemporary global population rate.

Show evidence (1 reference)

PMID:25282015 SUPPORT REVIEW SYNTHESIS Human Clinical

"Among all studies in asthmatic patients, regardless of method, the prevalence of AERD was 7.15% (95% CI, 5.26% to 9.03%)"

Meta-analytic pooled prevalence of AERD among asthmatic patients.

Adults with severe asthma

Point Prevalence 14890.0 per 100,000 >1 in 1,000

Highest prevalence stratum in the same meta-analysis, 14.89% (95% CI 6.48-23.29%). This is a pooled estimate from selected studies with differing ascertainment methods, searched through June 2013, not a contemporary global population rate.

Show evidence (1 reference)

PMID:25282015 SUPPORT REVIEW SYNTHESIS Human Clinical

"The prevalence of AERD was highest among patients with severe asthma (14.89% [95% CI, 6.48% to 23.29%])"

Meta-analytic prevalence of AERD in the severe-asthma stratum.

🔬

Clinical Trials

NCT04442256 PHASE_IV UNKNOWN

Single-center open-label dupilumab study in Vienna with repeat aspirin challenge after six months. The published cohort included 31 participants, with 30 paired challenges; 17 increased their tolerated dose, including 7 reaching the highest cumulative dose. A later 11-person nested mucosal/transcriptomic analysis did not identify a cytokine signature explaining tolerance.

Show evidence (3 references)

clinicaltrials:NCT04442256 SUPPORT PRIMARY RESULT Other

"To test the efficacy of dupilumab in patients with AERD regarding the intolerance to salicylic acid after 6 months. This will be evaluated by oral drug provocation testing with low dose salicylic acid after 6 months of dupilumab treatment."

The structured registry summary describes the planned challenge study; the published outcome cohort is cited separately.

PMID:36549708 SUPPORT PRIMARY RESULT Human Clinical

"After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses."

Published paired-challenge results, with tolerance limited to the tested doses.

PMID:41309110 SUPPORT PRIMARY RESULT Human Clinical

"The eleven N‐ERD patients included in this study were randomly selected from a cohort of thirty‐one N‐ERD patients under dupilumab therapy as reported previously"

The newer mechanistic analysis is a nested subset of the earlier cohort.

NCT03825757 NOT_APPLICABLE COMPLETED

AirGOs-medical randomized aspirin-maintenance trial in adults with AERD, uncontrolled CRSwNP and prior ethmoidal surgery. The published analysis randomized 26 successfully desensitized patients, 16 to aspirin and 10 to placebo, with 21 completing follow-up. No significant between-group change in the principal symptom/control/polyp outcomes was detected over the 11-month regimen.

Show evidence (2 references)

clinicaltrials:NCT03825757 SUPPORT PRIMARY RESULT Other

"The study is performed as a randomized double-blinded prospective controlled trial."

The live registry describes the planned controlled design and marks the trial completed in status metadata.

PMID:40726272 SUPPORT PRIMARY RESULT Human Clinical

Within-group changes cannot replace the nonsignificant between-group comparison.

NCT03595488 PHASE_II COMPLETED

Small dupilumab add-on study for sinonasal disease; actual enrollment 11.

Show evidence (1 reference)

clinicaltrials:NCT03595488 SUPPORT PRIMARY RESULT Other

"despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD."

The canonical registry summary describes enrollment and the planned add-on evaluation rather than proving efficacy.

NCT05031455 PHASE_II COMPLETED

Completed single-group phase 2 study of dupilumab effects on aspirin challenge/desensitization; actual enrollment 16.

Show evidence (1 reference)

clinicaltrials:NCT05031455 SUPPORT PRIMARY RESULT Other

"The primary objective is to determine the effect of dupilumab on reactions during aspirin challenge/desensitization."

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT02216357 PHASE_II COMPLETED

Small randomized phase 2 ifetroban safety/challenge study; actual enrollment 19, with 12 active and 4 placebo participants in posted outcome analyses.

Show evidence (1 reference)

clinicaltrials:NCT02216357 SUPPORT PRIMARY RESULT Other

"The primary objective of the study is to determine the safety of oral ifetroban compared to placebo"

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT01540032 NOT_APPLICABLE UNKNOWN

Randomized crossover study of a low-salicylate diet, planned enrollment 80, with six-week diet periods and SNOT-22 assessment.

Show evidence (1 reference)

clinicaltrials:NCT01540032 SUPPORT PRIMARY RESULT Other

"The purpose of this study is to determine whether a low salicylate diet will improve the quality of life of patients with Aspirin Exacerbated Respiratory Disease (AERD)."

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT01778465 NOT_APPLICABLE COMPLETED

Completed open-label crossover dietary-salicylate pilot with seven participants and urinary salicylates/cysteinyl leukotrienes plus SNOT-22 outcomes.

Show evidence (1 reference)

clinicaltrials:NCT01778465 SUPPORT PRIMARY RESULT Other

"Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma and nasal polyps."

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT04375293 NOT_APPLICABLE COMPLETED

Completed nasal-microbiome/basic-science comparison of N-ERD, other chronic-rhinosinusitis groups and controls; actual enrollment 80.

Show evidence (1 reference)

clinicaltrials:NCT04375293 SUPPORT PRIMARY RESULT Other

"the investigators plan to analyse the nasal microbiome in these patients and to compare it to nasal samples from CRSwNP and CRSsNP patients as well as healthy controls"

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT03627481 NOT_APPLICABLE UNKNOWN

Single-group study of sleep quality, symptoms and quality of life before and after sinonasal surgery in AERD, with planned enrollment 32.

Show evidence (1 reference)

clinicaltrials:NCT03627481 SUPPORT PRIMARY RESULT Other

"Aspirin exacerbated respiratory disease presents as a triad composed by asthma, eosinophilic rinosinusitis and intolerance to aspirin and NSAIDS."

The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.

NCT05797597 PHASE_III UNKNOWN

Registered randomized aspirin/placebo crossover study of airway viral-entry/interferon-related gene expression, with planned enrollment 76.

Show evidence (1 reference)

clinicaltrials:NCT05797597 SUPPORT PRIMARY RESULT Other

"the assessment of gene expression for interferon α1 (IFNA1), interferon β1 (IFNB1), interferon γ (IFNG), interferon λ1 and λ2 (IFNL1 and IFNL2) as well as for ACE2 and TMPRSS2 in sputum and nasal cells may shed new light on the course of this infection in patient with AERD during long term..."

The registered rationale describes an exploratory gene-expression assessment; no antiviral efficacy is inferred.

🧫

Experimental Models

AERD blood-progenitor-derived mast-cell culture PRIMARY_CELL_CULTURE

Anti-IgE-stimulated cultures showed greater cysteinyl leukotriene release in AERD donor cells. Basal release of the three tested mediators was similar between donor groups. PGE2 suppressed stimulated leukotriene release in the AERD cultures.

Cell source

Peripheral blood progenitors from AERD, aspirin-tolerant asthma and normal donors

Publication

PMID:17508965

Pathograph links

Mast Cell Activation perturbs fidelity: moderate observes: cellular Anti-IgE activates cultured mast cells for mediator-release measurement.

Limitations: This tests an IgE-dependent stimulus, not direct aspirin reactivity in intact airways.

Show evidence (1 reference)

PMID:17508965 SUPPORT PRIMARY RESULT In Vitro

"Mast cells were cultured from peripheral blood progenitors and were activated by anti-IgE. Histamine, PGD(2) and cys-LTs released were then determined."

Specifies cultured progenitor-derived mast cells and the activation assay.

Reduced PGE2-Mediated Restraint perturbs fidelity: moderate observes: cellular PGE2 inhibits stimulated cysteinyl leukotriene output in AERD cultures.

Limitations: The retained response limits a universal PGE2-insensitivity claim; it does not refute the tissue-level protective deficit.

Show evidence (1 reference)

PMID:17508965 SUPPORT PRIMARY RESULT In Vitro

"In contrast, PGE(2) suppressed only anti-IgE induced cys-LTs release from mast cells of AERD patients."

The tested AERD mast-cell cultures retain a PGE2-sensitive leukotriene response.

The available source is the complete abstract, not the full article. Differentiated blood-progenitor cells are not freshly isolated airway mast cells; the result does not establish universal basal overproduction or PGE2 resistance.

Show evidence (2 references)

PMID:17508965 SUPPORT PRIMARY RESULT In Vitro

"Mast cells were cultured from peripheral blood progenitors and were activated by anti-IgE. Histamine, PGD(2) and cys-LTs released were then determined."

Specifies cultured progenitor-derived mast cells and the activation assay.

PMID:17508965 SUPPORT PRIMARY RESULT In Vitro

"Basal release of all three mediators was similar in all subjects."

Basal mediator release did not distinguish groups under the reported culture conditions.

AERD granulocyte-platelet ex vivo preparations CO_CULTURE

Platelet stripping, exogenous LTA4-methyl-ester conversion, A23187 stimulation, fMLP stimulation and platelet add-back interrogated platelet-associated leukotriene production. Removal reduced both LTC4 synthase-associated activity and stimulated output; add-back restored robust generation.

Cell source

Freshly isolated human peripheral blood granulocytes and autologous platelets

Publication

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml

Pathograph links

Enhanced Transcellular Cysteinyl Leukotriene Synthesis measures fidelity: moderate observes: cellular Platelet removal lowers fMLP-stimulated cysteinyl leukotriene release.

Limitations: Cell preparations do not reproduce vascular recruitment, intact airway context or clinical treatment response.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml SUPPORT PRIMARY RESULT In Vitro

"Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%"

Quantifies the contribution of adherent platelets in the fMLP-stimulated cell assay.

Platelet-intrinsic LTC4 synthase activity did not significantly differ between AERD and aspirin-tolerant asthma. Substrate-conversion, ionophore and receptor-agonist assays had different sample subsets; the fMLP result came from three AERD preparations. Ex vivo removal/add-back supports a contribution but does not quantify in vivo necessity or establish antiplatelet treatment efficacy.

Show evidence (1 reference)

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml SUPPORT PRIMARY RESULT In Vitro

"Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%"

Quantifies the contribution of adherent platelets in the fMLP-stimulated cell assay.

Liraglutide perturbation of human platelet activation CO_CULTURE

Whole blood was pretreated with liraglutide for 30 minutes before 30-minute U46619 stimulation. Free-platelet CD62P and plasma CXCL7 responses decreased, but platelet-leukocyte aggregate formation and aggregate-associated CD62P were not significantly suppressed.

Cell source

Fresh human whole blood from adults with AERD and nonasthmatic controls

Publication

PMID:37870292

Pathograph links

Increased Platelet-Leukocyte Adherence measures fidelity: moderate observes: cellular TP stimulation and liraglutide pretreatment test platelet-leukocyte aggregate formation.

Limitations: No significant reduction in aggregate formation was demonstrated; the positive CD62P and CXCL7 responses cannot be substituted for an aggregate or leukotriene-flux endpoint.

Show evidence (1 reference)

PMID:37870292 SUPPORT PRIMARY RESULT In Vitro

"Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population"

The negative aggregate result limits inference from the positive free-platelet activation readout.

The body reports 33 AERD and 11 controls recruited, with samples from 30 AERD and all controls analyzable; the abstract instead states 31 AERD. CXCL7 analysis used 20 AERD samples. Treatment subgroups were small and not powered for comparative response. No clinical drug administration, aspirin-tolerance endpoint, leukotriene-flux mediation or durable airway benefit was tested.

Show evidence (2 references)

PMID:37870292 SUPPORT PRIMARY RESULT In Vitro

Describes the measured platelet-activation response in human blood preparations.

PMID:37870292 SUPPORT PRIMARY RESULT In Vitro

"Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population"

The negative aggregate result limits inference from the positive free-platelet activation readout.

🐁

Animal Models

Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations

Repeated intranasal Dermatophagoides farinae conditioning produces an eosinophilic, PGE2-deficient airway that responds to inhaled lysine aspirin or selected cysteinyl leukotrienes. Global Ltc4s deletion reduces IL-33 and eosinophilic inflammation. Anti-IL-33 antibody or soluble ST2-Fc given before challenge reduces airway-resistance and mediator responses.

Species

Mouse

Genotype

Ptges−/−, with additional Ltc4s deletion in genetic-dependency experiments

Background

C57BL/6; 6–8-week-old males

Publication

PMID:26342029

Pathograph links

Reduced Respiratory PGE2 Availability perturbs fidelity: moderate observes: tissue Loss of mPGES-1 impairs inducible PGE2 synthesis.

Limitations: Genetic deletion models one permissive component, not the established etiology of human AERD.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction."

The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.

Increased Airway IL-33 Availability measures fidelity: moderate observes: tissue Lung IL-33 abundance decreases with additional Ltc4s deletion.

Limitations: Global deletion can alter upstream inflammatory conditioning; it does not establish a direct epithelial receptor-to-IL33 step.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"The lungs of the ptges−/−/ltc4s−/− mice also contained substantially less IL-33 protein than did the lungs of the ptges−/− controls"

Whole-body Ltc4s deletion changes lung IL-33 abundance in the Ptges-null context.

Enhanced IL-33-ST2 Signaling perturbs fidelity: moderate observes: molecular IL-33 antibody or soluble ST2-Fc blocks signaling before challenge.

Limitations: The decoy is not an anti-ST2 antibody; no lineage-specific necessity or clinical efficacy is established.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2"

Anti-IL-33 and soluble ST2-Fc pretreatment prevent the model mediator response.

Mast Cell Activation measures fidelity: moderate observes: tissue BAL histamine, mMCP1 and PGD2 responses are reduced by IL-33/ST2 blockade.

Limitations: Mediator readouts do not substitute for mast-cell depletion or a mast-cell-specific conditional knockout.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2"

Anti-IL-33 and soluble ST2-Fc pretreatment prevent the model mediator response.

Airway Smooth Muscle Contraction partially recapitulates fidelity: moderate observes: organism Challenge produces increased airway resistance that is inhibited by upstream blockade.

Limitations: Airway resistance is an organ-level functional readout, not a direct isolated smooth-muscle assay.

Show evidence (1 reference)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction."

The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.

Notes

This induced model does not establish a human PTGES mutation etiology or reproduce the full acquired syndrome. Blocking agents were given 24 hours before challenge, not as treatment of established human disease. Tissue source and mast-cell-specific ST2 necessity were not tested. BAL histamine/mMCP1/PGD2 are activation-associated readouts; figure legends are absent from the generated main-body cache, so unverified figure sample sizes are not supplied.

Show evidence (2 references)

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction."

The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.

PMID:26342029 SUPPORT PRIMARY RESULT Model Organism

"Six- to 8-wk-old male mice were used."

Defines the age and sex of the model animals.

Liraglutide pretreatment in allergen-primed Ptges-null mice

Liraglutide was given intraperitoneally 24 hours before lysine-aspirin challenge in dust-mite-conditioned mice. It attenuated the airway-resistance response, lung CD41 staining and BAL CXCL7. Separate wild-type male/female blood experiments measured platelet GLP-1 receptor expression.

Species

Mouse

Genotype

Ptges−/−

Background

C57BL/6; male mice aged 6–12 weeks for the airway model

Publication

PMID:37870292

Pathograph links

Airway Smooth Muscle Contraction perturbs fidelity: moderate observes: organism Pretreatment blunts challenge-associated airway resistance.

Limitations: An induced mouse model does not establish a human AERD treatment indication or clinical benefit.

Show evidence (1 reference)

PMID:37870292 SUPPORT PRIMARY RESULT Model Organism

"In AERD-like Df challenged Ptges−/− mice, a single dose of GLP-1R agonist inhibited Lys-ASA-induced increases in airway resistance"

The living-mouse experiment tested prophylactic liraglutide in an induced challenge model.

Notes

Pretreatment is not reversal of established human disease. Whole-animal drug exposure does not isolate platelet GLP-1 receptor necessity, and histology cannot distinguish free platelets from platelet-leukocyte aggregates. Airway, mediator and recruitment changes do not prove that one measured intermediate mediates the others. Figure legends are absent from the generated body; no unverified group counts are supplied.

Show evidence (2 references)

PMID:37870292 SUPPORT PRIMARY RESULT Model Organism

"In AERD-like Df challenged Ptges−/− mice, a single dose of GLP-1R agonist inhibited Lys-ASA-induced increases in airway resistance"

The living-mouse experiment tested prophylactic liraglutide in an induced challenge model.

PMID:37870292 SUPPORT PRIMARY RESULT Model Organism

"Liraglutide was administered intraperitoneally (1.5mg/kg) 24 hours prior to challenge with aerosolized Lysine-aspirin (Lys-ASA)."

Defines dose, route and preventive timing.

{ }

Source YAML

click to show

name: Aspirin-Exacerbated Respiratory Disease
creation_date: '2026-08-27T16:00:00Z'
category: Complex
synonyms:
- NSAID-exacerbated respiratory disease
- N-ERD
- Samter triad
- aspirin triad
- aspirin-intolerant asthma
- aspirin-induced asthma
disease_term:
  preferred_term: Aspirin-exacerbated respiratory disease
  term:
    id: MONDO:0008834
    label: asthma, nasal polyps, and aspirin intolerance
parents:
- Asthma
description: A chronic inflammatory respiratory disorder classically comprising asthma, chronic rhinosinusitis with nasal polyps and acute respiratory reactions to aspirin or other strong COX-1 inhibitors. Components can emerge over months to years, and partial presentations occur. Dysregulated lipid mediators, impaired protective PGE2 signaling and a heterogeneous type 2 inflammatory network contribute. Cross-reactive NSAID reactions are pharmacologic rather than drug-specific IgE allergy; IgE-associated airway inflammation can still coexist. Avoiding triggers prevents exposure-related reactions but does not remove the underlying airway disease.
classifications:
  harrisons_chapter:
  - classification_value: RESPIRATORY
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors.
      explanation: The disease principally affects upper and lower respiratory tracts.
prevalence:
- population: Adults with asthma
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 7150.0
  notes: Pooled prevalence across all study designs in asthmatic populations, 7.15% (95% CI 5.26-9.03%), from a meta-analysis of 27 studies. This is a pooled estimate from selected studies with differing ascertainment methods, searched through June 2013, not a contemporary global population rate.
  evidence:
  - reference: PMID:25282015
    reference_title: 'Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: Among all studies in asthmatic patients, regardless of method, the prevalence of AERD was 7.15% (95% CI, 5.26% to 9.03%)
    explanation: Meta-analytic pooled prevalence of AERD among asthmatic patients.
    quote_role: REVIEW_SYNTHESIS
- population: Adults with severe asthma
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 14890.0
  notes: Highest prevalence stratum in the same meta-analysis, 14.89% (95% CI 6.48-23.29%). This is a pooled estimate from selected studies with differing ascertainment methods, searched through June 2013, not a contemporary global population rate.
  evidence:
  - reference: PMID:25282015
    reference_title: 'Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: The prevalence of AERD was highest among patients with severe asthma (14.89% [95% CI, 6.48% to 23.29%])
    explanation: Meta-analytic prevalence of AERD in the severe-asthma stratum.
    quote_role: REVIEW_SYNTHESIS
pathophysiology:
- name: Pharmacological COX-1 Inhibition
  biological_scale: MOLECULAR
  description: Aspirin and other strong COX-1 inhibitors suppress cyclooxygenase activity. This acute pharmacologic exposure triggers reactions in a susceptible airway; it does not explain the acquired chronic asthma and sinonasal disease.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Inhibition of COX-1 activity in patients with N-ERD further reduces the “braking” effects of PGE2/EP2 on mast cells and 5-LO activity, which increases the release of cysLTs in urine and airway fluids, precipitating respiratory symptoms.
    explanation: The statement describes the acute pharmacologic trigger in a susceptible airway; it does not identify the cause of the chronic disease.
  downstream:
  - target: Reduced Respiratory PGE2 Availability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: COX-1 inhibition reduces the residual COX-1-dependent prostaglandin supply during an acute reaction.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Inhibition of COX-1 activity in patients with N-ERD further reduces the “braking” effects of PGE2/EP2 on mast cells and 5-LO activity, which increases the release of cysLTs in urine and airway fluids, precipitating respiratory symptoms.
      explanation: The statement describes the acute pharmacologic trigger in a susceptible airway; it does not identify the cause of the chronic disease.
    intermediate_mechanisms:
    - reduced conversion of arachidonic acid to prostaglandin H2
    - reduced substrate supply for PGE2 synthesis
- name: Reduced Respiratory PGE2 Availability
  biological_scale: TISSUE
  description: Reduced production and/or increased catabolism lowers protective PGE2 availability in respiratory tissues. Chronic COX-2/mPGES-1 abnormalities and acute COX-1 inhibition are distinct contributors; neither complete PGE2 absence nor a single initiating lesion is established.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Several studies link AERD to diminished production (or increased catabolism) of PGE2 in the respiratory tract
    explanation: Reduced respiratory PGE2 availability is supported by several studies, with heterogeneous synthesis and degradation contributions.
  downstream:
  - target: Reduced PGE2-Mediated Restraint
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Lower ligand availability can reduce the protective PGE2 signal. The magnitude depends on cell type and receptor function.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: PGE2 stabilizes and prevents the activation of mast cells (2) and group 2 innate lymphoid cells (ILC2s)(3), and prevents the formation of cysLTs by inhibiting the translocation of 5-lipoxygenase (5-LO) (4).
      explanation: Summarizes inhibitory PGE2 actions on mediator synthesis and immune-cell activation.
    intermediate_mechanisms:
    - reduced engagement of protective PGE2 receptors
- name: Reduced Inflammatory-Cell EP2 Abundance
  biological_scale: CELLULAR
  description: A study of 12 aspirin-sensitive and 10 non-sensitive rhinosinusitis polyps found a lower fraction of inflammatory cells expressing EP2. Global mucosal EP2 staining was increased, largely in epithelial/goblet cells. Abundance is distinguished from a direct functional-response assay.
  evidence:
  - reference: PMID:16461132
    reference_title: Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: the percentages of neutrophils, mast cells, eosinophils, and T cells expressing EP(2), but not EP(1), EP(3), or EP(4), were significantly reduced (P < or = .04) in the aspirin-sensitive compared with nonaspirin-sensitive patients
    explanation: Nasal-polyp immunohistochemistry identifies a lower EP2-positive fraction of inflammatory cells, not global receptor absence.
  cell_types:
  - preferred_term: mast cell
    term:
      id: CL:0000097
      label: mast cell
  - preferred_term: eosinophil
    term:
      id: CL:0000771
      label: eosinophil
  - preferred_term: neutrophil
    term:
      id: CL:0000775
      label: neutrophil
  downstream:
  - target: Reduced PGE2-Mediated Restraint
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Reduced inflammatory-cell EP2 abundance may weaken the protective PGE2 response, but staining alone does not establish universal PGE2 resistance.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Diminished expression of the anti-inflammatory EP2 receptor of PGE2 on inflammatory and stromal cells contributes to the functional deficiency of PGE2.
      explanation: The synthesis connects reduced receptor abundance with reduced protective function.
      directness: INDIRECT
- name: Reduced PGE2-Mediated Restraint
  biological_scale: CELLULAR
  description: 'Loss of some PGE2-mediated inhibition permits greater mediator synthesis and cellular activation. This is a context-dependent signaling defect: PGE2 still suppressed anti-IgE-induced cysteinyl leukotriene release in cultured blood-progenitor-derived mast cells from AERD donors. Inhaled PGE2 also protected against aspirin challenge in a small crossover study.'
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: PGE2 stabilizes and prevents the activation of mast cells (2) and group 2 innate lymphoid cells (ILC2s)(3), and prevents the formation of cysLTs by inhibiting the translocation of 5-lipoxygenase (5-LO) (4).
    explanation: Reviews functional inhibition of mast cells, ILC2s and 5-lipoxygenase by PGE2.
  - reference: PMID:17508965
    reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: In contrast, PGE(2) suppressed only anti-IgE induced cys-LTs release from mast cells of AERD patients.
    explanation: The cultured-cell study tests a retained PGE2 response; its stimulus and differentiation conditions differ from airway tissue.
  - reference: PMID:8564100
    reference_title: Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Inhaled PGE2 provided almost complete protection in all patients.
    explanation: Seven aspirin-sensitive participants underwent placebo/PGE2 crossover challenges; this is mechanistic protection, not an established long-term treatment.
  downstream:
  - target: Increased Cysteinyl Leukotriene Availability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Reduced PGE2-dependent inhibition permits 5-lipoxygenase-dependent leukotriene synthesis during the reaction.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Inhibition of COX-1 activity in patients with N-ERD further reduces the “braking” effects of PGE2/EP2 on mast cells and 5-LO activity, which increases the release of cysLTs in urine and airway fluids, precipitating respiratory symptoms.
      explanation: Links reduced PGE2 restraint with increased airway and urinary cysteinyl leukotrienes.
    intermediate_mechanisms:
    - increased 5-lipoxygenase activity
    - increased leukotriene biosynthesis
  - target: Mast Cell Activation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Weakened PGE2 stabilization permits mast-cell activation; other activating signals remain relevant.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: PGE2 stabilizes and prevents the activation of mast cells (2) and group 2 innate lymphoid cells (ILC2s)(3), and prevents the formation of cysLTs by inhibiting the translocation of 5-lipoxygenase (5-LO) (4).
      explanation: Reviews functional inhibition of mast cells, ILC2s and 5-lipoxygenase by PGE2.
    intermediate_mechanisms:
    - reduced inhibitory PGE2 receptor signaling
- name: Increased Bronchial LTC4 Synthase-Positive Cells
  biological_scale: TISSUE
  description: Bronchial biopsies in a small selected cohort contained more LTC4-synthase-positive cells. This is a tissue cell-count observation, not quantified per-cell enzyme expression or the proven initiating defect. Baseline BAL leukotrienes correlated with these counts; the post-challenge increment did not.
  evidence:
  - reference: url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    reference_title: https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Counts of cells expressing the terminal enzyme for cys-LT synthesis, LTC4 synthase, were fivefold higher in AIA biopsies
    explanation: The study counted LTC4-synthase-positive cells in 10 AIA, 10 ATA and 9 normal bronchial biopsies; staining intensity per cell was not quantified.
  - reference: url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    reference_title: https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: no attempt was made to quantify the intensity of staining within each cell.
    explanation: The full Methods limits the interpretation to numbers of positively stained cells.
  biological_processes:
  - preferred_term: leukotriene biosynthetic process
    term:
      id: GO:0019370
      label: leukotriene biosynthetic process
    modifier: INCREASED
  downstream:
  - target: Increased Cysteinyl Leukotriene Availability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: A larger population capable of terminal leukotriene synthesis may contribute to baseline mediator excess; the human evidence is correlational.
    evidence:
    - reference: url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
      reference_title: https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: Enhanced baseline cys-LT levels in bronchoalveolar lavage (BAL) fluid of AIA patients correlated uniquely with bronchial counts of LTC4 synthase+ cells
      explanation: Supports an association with baseline output, not an independently perturbed causal mediator.
      directness: INDIRECT
- name: Increased Platelet-Leukocyte Adherence
  biological_scale: CELLULAR
  description: Increased platelet attachment to circulating myeloid leukocytes and colocalization in nasal polyps are observed in AERD. The platelet-intrinsic LTC4 synthase activity was not higher than in aspirin-tolerant controls. Enhanced adhesion-receptor expression on platelet-associated cells occurred across groups, not uniquely in AERD.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
    reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: the percentages of platelet-adherent eosinophils, neutrophils, and monocytes in the blood of subjects with AERD were much higher than in either the ATA or the nonasthmatic controls
    explanation: The blood study compared 15 AERD, 13 aspirin-tolerant asthma and 9 nonasthmatic participants; tissue comparisons were smaller.
  downstream:
  - target: Enhanced Transcellular Cysteinyl Leukotriene Synthesis
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Attachment brings platelet terminal synthase together with leukocyte-derived precursor; removal and add-back experiments support a contribution in isolated cell preparations.
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
      reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%
      explanation: Platelet stripping reduces stimulated cysteinyl leukotriene output in three AERD preparations.
      directness: INDIRECT
    intermediate_mechanisms:
    - transfer of leukocyte-derived LTA4 to adherent platelets
    - conversion of LTA4 by platelet LTC4 synthase
  cell_types:
  - preferred_term: platelet
    term:
      id: CL:0000233
      label: platelet
- name: Enhanced Transcellular Cysteinyl Leukotriene Synthesis
  biological_scale: CELLULAR
  description: Adherent platelets provide LTC4 synthase activity and augment stimulated leukotriene generation by isolated granulocytes. Trypsin removal reduced output and platelet add-back restored robust synthesis. This ex vivo contribution does not prove that adhesion is the sole source of systemic leukotriene excess or that antiplatelet therapy is effective.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
    reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%
    explanation: Platelet removal reduces stimulated cysteinyl leukotriene output in AERD preparations.
  downstream:
  - target: Increased Cysteinyl Leukotriene Availability
    causal_link_type: DIRECT
    description: Increased transcellular synthesis contributes to the available cysteinyl leukotriene pool; its quantitative contribution in vivo remains uncertain.
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
      reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%
      explanation: Platelet removal reduces stimulated cysteinyl leukotriene output in AERD preparations.
- name: Increased Cysteinyl Leukotriene Availability
  biological_scale: TISSUE
  description: Airway cysteinyl leukotrienes and urinary LTE4 are increased at baseline and can rise further during COX-1-inhibitor reactions. Multiple cellular sources and altered synthesis/regulation contribute. Urinary LTE4 is a systemic readout, not a specific measure of one cell type or a stand-alone diagnostic test.
  evidence:
  - reference: url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    reference_title: https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Lysine-aspirin challenge released additional cys-LTs into BAL fluid in AIA patients
    explanation: BAL assays document an additional mediator rise after challenge in the selected cohort.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: N-ERD patients have elevated levels of cysLTs
    explanation: Summarizes the mediator excess in human N-ERD.
  chemical_entities:
  - preferred_term: leukotriene C4
    term:
      id: CHEBI:16978
      label: leukotriene C4
  downstream:
  - target: Enhanced Cysteinyl Leukotriene Receptor Signaling
    causal_link_type: DIRECT
    description: Increased ligands engage cysteinyl leukotriene receptors, whose ligand preferences and tissue distribution differ.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
      explanation: Summarizes receptor-mediated effects of the cysteinyl leukotrienes.
- name: Enhanced Cysteinyl Leukotriene Receptor Signaling
  biological_scale: MOLECULAR
  description: Cysteinyl leukotrienes activate CysLT1, CysLT2 and CysLT3/GPR99 pathways with differing ligand preferences. These receptors support bronchomotor, vascular and inflammatory responses. A CysLT1 antagonist does not block every leukotriene receptor or suppress synthesis.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
    explanation: Distinguishes CysLT receptor activation from mediator production.
  downstream:
  - target: Airway Smooth Muscle Contraction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Receptor signaling promotes contraction of bronchial smooth muscle.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
      explanation: Distinguishes CysLT receptor activation from mediator production.
    intermediate_mechanisms:
    - contractile signaling in bronchial smooth-muscle cells
  - target: Increased Airway Vascular Permeability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Receptor signaling increases vascular permeability in the airway.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
      explanation: Distinguishes CysLT receptor activation from mediator production.
    intermediate_mechanisms:
    - endothelial barrier responses
  - target: Increased Airway IL-33 Availability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: A leukotriene-dependent increase in airway IL-33 is supported in dust-mite-primed Ptges-null mice. The human route, cellular receptor and intervening inflammatory effects are not established by this experiment.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: The lungs of the ptges−/−/ltc4s−/− mice also contained substantially less IL-33 protein than did the lungs of the ptges−/− controls
      explanation: Whole-body Ltc4s deletion lowers IL-33 in the model; it is not a direct epithelial receptor perturbation.
      directness: INDIRECT
    hypothesis_groups:
    - leukotriene_il33_amplification
- name: Increased Airway IL-33 Availability
  biological_scale: TISSUE
  description: Full-length and smaller IL-33 protein forms are increased in AERD nasal polyps. Epithelial staining is prominent, but sorted fibroblast and endothelial preparations also contain transcript. Protein abundance and cleavage-band size do not directly measure release or biologic activity.
  evidence:
  - reference: PMID:26342029
    reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Both the full-length form and the 18–21 kDa forms were more abundant in polyps from subjects with AERD than from controls
    explanation: Human polyp lysates show greater IL-33 protein abundance. All surgical subjects received preoperative prednisone.
  downstream:
  - target: Enhanced IL-33-ST2 Signaling
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Available extracellular IL-33 can engage ST2. Translation from greater tissue abundance to increased released, active ligand remains inferred in human AERD.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: These cytokines act directly on ILC2s, mast cells, and Th2 cells to drive T2I.
      explanation: Alarmin action provides the receptor-signaling context; human tissue abundance alone is not a release assay.
      directness: INDIRECT
    hypothesis_groups:
    - leukotriene_il33_amplification
- name: Enhanced IL-33-ST2 Signaling
  biological_scale: MOLECULAR
  description: IL-33/ST2 signaling is implicated by human polyp activation signatures and by blockade of aspirin- and LTE4-associated responses in Ptges-null mice. The experiments do not identify a necessary epithelial source or establish a mast-cell-specific ST2 requirement in patients.
  evidence:
  - reference: PMID:26342029
    reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2
    explanation: Anti-IL-33 and soluble ST2-Fc pretreatment inhibit mediator responses in the dust-mite-primed mouse model.
  downstream:
  - target: Mast Cell Activation
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: IL-33 blockade and soluble ST2-Fc reduce mast-cell-associated mediator release in the mouse model. Human cellular mediation remains an extrapolation.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2
      explanation: Anti-IL-33 and soluble ST2-Fc pretreatment inhibit mediator responses in the dust-mite-primed mouse model.
    hypothesis_groups:
    - leukotriene_il33_amplification
  - target: Type 2 Lymphoid Cell Activation
    causal_link_type: DIRECT
    description: IL-33 can activate type 2 innate lymphoid and T-helper cells; its necessary contribution in individual human AERD patients is unresolved.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: These cytokines act directly on ILC2s, mast cells, and Th2 cells to drive T2I.
      explanation: Reviewed alarmin stimulation supports this cellular route.
- name: Enhanced TSLP Signaling
  biological_scale: MOLECULAR
  description: Increased sinonasal TSLP expression and cultured mast-cell responses implicate TSLP signaling in the inflammatory network. Human correlations do not establish that TSLP is the initiating lesion or that every patient has the same dependence.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: Nasal polyp levels of TSLP mRNA correlate with mast cell-related transcripts and with urinary PGD2 metabolites, and TSLP stimulates human mast cells to generate PGD2 ex vivo
    explanation: Separates human tissue correlations from the ex vivo mast-cell perturbation.
  - reference: PMID:41309110
    reference_title: Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The epithelial alarmin TSLP was markedly elevated in N‐ERD patients as compared to CRSwNP and DC already after 60 min of symptom onset
    explanation: In the small challenge substudy, a nasal mediator increase was measured; no lineage-specific source or necessity was tested.
  downstream:
  - target: Mast Cell Activation
    causal_link_type: DIRECT
    description: TSLP stimulation promotes a mediator-producing mast-cell state in human culture experiments.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: Nasal polyp levels of TSLP mRNA correlate with mast cell-related transcripts and with urinary PGD2 metabolites, and TSLP stimulates human mast cells to generate PGD2 ex vivo
      explanation: Separates human tissue correlations from the ex vivo mast-cell perturbation.
  - target: Type 2 Lymphoid Cell Activation
    causal_link_type: DIRECT
    description: TSLP can stimulate type 2 lymphoid cells in the broader alarmin network.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: These cytokines act directly on ILC2s, mast cells, and Th2 cells to drive T2I.
      explanation: Reviewed alarmin effects support this cellular step.
- name: Mast Cell Activation
  biological_scale: CELLULAR
  description: Airway mast-cell activation releases lipid and granule mediators. Both innate and IgE-associated activation programs may contribute; this does not make cross-reactive COX-1-inhibitor reactions a drug-specific IgE allergy.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: a high degree of activation in nasal polyp mast cells, with enrichment for both IgE- and IL-33-driven transcriptional signatures.
    explanation: Human single-cell transcriptional observations support mast-cell activation, not one exclusive upstream trigger.
  cell_types:
  - preferred_term: mast cell
    term:
      id: CL:0000097
      label: mast cell
  downstream:
  - target: Increased PGD2 Production
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Activated mast cells contribute PGD2, although they are not its exclusive source.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: PGD2 is the dominant COX product of mast cells and tuft/brush cells and is also generated in lesser amounts by eosinophils, T helper type 2 (Th2) cells (30), and ILC2s(31).
      explanation: Reviews the cellular sources of PGD2.
    intermediate_mechanisms:
    - cyclooxygenase-dependent prostanoid synthesis
    - PGD synthase activity
  - target: Increased Cysteinyl Leukotriene Availability
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Activated mast cells contribute cysteinyl leukotrienes; anti-IgE stimulation of cultured AERD donor cells increases their release.
    evidence:
    - reference: PMID:17508965
      reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: mast cells from AERD patients produced significantly more cys-LTs (6.9 +/- 2.0 ng/10(6) cells) than normal and ATA subjects
      explanation: This difference was measured after anti-IgE stimulation, not at basal culture conditions.
    intermediate_mechanisms:
    - 5-lipoxygenase-dependent LTA4 production
    - LTC4 synthase-dependent conjugation
- name: Increased PGD2 Production
  biological_scale: TISSUE
  description: PGD2 output is increased in AERD and can rise during aspirin reactions despite COX-1 inhibition. It contributes bronchoconstrictor and inflammatory actions. Negative CRTH2-antagonist trials caution against equating receptor biology with established clinical benefit.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls, and often paradoxically increase in parallel with LTE4 during reactions to aspirin
    explanation: Human metabolite observations support enhanced prostanoid output; urinary metabolites do not uniquely identify source cells.
  downstream:
  - target: Airway Smooth Muscle Contraction
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: PGD2 promotes bronchoconstriction, including through thromboxane-prostanoid receptor signaling; model antagonist data do not establish PGD2 as the sole ligand.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: PGE2 exerts anti-inflammatory effects while PGD2 is a potent bronchoconstrictor and pro-inflammatory mediator produced mainly by mast cells.
      explanation: Reviews PGD2 bronchomotor activity.
    intermediate_mechanisms:
    - prostanoid receptor signaling
  - target: Type 2 Lymphoid Cell Activation
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: PGD2 can recruit and activate type 2 lymphoid cells through CRTH2; this route is not proven to dominate chronic polyp disease.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: PGD2 induces chemotaxis of Th2 cells (34) and ILC2s (35) and elicits their production of cytokines (35, 36), and also elicits eosinophil and basophil chemotaxis (34).
      explanation: Reviews chemotaxis and cytokine-response assays.
    intermediate_mechanisms:
    - CRTH2 signaling
- name: Type 2 Lymphoid Cell Activation
  biological_scale: CELLULAR
  description: Type 2 lymphoid cells, including ILC2s and Th2 cells, contribute cytokines to the airway network. Challenge-associated redistribution of ILC2s is observed in humans, whereas depletion-based necessity was tested in mice.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: REVIEW_SYNTHESIS
    snippet: large quantities of IL-5, IL-13 and other cytokines in response to both innate cytokines (IL-33, thymic stromal lymphopoietin (TSLP), IL-25) and lipid mediators.
    explanation: The reviewed ILC2 biology supports cytokine production after innate stimulation.
  downstream:
  - target: Enhanced IL-5 Signaling
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Type 2 lymphoid cytokine production supplies IL-5.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: REVIEW_SYNTHESIS
      snippet: large quantities of IL-5, IL-13 and other cytokines in response to both innate cytokines (IL-33, thymic stromal lymphopoietin (TSLP), IL-25) and lipid mediators.
      explanation: The reviewed ILC2 biology supports cytokine production after innate stimulation.
    intermediate_mechanisms:
    - IL-5 secretion and receptor engagement
  - target: Enhanced IL-4R-Alpha Signaling
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: Type 2 lymphoid cytokines supply IL-13 and related IL-4R-alpha ligands; mast cells are an additional IL-13 source.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: RNA-sequencing has revealed that mast cells and Th2 cells are the principal sources of IL-13 in the nasal polyps
      explanation: Identifies tissue cytokine sources, while receptor activity is inferred from broader functional evidence.
    intermediate_mechanisms:
    - IL-13 secretion
    - engagement of IL-4R-alpha-containing receptors
  cell_types:
  - preferred_term: group 2 innate lymphoid cell
    term:
      id: CL:0001069
      label: group 2 innate lymphoid cell
- name: Enhanced IL-5 Signaling
  biological_scale: MOLECULAR
  description: IL-5 signaling contributes to eosinophil development and survival in type 2 airway inflammation. IL5RA transcripts on additional polyp cell types do not by themselves demonstrate functional IL-5 responses in those cells.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: IL-5, produced by activated Th2 cells, ILCs, and mast cells, is elevated in the respiratory tissues of patients with AERD relative to controls and is required for the development of tissue eosinophilia.
    explanation: The review links elevated tissue IL-5 with tissue eosinophilia.
  downstream:
  - target: Eosinophilic Airway Infiltration
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES
    description: IL-5 supports the eosinophilic compartment through production and survival pathways; recruitment also depends on chemotactic signals.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: IL-5, produced by activated Th2 cells, ILCs, and mast cells, is elevated in the respiratory tissues of patients with AERD relative to controls and is required for the development of tissue eosinophilia.
      explanation: The review links elevated tissue IL-5 with tissue eosinophilia.
    intermediate_mechanisms:
    - eosinophil differentiation
    - eosinophil survival
- name: Enhanced IL-4R-Alpha Signaling
  biological_scale: MOLECULAR
  description: IL-4 and IL-13 signal through receptors containing IL-4R-alpha. Elevated nasal cytokines and epithelial response signatures support this pathway in AERD. Its pleiotropic effects are not reduced to a single established epithelial-to-polyp sequence.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: IL-4 and IL-13 are critical to the pathogenesis of T2I, signal through a shared common receptor subunit, IL-4Rα, and are elevated in the nasal fluid of AERD patients compared to controls
    explanation: Connects elevated airway cytokines with the common receptor pathway targeted by dupilumab.
  downstream:
  - target: Nasal polyposis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: IL-4R-alpha signaling contributes to the inflammatory process sustaining polyps; receptor blockade improves polyp burden, but the necessary intermediate cells and remodeling steps are incompletely resolved.
    evidence:
    - reference: PMID:36549708
      reference_title: Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: PRIMARY_RESULT
      snippet: Polyp burden was significantly reduced
      explanation: The clinical intervention supports pathway involvement in polyp burden rather than a single cellular mediator.
      directness: INDIRECT
  - target: Asthma
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Blocking this receptor pathway improves lower-airway disease in selected AERD cohorts; multiple cellular intermediates may contribute.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Treatment with dupilumab, a humanized antibody against IL-4Rα, leads to robust improvements in upper and lower respiratory tract symptoms in AERD patients, including improved sense of smell, reduced nasal polyp size, and improved lung function
      explanation: Reviews clinical effects consistent with pathway involvement.
      directness: INDIRECT
- name: Eosinophilic Airway Infiltration
  biological_scale: TISSUE
  description: 'Eosinophils accumulate in airway tissue and provide mediator-producing cells. Their presence does not establish that eosinophils alone cause polyps: marked depletion in a small CRSwNP study, including AERD, did not improve polyp size or smell.'
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Eosinophilia is a prominent histologic feature of CRSwNP and asthma, especially in AERD
    explanation: Histologic eosinophilia is distinct from a universal elevated blood count.
  cell_types:
  - preferred_term: eosinophil
    term:
      id: CL:0000771
      label: eosinophil
- name: Airway Smooth Muscle Contraction
  biological_scale: TISSUE
  description: Contraction of bronchial smooth muscle narrows the airways during acute mediator-driven reactions. Chronic asthma has additional inflammatory and structural components.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
    explanation: Reviews bronchial smooth-muscle contraction after cysteinyl leukotriene receptor stimulation.
  downstream:
  - target: Aspirin-induced respiratory reaction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Smooth-muscle contraction contributes to the bronchospastic component of the exposure-related reaction; upper-airway reactions can occur without bronchospasm.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
      explanation: Clinical bronchospasm is the manifestation of acute bronchomotor narrowing.
  - target: Wheezing
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Airway narrowing can produce expiratory wheeze.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Exam findings of expiratory wheeze and hyperinflation are supportive.
      explanation: The asthma assessment identifies wheeze; the bronchomotor connection is physiologic inference.
      directness: INDIRECT
  - target: Dyspnea
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Bronchomotor narrowing contributes to breathlessness during lower-airway reactions.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Asthma – The diagnosis requires a history of symptoms including cough, shortness of breath, wheeze, and/or chest tightness and evidence of variable airflow obstruction and/or airway hyperresponsiveness.
      explanation: Clinical airflow obstruction and breathlessness support an indirect symptom link.
      directness: INDIRECT
- name: Increased Airway Vascular Permeability
  biological_scale: TISSUE
  description: Cysteinyl leukotriene signaling increases vascular permeability, contributing to airway edema and upper-airway symptoms. Nasal obstruction also reflects fixed polyp burden and other inflammatory effects.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: 'Cysteinyl LTs (CysLTs) differentially stimulate 3 cysLT receptors: CysLT1R (LTD4), CysLT2R (LTC4), and CysLT3R/GPR99 (LTE4) contracting bronchial smooth muscles, increasing vascular permeability, and activating inflammatory cell influx.'
    explanation: Reviews vascular permeability effects of cysteinyl leukotriene receptors.
  downstream:
  - target: Nasal obstruction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: Mediator-associated edema contributes to congestion during acute reactions; chronic obstruction has additional causes.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
      explanation: The acute clinical syndrome supports the manifestation; edema as mediator is inferred from receptor physiology.
      directness: INDIRECT
phenotypes:
- name: Asthma
  category: Respiratory
  description: Asthma is a core lower-airway component, often beginning in adulthood. Severity and timing vary; all components of the triad need not already be present at first recognition.
  phenotype_term:
    preferred_term: Asthma
    term:
      id: HP:0002099
      label: Asthma
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors.
    explanation: The clinical statement identifies asthma in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Nasal polyposis
  category: Respiratory
  description: Bilateral polyps are characteristic and may recur after surgery. Early or partial presentations can precede the full triad.
  phenotype_term:
    preferred_term: Nasal polyposis
    term:
      id: HP:0100582
      label: Nasal polyposis
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors.
    explanation: The clinical statement identifies nasal polyposis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Chronic rhinosinusitis
  category: Respiratory
  description: Persistent sinonasal inflammation, obstruction and discharge accompany the characteristic polyp disease.
  phenotype_term:
    preferred_term: Chronic rhinosinusitis
    term:
      id: HP:0011109
      label: Chronic sinusitis
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors.
    explanation: The clinical statement identifies chronic rhinosinusitis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Aspirin-induced respiratory reaction
  category: Respiratory
  description: Acute respiratory reactions to strong COX-1 inhibitors distinguish N-ERD from NSAID-tolerant airway disease. Upper-airway symptoms, bronchospasm or both may occur.
  phenotype_term:
    preferred_term: Aspirin-induced respiratory reaction
    term:
      id: HP:0012042
      label: Aspirin-induced asthma
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: The clinical statement identifies aspirin-induced respiratory reaction in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Nasal obstruction
  category: Respiratory
  description: Persistent obstruction occurs with chronic sinonasal disease; abrupt congestion can accompany an NSAID reaction.
  phenotype_term:
    preferred_term: Nasal obstruction
    term:
      id: HP:0001742
      label: Nasal congestion
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: The clinical statement identifies nasal obstruction in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Rhinorrhea
  category: Respiratory
  description: Nasal discharge can occur chronically and increase during acute reactions.
  phenotype_term:
    preferred_term: Rhinorrhea
    term:
      id: HP:0031417
      label: Rhinorrhea
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: The clinical statement identifies rhinorrhea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Sneezing
  category: Respiratory
  description: Sneezing is an upper-airway manifestation during some acute NSAID reactions.
  phenotype_term:
    preferred_term: Sneezing
    term:
      id: HP:0025095
      label: Sneeze
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: The clinical statement identifies sneezing in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Chemosis
  category: Ophthalmologic
  description: Conjunctival swelling can accompany an acute reaction.
  phenotype_term:
    preferred_term: Chemosis
    term:
      id: HP:0012375
      label: Chemosis
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: The clinical statement identifies chemosis in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Wheezing
  category: Respiratory
  description: Expiratory wheeze reflects lower-airway disease and can accompany acute bronchospasm.
  phenotype_term:
    preferred_term: Wheezing
    term:
      id: HP:0030828
      label: Wheezing
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Asthma – The diagnosis requires a history of symptoms including cough, shortness of breath, wheeze, and/or chest tightness and evidence of variable airflow obstruction and/or airway hyperresponsiveness.
    explanation: The clinical statement identifies wheezing in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Dyspnea
  category: Respiratory
  description: Breathlessness accompanies variable lower-airway obstruction.
  phenotype_term:
    preferred_term: Dyspnea
    term:
      id: HP:0002094
      label: Dyspnea
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Asthma – The diagnosis requires a history of symptoms including cough, shortness of breath, wheeze, and/or chest tightness and evidence of variable airflow obstruction and/or airway hyperresponsiveness.
    explanation: The clinical statement identifies dyspnea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Cough
  category: Respiratory
  description: Cough can be part of the asthma presentation.
  phenotype_term:
    preferred_term: Cough
    term:
      id: HP:0012735
      label: Cough
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Asthma – The diagnosis requires a history of symptoms including cough, shortness of breath, wheeze, and/or chest tightness and evidence of variable airflow obstruction and/or airway hyperresponsiveness.
    explanation: The clinical statement identifies cough in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Anosmia
  category: Neurologic
  description: Loss of smell is a characteristic sinonasal manifestation; objective smell-test improvements describe cohort averages rather than universal recovery.
  phenotype_term:
    preferred_term: Anosmia
    term:
      id: HP:0000458
      label: Anosmia
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: CRSwNP – The diagnosis requires a history of symptoms including persistent nasal obstruction, anosmia, and anterior or posterior discharge.
    explanation: The clinical statement identifies anosmia in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Eosinophilia
  category: Hematologic
  description: Elevated blood eosinophils are common but neither sufficiently sensitive nor specific to establish N-ERD. Blood counts are distinct from tissue infiltration.
  phenotype_term:
    preferred_term: Eosinophilia
    term:
      id: HP:0001880
      label: Increased total eosinophil count
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD.
    explanation: The clinical statement identifies eosinophilia in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Urticaria
  category: Dermatologic
  description: Reported in the mixed N-ERD subset, often with COX-1-inhibitor exposure; this is not a feature required in every patient.
  phenotype_term:
    preferred_term: Urticaria
    term:
      id: HP:0001025
      label: Urticaria
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies urticaria in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Angioedema
  category: Dermatologic
  description: Reported in the mixed N-ERD subset, often with COX-1-inhibitor exposure; this is not a feature required in every patient.
  phenotype_term:
    preferred_term: Angioedema
    term:
      id: HP:0100665
      label: Angioedema
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies angioedema in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Pruritus
  category: Dermatologic
  description: Reported in the mixed N-ERD subset, often with COX-1-inhibitor exposure; this is not a feature required in every patient.
  phenotype_term:
    preferred_term: Pruritus
    term:
      id: HP:0000989
      label: Pruritus
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies pruritus in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Abdominal pain
  category: Gastrointestinal
  description: An extra-respiratory manifestation reported in the mixed N-ERD reaction spectrum; no individual-feature prevalence is inferred from the proportion with any extra-respiratory symptom.
  phenotype_term:
    preferred_term: Abdominal pain
    term:
      id: HP:0002027
      label: Abdominal pain
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies abdominal pain in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Nausea
  category: Gastrointestinal
  description: An extra-respiratory manifestation reported in the mixed N-ERD reaction spectrum; no individual-feature prevalence is inferred from the proportion with any extra-respiratory symptom.
  phenotype_term:
    preferred_term: Nausea
    term:
      id: HP:0002018
      label: Nausea
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies nausea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Vomiting
  category: Gastrointestinal
  description: An extra-respiratory manifestation reported in the mixed N-ERD reaction spectrum; no individual-feature prevalence is inferred from the proportion with any extra-respiratory symptom.
  phenotype_term:
    preferred_term: Vomiting
    term:
      id: HP:0002013
      label: Vomiting
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies vomiting in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
- name: Diarrhea
  category: Gastrointestinal
  description: An extra-respiratory manifestation reported in the mixed N-ERD reaction spectrum; no individual-feature prevalence is inferred from the proportion with any extra-respiratory symptom.
  phenotype_term:
    preferred_term: Diarrhea
    term:
      id: HP:0002014
      label: Diarrhea
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Extra-respiratory symptoms can include a pruritic macular cutaneous eruption, urticaria, angioedema, angina-like chest pain, abdominal pain, nausea, vomiting, and diarrhea.
    explanation: The clinical statement identifies diarrhea in the specified respiratory or mixed-reaction context; it does not provide an individual-feature prevalence.
inheritance:
- name: Multifactorial
  description: AERD is generally an acquired complex disorder with minimal reported heritability. Candidate genetic and epigenetic associations do not establish a monogenic cause, and no clinically diagnostic genotype is defined by these sources.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The adult onset of AERD, along with its minimal heritability, and intransient nature are consistent with a contribution from epigenetic changes, perhaps as a result of a prior insult.
    explanation: Minimal heritability and proposed epigenetic contributions are distinct from a demonstrated inherited causal allele.
biochemical:
- name: Urinary leukotriene E4
  presence: INCREASED
  context: A stable excreted cysteinyl leukotriene product that can be elevated at baseline and rise during reactions. It is an adjunctive systemic pathway readout, not a specific cell-source assay or stand-alone diagnostic/predictive test. Treatment-associated changes do not establish causal mediation of tolerance.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Additional measurement of urinary LTE4 levels is useful, but not sufficient, for the diagnosis of N-ERD.
    explanation: The guideline explicitly limits diagnostic sufficiency.
  readouts:
  - target: Increased Cysteinyl Leukotriene Availability
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Urinary LTE4 reflects systemic cysteinyl leukotriene generation with assay and clinical-context limitations.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Additional measurement of urinary LTE4 levels is useful, but not sufficient, for the diagnosis of N-ERD.
      explanation: Supports an adjunctive pathway biomarker rather than a definitive threshold.
- name: Urinary PGD2 metabolites
  presence: INCREASED
  context: Elevated metabolites can indicate increased prostanoid production at baseline or during reactions, but do not uniquely identify mast cells or establish a diagnostic threshold.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls, and often paradoxically increase in parallel with LTE4 during reactions to aspirin
    explanation: Documents the human mediator pattern.
  readouts:
  - target: Increased PGD2 Production
    relationship: READOUT_OF
    direction: POSITIVE
    endpoint_context: DIAGNOSTIC
    interpretation: Systemic PGD2 metabolite output is a research/adjunctive readout of production, not a validated stand-alone diagnostic test.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The levels of urinary PGD2 metabolites in patients with AERD exceed those in aspirin-tolerant controls
      explanation: Supports the biochemical association.
- name: Exhaled nitric oxide
  presence: INCREASED
  context: FeNO can be elevated in the type 2 airway phenotype, but is neither sensitive nor specific for N-ERD.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD.
    explanation: The threshold is a supportive observation, not a diagnostic criterion.
progression:
- phase: Variable emergence of chronic airway disease
  age_range: Peak incidence in the third and fourth decades; wider ages occur
  notes: Sinonasal symptoms and smell loss often precede asthma. Components develop over months to many years, rather than following a mandatory two-year/five-year sequence.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Each component of the triad can develop over a span of months to many years. Peak incidence is in the third and fourth decade of life, with cases reported as early as puberty onset and as late as the eighth decade of life.
    explanation: Describes both the broad onset range and variable temporal sequence.
- phase: Acute COX-1-inhibitor reaction
  notes: Upper and/or lower respiratory symptoms typically begin 30 minutes to 3 hours after exposure. Mixed presentations can include skin or gastrointestinal symptoms; ongoing asthma and CRSwNP require treatment between reactions.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The respiratory reactions to COX-1 inhibitors involve the acute onset of nasal congestion, rhinorrhea, sneezing, nasal pruritus, ocular chemosis, and/or bronchospasm within 30 min to 3 h of exposure.
    explanation: Provides the acute exposure-to-reaction time window.
diagnosis:
- name: Clinical history and respiratory assessment
  description: Document asthma, sinonasal disease and the timing/reproducibility of reactions to COX-1 inhibitors. A convincing history can establish the diagnosis; partial presentations occur and IgE-mediated single-drug allergy, NSAID-induced urticaria/anaphylaxis and other airway disorders require distinction.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: A clinical diagnosis of N-ERD can often be established by history and physical exam alone.
    explanation: Avoids requiring provocation in every clinically clear case.
- name: Supervised aspirin provocation when indicated
  description: Graded oral aspirin challenge is the reference test when the history is unclear. It requires specialist supervision, stable airway disease and rescue capability. Recent polyp surgery, leukotriene modifiers, systemic corticosteroids or biologics can attenuate reactions; a negative test in these settings needs contextual interpretation. The WAO diagnostic-challenge guidance requires stable patients with FEV1 at least 70% predicted and identifies current beta-blocker treatment as a contraindication.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Oral ASA challenge testing is the gold standard for diagnosing hypersensitivity to NSAIDs, and sensitive and specific for N-ERD.
    explanation: Supports the reference-test role.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: a negative DC does not fully exclude hypersensitivity, especially if the patient has well-controlled asthma, underwent recent surgical excision of nasal polyps, or is taking leukotriene (LT) receptor antagonists or high-dose systemic corticosteroids
    explanation: Identifies circumstances that can reduce reaction severity.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Patients undergoing oral or inhaled DC should be in a stable condition, with an FEV1 ≥ 70% of predicted value.
    explanation: Specifies the diagnostic-challenge respiratory safety criterion.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Current treatment with β-blockers is contraindicated in patients referred to the DC.
    explanation: The contraindication concerns diagnostic drug challenge.
- name: Spirometry and assessment of variable airflow obstruction
  description: Use bronchodilator-response spirometry or serial peak flow to establish and monitor the asthma component; these tests do not independently distinguish AERD from other asthma.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Spirometry with bronchodilator response testing or peak flow monitoring to capture variable airflow obstruction should be the first step.
    explanation: Guideline assessment of the lower-airway component.
- name: Sinonasal endoscopy and selected CT imaging
  description: Endoscopy documents polyps and sinonasal disease. CT is useful when surgery is being considered; routine diagnostic polyp biopsy is not required.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Sinus computed tomography (CT) scans may be reserved for those requiring surgery. Other imaging modalities are not recommended. A diagnosis of nasal polyposis is best established on nasal endoscopy.
    explanation: Defines the roles of endoscopy and surgical-planning imaging.
- name: Adjunctive inflammatory biomarkers
  description: Blood eosinophils, FeNO and urinary LTE4 can support phenotyping but cannot establish or exclude N-ERD alone. No reliable in-vitro diagnostic test replaces clinical evaluation and, when appropriate, challenge.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: No in vitro tests are sensitive or reliable to be recommended in the diagnosis of N-ERD.
    explanation: Limits biomarker and laboratory-test interpretation.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Peripheral blood eosinophilia (>300 cells/μL) and elevated exhaled breath nitric oxide levels (>25 ppb) are common in N-ERD but are neither sensitive nor specific for the diagnosis of N-ERD.
    explanation: Directly supports the limited sensitivity and specificity of the named laboratory findings.
treatments:
- name: Inhaled corticosteroid-based asthma therapy
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: Treat the asthma component with an inhaled corticosteroid-based regimen, adding a long-acting bronchodilator according to severity and control. Continue necessary controller therapy through specialist desensitization. This controls airway disease but does not establish unrestricted NSAID tolerance.
  evidence:
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Inhaled corticosteroids (ICSs) and ICSs combined with long-acting β2-agonists for asthma should be continued during aspirin desensitization.
    explanation: The work-group guidance preserves controller treatment during desensitization.
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Standard medical treatment for AERD focuses on managing the upper and lower respiratory tract symptoms and can include the use of corticosteroids, leukotriene-modifying drugs (LTMDs), and biologics that target type 2 inflammatory cytokines.
    explanation: Identifies corticosteroids as part of routine upper/lower airway management.
  target_mechanisms:
  - target: Asthma
    treatment_effect: MODULATES
    description: Controller therapy treats the lower-airway disease.
    evidence:
    - reference: PMID:33307116
      reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Inhaled corticosteroids (ICSs) and ICSs combined with long-acting β2-agonists for asthma should be continued during aspirin desensitization.
      explanation: The work-group guidance preserves controller treatment during desensitization.
- name: Topical sinonasal corticosteroids and saline irrigation
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: Use topical anti-inflammatory sinonasal therapy and saline irrigation as part of chronic rhinosinusitis care, including after surgery when appropriate. Delivery and adherence matter; extensive polyps may limit topical penetration.
  evidence:
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids.
    explanation: The guidance identifies saline and corticosteroids as topical sinonasal treatments.
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Standard medical treatment for AERD focuses on managing the upper and lower respiratory tract symptoms and can include the use of corticosteroids, leukotriene-modifying drugs (LTMDs), and biologics that target type 2 inflammatory cytokines.
    explanation: Corticosteroids are part of standard upper-airway management.
  target_mechanisms:
  - target: Chronic rhinosinusitis
    treatment_effect: MODULATES
    description: Topical therapy treats sinonasal inflammatory symptoms; saline also clears secretions.
    evidence:
    - reference: PMID:33307116
      reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids.
      explanation: The guidance identifies saline and corticosteroids as topical sinonasal treatments.
- name: Montelukast
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: A CysLT1 receptor antagonist used as an adjunct to airway controller treatment. It can reduce leukotriene-mediated symptoms and blunt reactions during supervised challenge/desensitization, but it does not inhibit leukotriene synthesis or block all CysLT receptors.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: zafirlukast and montelukast, which only block CysLT1R.
    explanation: Identifies receptor specificity rather than inhibition of leukotriene synthesis.
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The use of the leukotriene receptor antagonist montelukast, or the 5-lipooxygenase inhibitor zileuton, can in some instances pharmacologically blunt or sufficiently prevent the clinical manifestations of NSAID-induced reactions so that the reactions are not noticed by the patient.
    explanation: Explains both clinical utility and potential masking of reactions.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: montelukast
      term:
        id: CHEBI:50730
        label: montelukast
  target_mechanisms:
  - target: Enhanced Cysteinyl Leukotriene Receptor Signaling
    treatment_effect: INHIBITS
    description: Blocks the CysLT1 component of the receptor network.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: zafirlukast and montelukast, which only block CysLT1R.
      explanation: Identifies receptor specificity rather than inhibition of leukotriene synthesis.
- name: Zileuton
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: A 5-lipoxygenase inhibitor that reduces leukotriene production. It is a selected adjunct for persistent airway symptoms and can attenuate reactions; its use requires attention to drug-specific contraindications, interactions and monitoring.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Treatment with zileuton, which inhibits 5-LO and decreases production of leukotrienes, attenuates the sinonasal symptoms (16), lung function changes (17), and gastrointestinal and cutaneous symptoms that occur during aspirin-induced reactions in AERD.
    explanation: Identifies the synthetic target and reported clinical effects.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: zileuton
      term:
        id: CHEBI:10112
        label: zileuton
  target_mechanisms:
  - target: Increased Cysteinyl Leukotriene Availability
    treatment_effect: INHIBITS
    description: Reduces leukotriene synthesis upstream of LTC4 synthase.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Treatment with zileuton, which inhibits 5-LO and decreases production of leukotrienes, attenuates the sinonasal symptoms (16), lung function changes (17), and gastrointestinal and cutaneous symptoms that occur during aspirin-induced reactions in AERD.
      explanation: Identifies the synthetic target and reported clinical effects.
- name: Endoscopic sinus surgery
  action_category: THERAPEUTIC
  therapeutic_modality: SURGERY
  description: Consider surgery for substantial or refractory polyp/sinus disease. It removes polyp burden and improves access for topical treatment; recurrence remains possible. It may precede aspirin therapy after desensitization in suitable patients, but every patient does not require the same surgery-plus-aspirin sequence.
  evidence:
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids.
    explanation: Supports mechanical debulking and improved topical access.
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
    reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: From an economic and efficacy perspective, ESS and/or ATAD as initial treatment for patients with NSAID‐ERD should be performed in experienced centres if there are no contraindications
    explanation: The 2026 consensus presents selection-dependent options rather than a mandatory combined regimen.
  treatment_term:
    preferred_term: Endoscopic Sinus Surgery
    term:
      id: NCIT:C157836
      label: Endoscopic Sinus Surgery
  target_mechanisms:
  - target: Nasal polyposis
    treatment_effect: MODULATES
    description: Surgery removes polyps directly; it does not bypass a single established molecular pathway.
    evidence:
    - reference: PMID:33307116
      reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Functional endoscopic sinus surgery (FESS) is also used to debulk nasal polyps and improve topical penetration of saline or corticosteroids.
      explanation: Supports mechanical debulking and improved topical access.
- name: Aspirin desensitization followed by maintenance aspirin
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: 'A specialist option for confirmed AERD with persistent symptoms, recurrent polyps or a separate need for aspirin. Benefits vary by patient and regimen: one 34-person randomized trial reported symptom/medication benefit, whereas a 2025 trial randomizing 26 successfully desensitized participants found no significant between-group difference in SNOT-22, asthma-control or polyp scores over 11 months. That trial used 125 mg daily initially then 250 mg and does not exclude benefit from other regimens. Screen for uncontrolled asthma, ulcer/bleeding risk, pregnancy and ability to adhere. Daily maintenance is needed; more than two missed days requires reassessment before unsupervised resumption.'
  evidence:
  - reference: PMID:26083948
    reference_title: 'Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Symptom scores and medication needs of patients with AERD who have undergone AD were significantly lower compared to the placebo group after 6 months
    explanation: The small randomized study reported benefit under its maintenance regimen.
  - reference: PMID:40726272
    reference_title: Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non-steroidal Anti-inflammatory Drug Exacerbated Respiratory Disease -A Randomized Clinical Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: In the linear mixed effects model, p-values for the combined effect of group and time showed no difference between placebo and ATAD for SNOT-22, ACT, and NPS, with p-values 0.17, 0.45, and 0.18, respectively.
    explanation: A later small randomized trial did not show between-group benefit under its 125-to-250-mg daily protocol.
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: if a desensitized patient misses more than 2 days of aspirin it is strongly recommended they be evaluated for repeat desensitization before resuming therapy.
    explanation: The tolerant state may be lost after interruption.
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
    reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: indication for ATAD is having NSAID‐ERD, for which standard medical treatment is failing to control both the upper and lower airway disease.
    explanation: The consensus frames aspirin maintenance as a selected option.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: acetylsalicylic acid
      term:
        id: CHEBI:15365
        label: acetylsalicylic acid
  target_mechanisms:
  - target: Aspirin-induced respiratory reaction
    treatment_effect: MODULATES
    description: Desensitization establishes a temporary tolerant state that requires ongoing dosing.
    evidence:
    - reference: PMID:33307116
      reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: After patients have been desensitized to aspirin, they should continue taking aspirin daily.
      explanation: Supports maintenance of the desensitized state, with interruption limits stated separately.
- name: Dupilumab
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: An IL-4R-alpha blocker used in eligible uncontrolled asthma/CRSwNP. In an open-label AERD cohort, 7 of 30 tolerated the highest aspirin challenge dose after six months and another 10 tolerated higher doses; this was not universal tolerance or a placebo-controlled comparison. Average polyp, asthma and smell outcomes improved. A nested 11-person 2026 mechanistic analysis found reduced nasal type 2 responses without a cytokine pattern reliably distinguishing tolerance; transcriptional associations do not establish mediation. NSAID use still requires individual specialist assessment.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Treatment with dupilumab, a humanized antibody against IL-4Rα, leads to robust improvements in upper and lower respiratory tract symptoms in AERD patients, including improved sense of smell, reduced nasal polyp size, and improved lung function
    explanation: Supports the target and reported clinical response.
  - reference: PMID:36549708
    reference_title: Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses.
    explanation: Complete tolerance refers to the tested cumulative dose, not all possible exposures.
  - reference: PMID:41309110
    reference_title: Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Interestingly, the development of tolerance was not associated with specific cytokine patterns.
    explanation: The small nested analysis does not validate a type 2 cytokine predictor or mediator of tolerance.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Dupilumab
      term:
        id: NCIT:C162455
        label: Dupilumab
  target_mechanisms:
  - target: Enhanced IL-4R-Alpha Signaling
    treatment_effect: INHIBITS
    description: Blocks IL-4R-alpha-mediated IL-4/IL-13 signaling.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: Treatment with dupilumab, a humanized antibody against IL-4Rα, leads to robust improvements in upper and lower respiratory tract symptoms in AERD patients, including improved sense of smell, reduced nasal polyp size, and improved lung function
      explanation: Supports the target and reported clinical response.
- name: Omalizumab
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: Anti-IgE treatment may be selected under the applicable asthma/CRSwNP indication. A 16-person atopic AERD crossover trial reduced challenge-associated urinary LTE4 and allowed 10 participants to tolerate the highest tested aspirin dose after three months. Six still reacted; generalization to nonatopic or uncontrolled severe disease is limited. Biomarker reductions imply reduced mediator activity but do not directly identify the responsible airway cell population.
  evidence:
  - reference: PMID:32142372
    reference_title: Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Ten of 16 patients (62.5%) developed oral aspirin tolerance up to cumulative doses of 930 mg in the omalizumab phase
    explanation: This was a randomized double-blind crossover study in selected atopic, stable Japanese adults; the primary endpoint was urinary LTE4 log-AUC.
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The mechanisms by which IgE can induce a chronically activated mast cell population, and the antigen specificity of the locally produced IgE remain to be determined.
    explanation: The upstream IgE mechanism and antigen specificity remain unresolved.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Omalizumab
      term:
        id: NCIT:C29299
        label: Omalizumab
  target_mechanisms:
  - target: Mast Cell Activation
    treatment_effect: INHIBITS
    description: Neutralizing IgE can reduce the IgE-associated component of mast-cell activation; this is indirect and does not block all innate triggers.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: These findings support a role for IgE, likely derived locally from plasma cells in the respiratory tract (56), in driving both the steady-state eicosanoid formation and the mast cell-dependent clinical reactions to aspirin
      explanation: The reviewed treatment response supports an IgE contribution with unresolved cellular mediation.
      directness: INDIRECT
- name: Mepolizumab
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: An anti-IL-5 option for appropriately selected eosinophilic asthma/CRSwNP. AERD-specific studies report symptomatic benefit, but aspirin reactions can persist. IL5RA expression on non-eosinophil cells does not itself prove a functional therapeutic mechanism in those cells.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: Open label studies reveal that mepolizumab provides moderate symptomatic benefit for patients with AERD (64, 65), but does not consistently block NSAID-induced reactions (66).
    explanation: The AERD-specific evidence does not guarantee NSAID tolerance.
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Neutralization of IL-5 with the humanized antibody mepolizumab reduces blood and tissue eosinophilia in patients with severe asthma and CRSwNP and improves symptomatic control over placebo.
    explanation: Distinguishes the broader asthma/CRSwNP trial evidence from AERD-specific cohorts.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Mepolizumab
      term:
        id: NCIT:C157376
        label: Mepolizumab
  target_mechanisms:
  - target: Enhanced IL-5 Signaling
    treatment_effect: INHIBITS
    description: Neutralizes IL-5 and reduces downstream eosinophilic signaling.
    evidence:
    - reference: PMID:36184313
      reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Neutralization of IL-5 with the humanized antibody mepolizumab reduces blood and tissue eosinophilia in patients with severe asthma and CRSwNP and improves symptomatic control over placebo.
      explanation: Distinguishes the broader asthma/CRSwNP trial evidence from AERD-specific cohorts.
- name: Acute bronchospasm treatment
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: Promptly treat acute lower-airway reactions with inhaled short-acting bronchodilators and clinical monitoring in an appropriately equipped setting. Severity determines additional emergency treatment; chronic controller therapy is separate.
  evidence:
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Respiratory reactions with shortness of breath and wheezing can be treated with nebulized or meter-dose inhaled short-acting beta agonists, short-acting anticholinergics, short-acting beta-agonist/anticholinergic combination therapy, or intramuscular epinephrine.
    explanation: Provides rescue treatment in the supervised reaction setting.
  target_mechanisms:
  - target: Airway Smooth Muscle Contraction
    treatment_effect: INHIBITS
    description: Bronchodilator rescue opposes acute bronchomotor narrowing.
    evidence:
    - reference: PMID:33307116
      reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Respiratory reactions with shortness of breath and wheezing can be treated with nebulized or meter-dose inhaled short-acting beta agonists, short-acting anticholinergics, short-acting beta-agonist/anticholinergic combination therapy, or intramuscular epinephrine.
      explanation: Provides rescue treatment in the supervised reaction setting.
- name: Emergency treatment of systemic reactions
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: Use intramuscular epinephrine for anaphylactic/systemic reactions, with emergency support according to severity. Isolated upper-airway symptoms are assessed and treated according to their actual presentation.
  evidence:
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Systemic reactions should be treated with intramuscular epinephrine, and very occasionally intravenous fluids are needed.
    explanation: The work group specifies systemic-reaction rescue, not routine epinephrine for every nasal symptom.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: (R)-adrenaline
      term:
        id: CHEBI:28918
        label: (R)-adrenaline
- name: NSAID avoidance and assessment of alternatives
  action_category: COUNSELING_INFORMATIONAL
  therapeutic_modality: OTHER
  description: Counsel patients about strong COX-1 inhibitors and accidental exposure. Selective COX-2 agents are usually tolerated, but tolerance is not guaranteed; high-dose acetaminophen can trigger reactions in a minority. Select an alternative and supervised challenge according to the reaction history and clinical need. Avoidance does not replace asthma and sinonasal care.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: patients with N-ERD almost always tolerate selective COX-2 inhibitors during observed drug challenges
    explanation: Observed tolerance is common rather than absolute.
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: The inhibition of COX-1 by NSAIDs, and high-dose paracetamol (acetaminophen) in a minority of patients, precipitates respiratory tract reactions.
    explanation: High-dose acetaminophen is not uniformly safe.
- name: Shared treatment selection and longitudinal monitoring
  action_category: MONITORING
  therapeutic_modality: OTHER
  description: Coordinate allergy, respiratory and rhinology care. Reassess asthma control, exacerbations, smell, polyp burden, quality of life, treatment adverse effects and adherence. Select surgery, aspirin maintenance or biologics using disease burden, contraindications, comorbid indications, patient preferences and access; comparative superiority is not established by uncontrolled cohorts or indirect network comparisons.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
    reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: The treatment approach thus should be based on shared decision‐making, considering the patient's clinical characteristics, the likelihood of patient adherence, the availability of endoscopic sinus surgery options, the cost of the medications, and access to biologic therapies
    explanation: The 2026 consensus supports individualized treatment selection.
- name: Tezepelumab
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: A TSLP-blocking option for patients meeting a relevant severe-asthma indication. In the 52-week NAVIGATOR analysis, the post hoc subgroup with a history of aspirin or NSAID sensitivity had an estimated 83% lower annualized exacerbation rate than placebo (95% CI 66–91). This subgroup is distinct from the smaller recorded AERD/N-ERD/Samter triad subgroup. No formal hypothesis testing or between-biologic comparison was performed; the result does not establish aspirin tolerance or superiority for challenge-confirmed AERD.
  evidence:
  - reference: PMID:38802635
    reference_title: Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: 'Reductions with tezepelumab compared with placebo in patients with asthma‑related comorbidities ranged from 58% (95% CI: 47, 67) in patients with rhinitis to 83% (95% CI: 66, 91) in patients with aspirin or NSAID sensitivity'
    explanation: The reported NSAID-sensitivity subgroup result is exploratory, distinct from a prospectively powered challenge-confirmed AERD trial.
  - reference: PMID:38802635
    reference_title: Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: No formal hypothesis testing was performed to compare tezepelumab with placebo or to compare effects between the subgroups investigated.
    explanation: Limits the exploratory subgroup comparisons.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Tezepelumab
      term:
        id: NCIT:C152582
        label: Tezepelumab
  target_mechanisms:
  - target: Enhanced TSLP Signaling
    treatment_effect: INHIBITS
    description: Neutralizes TSLP signaling; this target is broader than the source or trigger of airway TSLP production.
    evidence:
    - reference: PMID:38802635
      reference_title: Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: BACKGROUND
      snippet: Tezepelumab binds specifically to thymic stromal lymphopoietin (TSLP)
      explanation: The article describes the established pharmacological target.
- name: Benralizumab
  action_category: THERAPEUTIC
  therapeutic_modality: MONOCLONAL_ANTIBODY
  description: An IL-5R-alpha-directed antibody that can be selected for a qualifying eosinophilic-asthma indication. Eosinophil depletion and asthma benefit do not establish universal control of polyp disease or aspirin tolerance. A small retrospective NSAID-ERD series mixing benralizumab, mepolizumab and reslizumab reported substantial nonresponse; those pooled observations do not provide a drug-specific response rate or a head-to-head comparison.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
    reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Benralizumab is a humanized IgG1κ antibody that binds to and inhibits extracellular IL‐5Rα, preventing IL‐5 signaling
    explanation: Identifies the receptor-directed action, distinct from ligand neutralization by mepolizumab.
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: the modest therapeutic efficacy of anti-IL-5 treatments, such as benralizumab, mepolizumab, or reslizumab
    explanation: The review describes limited clinical efficacy and cautions against an eosinophil-only account of disease.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: Benralizumab
      term:
        id: NCIT:C88594
        label: Benralizumab
  target_mechanisms:
  - target: Enhanced IL-5 Signaling
    treatment_effect: INHIBITS
    description: Blocks IL-5 receptor signaling and supports depletion of receptor-bearing eosinophils.
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
      reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
      supports: SUPPORT
      evidence_source: OTHER
      quote_role: REVIEW_SYNTHESIS
      snippet: Benralizumab is a humanized IgG1κ antibody that binds to and inhibits extracellular IL‐5Rα, preventing IL‐5 signaling
      explanation: Identifies the receptor-directed action, distinct from ligand neutralization by mepolizumab.
- name: Selected short-course systemic corticosteroids
  action_category: THERAPEUTIC
  therapeutic_modality: SMALL_MOLECULE
  description: Systemic corticosteroids may be needed for severe airway exacerbations or reactions, selected according to presentation. They are an adjunct to immediate rescue when indicated; cumulative exposure and adverse effects should inform long-term steroid-sparing treatment decisions.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
    reference_title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Consider systemic corticosteroids for severe reactions
    explanation: The consensus desensitization protocol identifies systemic steroids as a severity-dependent adjunct.
  - reference: PMID:33307116
    reference_title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: REVIEW_SYNTHESIS
    snippet: Standard medical treatment for AERD focuses on managing the upper and lower respiratory tract symptoms and can include the use of corticosteroids, leukotriene-modifying drugs (LTMDs), and biologics that target type 2 inflammatory cytokines.
    explanation: Corticosteroids remain among the medical options for upper and lower airway disease.
environmental:
- name: Aspirin and other strong COX-1 inhibitors
  description: Exposure can trigger an acute reaction in susceptible patients. This is distinct from causing the underlying chronic airway disease.
  influences_mechanisms:
  - target: Pharmacological COX-1 Inhibition
    environmental_effect: TRIGGERS
    causal_link_type: DIRECT
    description: The drug inhibits COX-1 activity, initiating the acute pharmacologic perturbation.
    evidence:
    - reference: PMID:40837856
      reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      quote_role: REVIEW_SYNTHESIS
      snippet: The inhibition of COX-1 by NSAIDs, and high-dose paracetamol (acetaminophen) in a minority of patients, precipitates respiratory tract reactions.
      explanation: Identifies the exposure and target-linked acute response.
  evidence:
  - reference: PMID:40837856
    reference_title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: N-ERD is characterized by the triad of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and respiratory reactions to cyclooxygenase (COX)-1 inhibitors.
    explanation: Defines the characteristic triggering drug class.
discussions:
- discussion_id: aerd_initiating_lesion
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Reduced Respiratory PGE2 Availability
  - pathophysiology#Increased Bronchial LTC4 Synthase-Positive Cells
  - pathophysiology#Reduced Inflammatory-Cell EP2 Abundance
  prompt: What initiates the acquired chronic airway phenotype and determines which mediator abnormalities are causal?
  rationale: Cell counts, receptor abundance, urinary mediators and tissue transcriptional programs are measured in established disease. They do not identify a single first lesion or explain every clinical presentation. Genetic susceptibility and epigenetic observations do not establish a diagnostic monogenic cause.
- discussion_id: aerd_desensitization_mechanism
  kind: KNOWLEDGE_GAP
  attaches_to:
  - treatments#Aspirin desensitization followed by maintenance aspirin
  prompt: Which mechanisms and patient characteristics determine benefit from maintenance aspirin?
  rationale: Clinical effects vary between regimens and trials. Aspirin maintenance does not consistently suppress cysteinyl leukotriene production; lack of changes in three serum cytokines does not exclude local or unmeasured immune effects. Safe patient selection and maintained tolerance are separate from proving disease modification.
  evidence:
  - reference: PMID:26083948
    reference_title: 'Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.'
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: no significant difference was observed in serum concentration of IL-10, IFN-γ, and TGF-β between two groups neither at baseline nor at the end of study
    explanation: Limits the measured systemic cytokine response without excluding other mechanisms.
- discussion_id: aerd_eosinophil_mediation
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Eosinophilic Airway Infiltration
  - phenotypes#Nasal polyposis
  prompt: Which inflammatory cells and remodeling processes are necessary for persistent polyp disease?
  rationale: Tissue eosinophilia is prominent, but depletion need not improve polyps. Likewise, mediator biology and receptor activation do not guarantee efficacy of a proposed blocking drug.
  evidence:
  - reference: PMID:36184313
    reference_title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: In an open-label study of 16 patients with CRSwNP, several of whom had AERD, dexpramipexole induced a 97% reduction from baseline in nasal polyp tissue eosinophilia. Nonetheless, there was no significant reduction in nasal polyp score, nor any significant improvement in measures of olfaction or measures of sinus disease symptoms
    explanation: The small mixed CRSwNP study limits an eosinophil-only explanation.
- discussion_id: aerd_tolerance_biomarkers
  kind: KNOWLEDGE_GAP
  attaches_to:
  - treatments#Dupilumab
  - biochemical#Urinary leukotriene E4
  prompt: Can a reproducible biomarker predict aspirin tolerance during biologic therapy?
  rationale: In the 2026 nested challenge study, ten NSAID-tolerant CRSwNP controls lacked asthma and disease controls were younger. N-ERD kinetics were aligned to reaction onset while controls were aligned to dosing; repeat challenge was only in the 11 N-ERD patients. Clinical and type 2 mediator improvement did not uniquely distinguish the five complete/partial tolerance responders from six remaining intolerant participants. Bulk nasal transcripts cannot establish protein flux, pathway mediation or a clinical decision threshold.
  evidence:
  - reference: PMID:41309110
    reference_title: Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: Interestingly, the development of tolerance was not associated with specific cytokine patterns.
    explanation: A small exploratory study does not validate a tolerance predictor.
- discussion_id: aerd_glp1_translation
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Enhanced Transcellular Cysteinyl Leukotriene Synthesis
  prompt: Can GLP-1 receptor agonism improve clinical AERD outcomes independently of metabolic indications?
  rationale: The recovered primary study combines mouse pretreatment and human ex-vivo platelet assays. Platelet-leukocyte aggregates were not significantly reduced, and no human aspirin-challenge or clinical efficacy study was performed. GLP-1 agonism remains a translational lead rather than an established AERD treatment.
  evidence:
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Pretreatment with GLP-1R agonist liraglutide at doses comparable to the serum concentrations achieved in vivo during active clinical treatment (50nM) attenuated TP-induced CD62P expression on CD41+ platelets in both groups
    explanation: Describes the measured platelet-activation response in human blood preparations.
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population
    explanation: The negative aggregate result limits inference from the positive free-platelet activation readout.
- discussion_id: aerd_registry_04261582
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Reduced Respiratory PGE2 Availability
  prompt: What can the Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD) study establish?
  rationale: Suspended observational genetics/epithelial transcriptomics study, planned enrollment 245. No results are posted; proposed EGR/ERBB2 mechanisms are hypotheses rather than confirmed AERD causal genes.
  evidence:
  - reference: clinicaltrials:NCT04261582
    reference_title: Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: the objective of the proposed study is to determine whether EGR gene are also down-regulated in AERD
    explanation: The registry defines an exploratory observational question or sample-analyzability endpoint.
- discussion_id: aerd_registry_01631773
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Reduced Respiratory PGE2 Availability
  prompt: What can the A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only study establish?
  rationale: Completed observational nasal microRNA comparison, actual enrollment 26. No results are posted; the registry does not validate a diagnostic microRNA signature.
  evidence:
  - reference: clinicaltrials:NCT01631773
    reference_title: A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).
    explanation: The registry defines an exploratory observational question or sample-analyzability endpoint.
- discussion_id: aerd_registry_05672030
  kind: KNOWLEDGE_GAP
  attaches_to:
  - pathophysiology#Enhanced IL-5 Signaling
  prompt: What can the Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP study establish?
  rationale: Completed 30-participant observational tissue study with 10 AERD, 10 aspirin-tolerant CRSwNP and 10 controls. Posted outcomes count analyzable specimens for transcriptomic/IL-5R assays, not effect sizes demonstrating a receptor-mediated disease mechanism.
  evidence:
  - reference: clinicaltrials:NCT05672030
    reference_title: Role of Interleukin 5 (IL-5) and IL-5R Signaling in Non-eosinophil Upper Airway Cells in Chronic Rhinosinusitis With Nasal Polyps
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The overarching hypothesis of this proposal is that IL-5 acts on multiple sinus tissue cell types, including plasma cells and epithelial cells, to promote immune dysregulation, and that inhibition of IL-5 affects several relevant effector pathways that lead to clinical benefit.
    explanation: This registered hypothesis motivates the observational study; it is not evidence that the proposed non-eosinophil mechanism or clinical benefit has been established.
mechanistic_hypotheses:
- hypothesis_group_id: leukotriene_il33_amplification
  hypothesis_label: Leukotriene-dependent IL-33 amplification in the PGE2-deficient airway
  status: EMERGING
  description: Human polyp IL-33 abundance and activation signatures are consistent with this route, but causal dependency is established chiefly in dust-mite-primed Ptges-null mice. Global Ltc4s deletion and IL-33/ST2 blockade do not identify a direct epithelial receptor mechanism or prove necessity in all human AERD.
  evidence:
  - reference: PMID:26342029
    reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: The lungs of the ptges−/−/ltc4s−/− mice also contained substantially less IL-33 protein than did the lungs of the ptges−/− controls
    explanation: Genetic dependency in a conditioned mouse model supports the proposed amplification route.
animal_models:
- name: Dust-mite-primed Ptges-null mice with leukotriene and IL-33 perturbations
  species: Mouse
  genotype: Ptges−/−, with additional Ltc4s deletion in genetic-dependency experiments
  background: C57BL/6; 6–8-week-old males
  publication: PMID:26342029
  description: Repeated intranasal Dermatophagoides farinae conditioning produces an eosinophilic, PGE2-deficient airway that responds to inhaled lysine aspirin or selected cysteinyl leukotrienes. Global Ltc4s deletion reduces IL-33 and eosinophilic inflammation. Anti-IL-33 antibody or soluble ST2-Fc given before challenge reduces airway-resistance and mediator responses.
  notes: This induced model does not establish a human PTGES mutation etiology or reproduce the full acquired syndrome. Blocking agents were given 24 hours before challenge, not as treatment of established human disease. Tissue source and mast-cell-specific ST2 necessity were not tested. BAL histamine/mMCP1/PGD2 are activation-associated readouts; figure legends are absent from the generated main-body cache, so unverified figure sample sizes are not supplied.
  evidence:
  - reference: PMID:26342029
    reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction.
    explanation: The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.
  - reference: PMID:26342029
    reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Six- to 8-wk-old male mice were used.
    explanation: Defines the age and sex of the model animals.
  modeled_mechanisms:
  - target: Reduced Respiratory PGE2 Availability
    relationship: PERTURBS
    model_scale: TISSUE
    fidelity: MODERATE
    description: Loss of mPGES-1 impairs inducible PGE2 synthesis.
    limitations: Genetic deletion models one permissive component, not the established etiology of human AERD.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction.
      explanation: The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.
  - target: Increased Airway IL-33 Availability
    relationship: MEASURES
    model_scale: TISSUE
    fidelity: MODERATE
    description: Lung IL-33 abundance decreases with additional Ltc4s deletion.
    limitations: Global deletion can alter upstream inflammatory conditioning; it does not establish a direct epithelial receptor-to-IL33 step.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: The lungs of the ptges−/−/ltc4s−/− mice also contained substantially less IL-33 protein than did the lungs of the ptges−/− controls
      explanation: Whole-body Ltc4s deletion changes lung IL-33 abundance in the Ptges-null context.
  - target: Enhanced IL-33-ST2 Signaling
    relationship: PERTURBS
    model_scale: MOLECULAR
    fidelity: MODERATE
    description: IL-33 antibody or soluble ST2-Fc blocks signaling before challenge.
    limitations: The decoy is not an anti-ST2 antibody; no lineage-specific necessity or clinical efficacy is established.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2
      explanation: Anti-IL-33 and soluble ST2-Fc pretreatment prevent the model mediator response.
  - target: Mast Cell Activation
    relationship: MEASURES
    model_scale: TISSUE
    fidelity: MODERATE
    description: BAL histamine, mMCP1 and PGD2 responses are reduced by IL-33/ST2 blockade.
    limitations: Mediator readouts do not substitute for mast-cell depletion or a mast-cell-specific conditional knockout.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: Both blockers also prevented the increases in BAL fluid mMCP-1, histamine, and PGD2
      explanation: Anti-IL-33 and soluble ST2-Fc pretreatment prevent the model mediator response.
  - target: Airway Smooth Muscle Contraction
    relationship: PARTIALLY_RECAPITULATES
    model_scale: ORGANISM
    fidelity: MODERATE
    description: Challenge produces increased airway resistance that is inhibited by upstream blockade.
    limitations: Airway resistance is an organ-level functional readout, not a direct isolated smooth-muscle assay.
    evidence:
    - reference: PMID:26342029
      reference_title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: Challenges of dust mite-primed ptges(-/-) mice with lysine aspirin induce IL-33-dependent MC activation and bronchoconstriction.
      explanation: The living model combines genetic PGE2 deficiency, allergen priming and drug challenge.
- name: Liraglutide pretreatment in allergen-primed Ptges-null mice
  species: Mouse
  genotype: Ptges−/−
  background: C57BL/6; male mice aged 6–12 weeks for the airway model
  publication: PMID:37870292
  description: Liraglutide was given intraperitoneally 24 hours before lysine-aspirin challenge in dust-mite-conditioned mice. It attenuated the airway-resistance response, lung CD41 staining and BAL CXCL7. Separate wild-type male/female blood experiments measured platelet GLP-1 receptor expression.
  notes: Pretreatment is not reversal of established human disease. Whole-animal drug exposure does not isolate platelet GLP-1 receptor necessity, and histology cannot distinguish free platelets from platelet-leukocyte aggregates. Airway, mediator and recruitment changes do not prove that one measured intermediate mediates the others. Figure legends are absent from the generated body; no unverified group counts are supplied.
  evidence:
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: In AERD-like Df challenged Ptges−/− mice, a single dose of GLP-1R agonist inhibited Lys-ASA-induced increases in airway resistance
    explanation: The living-mouse experiment tested prophylactic liraglutide in an induced challenge model.
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    quote_role: PRIMARY_RESULT
    snippet: Liraglutide was administered intraperitoneally (1.5mg/kg) 24 hours prior to challenge with aerosolized Lysine-aspirin (Lys-ASA).
    explanation: Defines dose, route and preventive timing.
  modeled_mechanisms:
  - target: Airway Smooth Muscle Contraction
    relationship: PERTURBS
    model_scale: ORGANISM
    fidelity: MODERATE
    description: Pretreatment blunts challenge-associated airway resistance.
    limitations: An induced mouse model does not establish a human AERD treatment indication or clinical benefit.
    evidence:
    - reference: PMID:37870292
      reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      quote_role: PRIMARY_RESULT
      snippet: In AERD-like Df challenged Ptges−/− mice, a single dose of GLP-1R agonist inhibited Lys-ASA-induced increases in airway resistance
      explanation: The living-mouse experiment tested prophylactic liraglutide in an induced challenge model.
experimental_models:
- name: AERD blood-progenitor-derived mast-cell culture
  experimental_model_type: PRIMARY_CELL_CULTURE
  publication: PMID:17508965
  cell_source: Peripheral blood progenitors from AERD, aspirin-tolerant asthma and normal donors
  description: Anti-IgE-stimulated cultures showed greater cysteinyl leukotriene release in AERD donor cells. Basal release of the three tested mediators was similar between donor groups. PGE2 suppressed stimulated leukotriene release in the AERD cultures.
  notes: The available source is the complete abstract, not the full article. Differentiated blood-progenitor cells are not freshly isolated airway mast cells; the result does not establish universal basal overproduction or PGE2 resistance.
  evidence:
  - reference: PMID:17508965
    reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Mast cells were cultured from peripheral blood progenitors and were activated by anti-IgE. Histamine, PGD(2) and cys-LTs released were then determined.
    explanation: Specifies cultured progenitor-derived mast cells and the activation assay.
  - reference: PMID:17508965
    reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Basal release of all three mediators was similar in all subjects.
    explanation: Basal mediator release did not distinguish groups under the reported culture conditions.
  modeled_mechanisms:
  - target: Mast Cell Activation
    relationship: PERTURBS
    model_scale: CELLULAR
    fidelity: MODERATE
    description: Anti-IgE activates cultured mast cells for mediator-release measurement.
    limitations: This tests an IgE-dependent stimulus, not direct aspirin reactivity in intact airways.
    evidence:
    - reference: PMID:17508965
      reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: Mast cells were cultured from peripheral blood progenitors and were activated by anti-IgE. Histamine, PGD(2) and cys-LTs released were then determined.
      explanation: Specifies cultured progenitor-derived mast cells and the activation assay.
  - target: Reduced PGE2-Mediated Restraint
    relationship: PERTURBS
    model_scale: CELLULAR
    fidelity: MODERATE
    description: PGE2 inhibits stimulated cysteinyl leukotriene output in AERD cultures.
    limitations: The retained response limits a universal PGE2-insensitivity claim; it does not refute the tissue-level protective deficit.
    evidence:
    - reference: PMID:17508965
      reference_title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: In contrast, PGE(2) suppressed only anti-IgE induced cys-LTs release from mast cells of AERD patients.
      explanation: The tested AERD mast-cell cultures retain a PGE2-sensitive leukotriene response.
- name: AERD granulocyte-platelet ex vivo preparations
  experimental_model_type: CO_CULTURE
  publication: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
  cell_source: Freshly isolated human peripheral blood granulocytes and autologous platelets
  description: Platelet stripping, exogenous LTA4-methyl-ester conversion, A23187 stimulation, fMLP stimulation and platelet add-back interrogated platelet-associated leukotriene production. Removal reduced both LTC4 synthase-associated activity and stimulated output; add-back restored robust generation.
  notes: Platelet-intrinsic LTC4 synthase activity did not significantly differ between AERD and aspirin-tolerant asthma. Substrate-conversion, ionophore and receptor-agonist assays had different sample subsets; the fMLP result came from three AERD preparations. Ex vivo removal/add-back supports a contribution but does not quantify in vivo necessity or establish antiplatelet treatment efficacy.
  evidence:
  - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
    reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%
    explanation: Quantifies the contribution of adherent platelets in the fMLP-stimulated cell assay.
  modeled_mechanisms:
  - target: Enhanced Transcellular Cysteinyl Leukotriene Synthesis
    relationship: MEASURES
    model_scale: CELLULAR
    fidelity: MODERATE
    description: Platelet removal lowers fMLP-stimulated cysteinyl leukotriene release.
    limitations: Cell preparations do not reproduce vascular recruitment, intact airway context or clinical treatment response.
    evidence:
    - reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
      reference_title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: Removal of platelets also reduced fMLP-induced generation of cysLTs by 64 ± 16%
      explanation: Quantifies the contribution of adherent platelets in the fMLP-stimulated cell assay.
- name: Liraglutide perturbation of human platelet activation
  experimental_model_type: CO_CULTURE
  cell_source: Fresh human whole blood from adults with AERD and nonasthmatic controls
  publication: PMID:37870292
  description: Whole blood was pretreated with liraglutide for 30 minutes before 30-minute U46619 stimulation. Free-platelet CD62P and plasma CXCL7 responses decreased, but platelet-leukocyte aggregate formation and aggregate-associated CD62P were not significantly suppressed.
  notes: The body reports 33 AERD and 11 controls recruited, with samples from 30 AERD and all controls analyzable; the abstract instead states 31 AERD. CXCL7 analysis used 20 AERD samples. Treatment subgroups were small and not powered for comparative response. No clinical drug administration, aspirin-tolerance endpoint, leukotriene-flux mediation or durable airway benefit was tested.
  evidence:
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Pretreatment with GLP-1R agonist liraglutide at doses comparable to the serum concentrations achieved in vivo during active clinical treatment (50nM) attenuated TP-induced CD62P expression on CD41+ platelets in both groups
    explanation: Describes the measured platelet-activation response in human blood preparations.
  - reference: PMID:37870292
    reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
    supports: SUPPORT
    evidence_source: IN_VITRO
    quote_role: PRIMARY_RESULT
    snippet: Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population
    explanation: The negative aggregate result limits inference from the positive free-platelet activation readout.
  modeled_mechanisms:
  - target: Increased Platelet-Leukocyte Adherence
    relationship: MEASURES
    model_scale: CELLULAR
    fidelity: MODERATE
    description: TP stimulation and liraglutide pretreatment test platelet-leukocyte aggregate formation.
    limitations: No significant reduction in aggregate formation was demonstrated; the positive CD62P and CXCL7 responses cannot be substituted for an aggregate or leukotriene-flux endpoint.
    evidence:
    - reference: PMID:37870292
      reference_title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
      supports: SUPPORT
      evidence_source: IN_VITRO
      quote_role: PRIMARY_RESULT
      snippet: Liraglutide pretreatment did not significantly reduce TP-induced PLA formation in either patient population
      explanation: The negative aggregate result limits inference from the positive free-platelet activation readout.
clinical_trials:
- name: NCT04442256
  phase: PHASE_IV
  status: UNKNOWN
  description: Single-center open-label dupilumab study in Vienna with repeat aspirin challenge after six months. The published cohort included 31 participants, with 30 paired challenges; 17 increased their tolerated dose, including 7 reaching the highest cumulative dose. A later 11-person nested mucosal/transcriptomic analysis did not identify a cytokine signature explaining tolerance.
  notes: Live registry retrieved 2026-09-21 remains UNKNOWN with last known RECRUITING and an April 2022 status update, despite published completed follow-up. Registry estimated enrollment of 30 differs from published enrollment of 31. The record inconsistently says monthly versus biweekly dosing; the primary report is used for actual treatment. The 2026 substudy is not an independent replication and lacks a placebo group or repeated comparator challenge.
  evidence:
  - reference: clinicaltrials:NCT04442256
    reference_title: Effect of Dupilumab on ASS Intolerance and Its Mechanisms in Patients With Aspirin-exacerbated Respiratory Disease (AERD)
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: To test the efficacy of dupilumab in patients with AERD regarding the intolerance to salicylic acid after 6 months. This will be evaluated by oral drug provocation testing with low dose salicylic acid after 6 months of dupilumab treatment.
    explanation: The structured registry summary describes the planned challenge study; the published outcome cohort is cited separately.
  - reference: PMID:36549708
    reference_title: Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: After 6 months of treatment with dupilumab, 23% of patients (n=7 of 30) developed complete aspirin tolerance and an additional 33% of patients (n=10 of 30) tolerated higher doses.
    explanation: Published paired-challenge results, with tolerance limited to the tested doses.
  - reference: PMID:41309110
    reference_title: Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: The eleven N‐ERD patients included in this study were randomly selected from a cohort of thirty‐one N‐ERD patients under dupilumab therapy as reported previously
    explanation: The newer mechanistic analysis is a nested subset of the earlier cohort.
- name: NCT03825757
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: AirGOs-medical randomized aspirin-maintenance trial in adults with AERD, uncontrolled CRSwNP and prior ethmoidal surgery. The published analysis randomized 26 successfully desensitized patients, 16 to aspirin and 10 to placebo, with 21 completing follow-up. No significant between-group change in the principal symptom/control/polyp outcomes was detected over the 11-month regimen.
  notes: Registry retrieved 2026-09-21 lists actual enrollment 40; the paper reports 41 recruited and only 26 randomized after screening/challenge/desensitization. Registry design text says double-blind but structured masking says SINGLE. Registry primary outcome is endoscopic polyp score, while publication prose describes SNOT-22 as primary; the entry records the discrepancy instead of silently reconciling it. Stable asthma selection, small sample, baseline sex imbalance and limited immediate pretrial polypectomy constrain generalization.
  evidence:
  - reference: clinicaltrials:NCT03825757
    reference_title: 'Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical)'
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The study is performed as a randomized double-blinded prospective controlled trial.
    explanation: The live registry describes the planned controlled design and marks the trial completed in status metadata.
  - reference: PMID:40726272
    reference_title: Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non-steroidal Anti-inflammatory Drug Exacerbated Respiratory Disease -A Randomized Clinical Trial.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: PRIMARY_RESULT
    snippet: In the linear mixed effects model, p-values for the combined effect of group and time showed no difference between placebo and ATAD for SNOT-22, ACT, and NPS, with p-values 0.17, 0.45, and 0.18, respectively.
    explanation: Within-group changes cannot replace the nonsignificant between-group comparison.
- name: NCT03595488
  phase: PHASE_II
  status: COMPLETED
  description: Small dupilumab add-on study for sinonasal disease; actual enrollment 11.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Registry prose describes single-blind placebo treatment, whereas structured design records a single group with no masking. No results are posted; registry intentions are not efficacy evidence.
  evidence:
  - reference: clinicaltrials:NCT03595488
    reference_title: Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.
    explanation: The canonical registry summary describes enrollment and the planned add-on evaluation rather than proving efficacy.
- name: NCT05031455
  phase: PHASE_II
  status: COMPLETED
  description: Completed single-group phase 2 study of dupilumab effects on aspirin challenge/desensitization; actual enrollment 16.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. No results are posted. Eligibility requires at least 12 weeks of current dupilumab whereas the outcome timing mentions six weeks after starting dupilumab/placebo; the inconsistency is retained, not resolved by inference.
  evidence:
  - reference: clinicaltrials:NCT05031455
    reference_title: Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, With a Focus on Innate Type 2 Inflammatory Responses
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The primary objective is to determine the effect of dupilumab on reactions during aspirin challenge/desensitization.
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT02216357
  phase: PHASE_II
  status: COMPLETED
  description: Small randomized phase 2 ifetroban safety/challenge study; actual enrollment 19, with 12 active and 4 placebo participants in posted outcome analyses.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. The primary endpoint concerns a 20% FEV1 decrease before aspirin challenge, with zero events in both analyzed groups. Small safety/challenge results do not establish long-term AERD benefit or exclude uncommon harm.
  evidence:
  - reference: clinicaltrials:NCT02216357
    reference_title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The primary objective of the study is to determine the safety of oral ifetroban compared to placebo
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT01540032
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: Randomized crossover study of a low-salicylate diet, planned enrollment 80, with six-week diet periods and SNOT-22 assessment.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Status is UNKNOWN and results are not posted. Protocol hypotheses do not establish dietary salicylates as equivalent to pharmacological COX-1 inhibition or support routine restrictive diets.
  evidence:
  - reference: clinicaltrials:NCT01540032
    reference_title: Low Salicylate Diet in Aspirin Exacerbated Respiratory Disease
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: The purpose of this study is to determine whether a low salicylate diet will improve the quality of life of patients with Aspirin Exacerbated Respiratory Disease (AERD).
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT01778465
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: Completed open-label crossover dietary-salicylate pilot with seven participants and urinary salicylates/cysteinyl leukotrienes plus SNOT-22 outcomes.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Posted results contain seven observations per dietary condition, not fourteen independent people. Short-term descriptive measurements without a robust comparative efficacy estimate do not establish durable benefit or a leukotriene-mediated effect.
  evidence:
  - reference: clinicaltrials:NCT01778465
    reference_title: Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: Aspirin-Exacerbated Respiratory Disease, or AERD, consists of aspirin sensitivity, asthma and nasal polyps.
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT04375293
  phase: NOT_APPLICABLE
  status: COMPLETED
  description: Completed nasal-microbiome/basic-science comparison of N-ERD, other chronic-rhinosinusitis groups and controls; actual enrollment 80.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Registry labels the sampling study interventional, nonrandomized and unmasked. No results are posted; microbiome differences or proposed disease-driving effects are not established by the registry.
  evidence:
  - reference: clinicaltrials:NCT04375293
    reference_title: Characterisation of the Nasal Microbiome in Patients Suffering From Non-steroidal Anti-inflammatory Drugs-exacerbated Respiratory Disease (N-ERD) - a Pilot Study
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: the investigators plan to analyse the nasal microbiome in these patients and to compare it to nasal samples from CRSwNP and CRSsNP patients as well as healthy controls
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT03627481
  phase: NOT_APPLICABLE
  status: UNKNOWN
  description: Single-group study of sleep quality, symptoms and quality of life before and after sinonasal surgery in AERD, with planned enrollment 32.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Status is UNKNOWN and results are not posted. A protocol for postoperative assessment does not itself establish a treatment effect on sleep.
  evidence:
  - reference: clinicaltrials:NCT03627481
    reference_title: Sleep Quality After Nasosinusal Surgery in AERD Patients
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: Aspirin exacerbated respiratory disease presents as a triad composed by asthma, eosinophilic rinosinusitis and intolerance to aspirin and NSAIDS.
    explanation: The registry documents the study question or endpoint; design, enrollment and status are read from its structured fields, not interpreted as proof of benefit.
- name: NCT05797597
  phase: PHASE_III
  status: UNKNOWN
  description: Registered randomized aspirin/placebo crossover study of airway viral-entry/interferon-related gene expression, with planned enrollment 76.
  notes: ClinicalTrials.gov record retrieved 2026-09-21. Status is UNKNOWN and results are not posted. Its gene-expression endpoint and motivating anecdote do not establish aspirin prevention of SARS-CoV-2 infection or COVID-19.
  evidence:
  - reference: clinicaltrials:NCT05797597
    reference_title: Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease
    supports: SUPPORT
    evidence_source: OTHER
    quote_role: PRIMARY_RESULT
    snippet: the assessment of gene expression for interferon α1 (IFNA1), interferon β1 (IFNB1), interferon γ (IFNG), interferon λ1 and λ2 (IFNL1 and IFNL2) as well as for ACE2 and TMPRSS2 in sputum and nasal cells may shed new light on the course of this infection in patient with AERD during long term aspirin therapy.
    explanation: The registered rationale describes an exploratory gene-expression assessment; no antiviral efficacy is inferred.
references:
- reference: PMID:16461132
  title: Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.
  findings:
  - statement: Nasal inflammatory-cell EP2-positive fractions were reduced, while global mucosal staining was increased; abstract-only evidence does not directly assay receptor function.
- reference: PMID:17508965
  title: PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.
  findings:
  - statement: Blood-progenitor-derived mast-cell cultures had similar basal mediator release; anti-IgE-stimulated leukotrienes were elevated and remained suppressible by PGE2. Abstract only.
- reference: PMID:25282015
  title: 'Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.'
  findings:
  - statement: Meta-analysis gives pooled asthma and severe-asthma prevalence with heterogeneous methods; no arbitrary midpoint is used for general-population prevalence.
- reference: PMID:26083948
  title: 'Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.'
  findings:
  - statement: Small maintenance-aspirin randomized trial reported symptom and medication benefits but no change in the three measured serum cytokines. Abstract only.
- reference: PMID:26342029
  title: Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.
  findings:
  - statement: Human IL-33 polyp observations accompany induced mouse genetic/blockade experiments. Entire generated Methods/Results/Discussion reviewed; figure legends are not present in this cache.
- reference: PMID:30884882
  title: 'Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management.'
  findings:
  - statement: Full 2019 overview supplies historical context. Its universal surgery-plus-aspirin framing and statement that montelukast decreases synthesis are superseded by more precise current sources.
- reference: PMID:36549708
  title: Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.
  findings:
  - statement: Full open-label 31-person dupilumab study, 30 paired challenges; clinical averages and tolerance subsets are distinct. Clinical table captions are present but some table cells are absent from this generated representation.
- reference: PMID:33307116
  title: 'The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.'
  findings:
  - statement: Full AAAAI work-group report and tables reviewed for selection, desensitization, maintenance, interruption, contraindications and rescue treatment.
- reference: PMID:40837856
  title: 'Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.'
  findings:
  - statement: Full N-ERD, differential-diagnosis and alternative-analgesic portions of the 2025 WAO statement reviewed. Partial and mixed presentations, diagnostic limitations and supervised challenge are represented.
- reference: PMID:36184313
  title: Updates on immune mechanisms in aspirin-exacerbated respiratory disease.
  findings:
  - statement: Full mechanistic review reviewed, including negative eosinophil-depletion, CRTH2 and platelet-inhibition results and limitations of cytokine receptor expression.
- reference: PMID:8564100
  title: Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.
  findings:
  - statement: Seven-person randomized crossover inhaled-PGE2 challenge supports acute mechanistic protection; it does not establish long-term routine treatment. Abstract only.
- reference: PMID:32142372
  title: Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.
  findings:
  - statement: Full 16-person atopic Japanese omalizumab crossover study reviewed; urinary LTE4 log-AUC was primary, tolerance was incomplete and no untreated long-term steroid-sparing endpoint was established.
- reference: PMID:40726272
  title: Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non-steroidal Anti-inflammatory Drug Exacerbated Respiratory Disease -A Randomized Clinical Trial.
  findings:
  - statement: Full 2025 aspirin-maintenance trial reviewed, including selection/attrition, actual dose, adverse events and nonsignificant between-group results.
- reference: PMID:41309110
  title: Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.
  findings:
  - statement: Full 2026 nested 11-person mucosal/transcriptomic study reviewed, including controls, assay kinetics, missing samples, multiplicity adjustment and mediation limits. Supplements are linked but not independently mined.
- reference: url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
  title: https://www.jci.org/articles/view/620/version/1/pdf/render.pdf
  findings:
  - statement: Genuine full primary 1998 JCI PDF (PMID:9466979) reviewed. Staining counted positive cells, not intensity per cell; baseline BAL correlations do not extend to the challenge increment.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml
  title: Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC
  findings:
  - statement: Genuine full primary platelet paper (PMID:22262771) recovered through the canonical PMC URL. Tissue/blood observations, removal/add-back assays, sample subsets and clinical-extrapolation limits reviewed.
- reference: url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/
  title: 'Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC'
  findings:
  - statement: Full 2026 EAACI report (PMID:41641665), clinical algorithms, tables and relevant comparative-treatment discussion reviewed. Shared selection, access and contraindications replace a universal regimen.
- reference: clinicaltrials:NCT04442256
  title: Effect of Dupilumab on ASS Intolerance and Its Mechanisms in Patients With Aspirin-exacerbated Respiratory Disease (AERD)
  findings:
  - statement: Live complete ClinicalTrials.gov API record inspected; stale UNKNOWN status and internal dosing/enrollment inconsistencies retained separately from published outcomes.
- reference: clinicaltrials:NCT03825757
  title: 'Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical)'
  findings:
  - statement: Live complete ClinicalTrials.gov API record inspected; actual enrollment, masking and primary-outcome discrepancies with publication are explicitly recorded.
- reference: PMID:38802635
  title: Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.
  findings:
  - statement: Complete NAVIGATOR subgroup report reviewed, including Methods, Results, figures/captions and limitations. Aspirin/NSAID sensitivity and the smaller triad subgroup are distinct; exploratory analyses do not demonstrate aspirin tolerance.
- reference: PMID:37870292
  title: Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.
  findings:
  - statement: Complete liraglutide main body, Methods, Results, Discussion and participant table reviewed. Mouse pretreatment and ex-vivo human blood effects are distinct from clinical treatment; body/abstract recruitment counts conflict. Figure legends are absent.
- reference: clinicaltrials:NCT03595488
  title: Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT05031455
  title: Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, With a Focus on Innate Type 2 Inflammatory Responses
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT02216357
  title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT01540032
  title: Low Salicylate Diet in Aspirin Exacerbated Respiratory Disease
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT01778465
  title: Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT04375293
  title: Characterisation of the Nasal Microbiome in Patients Suffering From Non-steroidal Anti-inflammatory Drugs-exacerbated Respiratory Disease (N-ERD) - a Pilot Study
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT03627481
  title: Sleep Quality After Nasosinusal Surgery in AERD Patients
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT05797597
  title: Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT04261582
  title: Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT01631773
  title: A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
- reference: clinicaltrials:NCT05672030
  title: Role of Interleukin 5 (IL-5) and IL-5R Signaling in Non-eosinophil Upper Airway Cells in Chronic Rhinosinusitis With Nasal Polyps
  findings:
  - statement: Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.
review_notes: Comprehensive review of all eight original cited sources, matching deep-research report and its actual citation list, recovered primary full texts and 2025–2026 guidance. Sources were assessed by actual body content rather than cache content_type. No dedicated GeneReviews chapter is applicable to this acquired complex inflammatory disorder. Abstract-only limitations are identified in the bibliography. Clinical observations, culture experiments, induced mice and guideline recommendations are kept distinct; unmeasured human mediator chains, unsupported frequency bands and arbitrary prevalence estimates were removed. Baseline, reaction-associated and treatment-response measurements are not interchangeable.
updated_date: '2026-09-21T12:31:46Z'

📚

References & Deep Research

References

PMID:16461132

Aspirin-sensitive rhinosinusitis is associated with reduced E-prostanoid 2 receptor expression on nasal mucosal inflammatory cells.

1 finding

Nasal inflammatory-cell EP2-positive fractions were reduced, while global mucosal staining was increased; abstract-only evidence does not directly assay receptor function.

PMID:17508965

PGE suppresses excessive anti-IgE induced cysteinyl leucotrienes production in mast cells of patients with aspirin exacerbated respiratory disease.

1 finding

Blood-progenitor-derived mast-cell cultures had similar basal mediator release; anti-IgE-stimulated leukotrienes were elevated and remained suppressible by PGE2. Abstract only.

PMID:25282015

Prevalence of aspirin-exacerbated respiratory disease among asthmatic patients: A meta-analysis of the literature.

1 finding

Meta-analysis gives pooled asthma and severe-asthma prevalence with heterogeneous methods; no arbitrary midpoint is used for general-population prevalence.

PMID:26083948

Aspirin desensitization for patients with aspirin-exacerbated respiratory disease: A randomized double-blind placebo-controlled trial.

1 finding

Small maintenance-aspirin randomized trial reported symptom and medication benefits but no change in the three measured serum cytokines. Abstract only.

PMID:26342029

Aspirin-Exacerbated Respiratory Disease Involves a Cysteinyl Leukotriene-Driven IL-33-Mediated Mast Cell Activation Pathway.

1 finding

Human IL-33 polyp observations accompany induced mouse genetic/blockade experiments. Entire generated Methods/Results/Discussion reviewed; figure legends are not present in this cache.

PMID:30884882

Aspirin Exacerbated Respiratory Disease: Epidemiology, Pathophysiology, and Management.

1 finding

Full 2019 overview supplies historical context. Its universal surgery-plus-aspirin framing and statement that montelukast decreases synthesis are superseded by more precise current sources.

PMID:36549708

Dupilumab increases aspirin tolerance in NSAID-exacerbated respiratory disease.

1 finding

Full open-label 31-person dupilumab study, 30 paired challenges; clinical averages and tolerance subsets are distinct. Clinical table captions are present but some table cells are absent from this generated representation.

PMID:33307116

The role of aspirin desensitization followed by oral aspirin therapy in managing patients with aspirin-exacerbated respiratory disease: A Work Group Report from the Rhinitis, Rhinosinusitis and Ocular Allergy Committee of the American Academy of Allergy, Asthma & Immunology.

1 finding

Full AAAAI work-group report and tables reviewed for selection, desensitization, maintenance, interruption, contraindications and rescue treatment.

PMID:40837856

Updating the classification and routine diagnosis of NSAID hypersensitivity reactions: A WAO Statement.

1 finding

Full N-ERD, differential-diagnosis and alternative-analgesic portions of the 2025 WAO statement reviewed. Partial and mixed presentations, diagnostic limitations and supervised challenge are represented.

PMID:36184313

Updates on immune mechanisms in aspirin-exacerbated respiratory disease.

1 finding

Full mechanistic review reviewed, including negative eosinophil-depletion, CRTH2 and platelet-inhibition results and limitations of cytokine receptor expression.

PMID:8564100

Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma.

1 finding

Seven-person randomized crossover inhaled-PGE2 challenge supports acute mechanistic protection; it does not establish long-term routine treatment. Abstract only.

PMID:32142372

Omalizumab for Aspirin Hypersensitivity and Leukotriene Overproduction in Aspirin-exacerbated Respiratory Disease. A Randomized Controlled Trial.

1 finding

Full 16-person atopic Japanese omalizumab crossover study reviewed; urinary LTE4 log-AUC was primary, tolerance was incomplete and no untreated long-term steroid-sparing endpoint was established.

PMID:40726272

Efficacy of Aspirin Therapy After Desensitization on Chronic Rhinosinusitis With Nasal Polyps Patients With Asthma and Non-steroidal Anti-inflammatory Drug Exacerbated Respiratory Disease -A Randomized Clinical Trial.

1 finding

Full 2025 aspirin-maintenance trial reviewed, including selection/attrition, actual dose, adverse events and nonsignificant between-group results.

PMID:41309110

Dupilumab Dampens Mucosal Type 2 Response During Acetylsalicylic Acid Challenge in N-ERD Patients.

1 finding

Full 2026 nested 11-person mucosal/transcriptomic study reviewed, including controls, assay kinetics, missing samples, multiplicity adjustment and mediation limits. Supplements are linked but not independently mined.

url:https://www.jci.org/articles/view/620/version/1/pdf/render.pdf

https://www.jci.org/articles/view/620/version/1/pdf/render.pdf

1 finding

Genuine full primary 1998 JCI PDF (PMID:9466979) reviewed. Staining counted positive cells, not intensity per cell; baseline BAL correlations do not extend to the challenge increment.

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC3335383/?report=xml

Cysteinyl leukotriene overproduction in aspirin-exacerbated respiratory disease is driven by platelet-adherent leukocytes - PMC

1 finding

Genuine full primary platelet paper (PMID:22262771) recovered through the canonical PMC URL. Tissue/blood observations, removal/add-back assays, sample subsets and clinical-extrapolation limits reviewed.

url:https://pmc.ncbi.nlm.nih.gov/articles/PMC13466261/

Updated Treatment of Non‐Steroidal Anti‐Inflammatory Drug‐Exacerbated Respiratory Disease: How to Decide on Aspirin Therapy After Desensitization or Biologics? When? How? An EAACI Task Force Report - PMC

1 finding

Full 2026 EAACI report (PMID:41641665), clinical algorithms, tables and relevant comparative-treatment discussion reviewed. Shared selection, access and contraindications replace a universal regimen.

clinicaltrials:NCT04442256

Effect of Dupilumab on ASS Intolerance and Its Mechanisms in Patients With Aspirin-exacerbated Respiratory Disease (AERD)

1 finding

Live complete ClinicalTrials.gov API record inspected; stale UNKNOWN status and internal dosing/enrollment inconsistencies retained separately from published outcomes.

clinicaltrials:NCT03825757

Aggravated Airway Inflammation: Research on Genomics and Optimal Medical Care (AirGOs-medical)

1 finding

Live complete ClinicalTrials.gov API record inspected; actual enrollment, masking and primary-outcome discrepancies with publication are explicitly recorded.

PMID:38802635

Efficacy of Tezepelumab in Patients with Severe, Uncontrolled Asthma Across Multiple Clinically Relevant Subgroups in the NAVIGATOR Study.

1 finding

Complete NAVIGATOR subgroup report reviewed, including Methods, Results, figures/captions and limitations. Aspirin/NSAID sensitivity and the smaller triad subgroup are distinct; exploratory analyses do not demonstrate aspirin tolerance.

PMID:37870292

Glucagon-like Peptide-1 Receptor Pathway Attenuates Platelet Activation in Aspirin-Exacerbated Respiratory Disease.

1 finding

Complete liraglutide main body, Methods, Results, Discussion and participant table reviewed. Mouse pretreatment and ex-vivo human blood effects are distinct from clinical treatment; body/abstract recruitment counts conflict. Figure legends are absent.

clinicaltrials:NCT03595488

Dupilumab as add-on Therapy for Aspirin-exacerbated Respiratory Disease (AERD)

1 finding

Live registry design, enrollment, eligibility, outcomes and status reviewed; posted results were inspected when present. Registry hypotheses and specimen counts are not promoted to demonstrated causal mechanisms or treatment efficacy.

clinicaltrials:NCT05031455

Mechanisms of Dupilumab in AERD - Effects on Aspirin Hypersensitivity Response, With a Focus on Innate Type 2 Inflammatory Responses

1 finding

clinicaltrials:NCT02216357

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease

1 finding

clinicaltrials:NCT01540032

Low Salicylate Diet in Aspirin Exacerbated Respiratory Disease

1 finding

clinicaltrials:NCT01778465

Effect of Low Dietary Salicylate on Biochemical Markers of Aspirin Exacerbated Respiratory Disease

1 finding

clinicaltrials:NCT04375293

Characterisation of the Nasal Microbiome in Patients Suffering From Non-steroidal Anti-inflammatory Drugs-exacerbated Respiratory Disease (N-ERD) - a Pilot Study

1 finding

clinicaltrials:NCT03627481

Sleep Quality After Nasosinusal Surgery in AERD Patients

1 finding

clinicaltrials:NCT05797597

Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease

1 finding

clinicaltrials:NCT04261582

Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)

1 finding

clinicaltrials:NCT01631773

A Comparison of microRNA Samples in Patients With Nasal Polyps and Aspirin Exacerbated Respiratory Disease and Those With Nasal Polyps Only

1 finding

clinicaltrials:NCT05672030

Role of Interleukin 5 (IL-5) and IL-5R Signaling in Non-eosinophil Upper Airway Cells in Chronic Rhinosinusitis With Nasal Polyps

1 finding

Deep Research

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (3)

Record review notes

Comprehensive review of all eight original cited sources, matching deep-research report and its actual citation list, recovered primary full texts and 2025–2026 guidance. Sources were assessed by actual body content rather than cache content_type. No dedicated GeneReviews chapter is applicable to this acquired complex inflammatory disorder. Abstract-only limitations are identified in the bibliography. Clinical observations, culture experiments, induced mice and guideline recommendations are kept distinct; unmeasured human mediator chains, unsupported frequency bands and arbitrary prevalence estimates were removed. Baseline, reaction-associated and treatment-response measurements are not interchangeable.

Review AERD mediator mechanisms, variable clinical spectrum and current treatment evidence · 2026-09-21T12:18:55Z · View source

Comprehensive review of all eight original cited references, the complete matching deep-research report and actual citation list, and current 2025–2026 guideline and primary literature. Genuine JCI and platelet full texts were recovered through sanctioned fetch-reference URLs after misleading metadata and access failures; all cached scientific bodies were read in their applicable scope. Rebuilt twenty atomic events to distinguish mediator supply, receptor abundance and signaling, cellular activation and bronchomotor/vascular effects. Removed the asserted defining LTC4-synthase lesion, universal PGE2 resistance, direct unqualified human IL33 chain, eosinophil-only polyp causation and maintenance-aspirin leukotriene suppression. Added twenty clinical findings without unsupported frequency bands, corrected blood-versus-tissue eosinophilia, retained variable and mixed presentations, and removed a fabricated prevalence midpoint. Expanded sixteen care records using specialist selection and trial-specific limitations, including the negative 2025 aspirin trial and nested 2026 dupilumab analysis. Added two induced mouse and three culture systems with perturbation, timing and translational limits, and ten live interventional trial records plus three observational research records with registry-publication discrepancies explicit. Fully read the NAVIGATOR subgroup report and GLP-1 platelet study: exploratory NSAID-sensitivity subgroup effects, mouse pretreatment, ex-vivo activation without aggregate suppression, and inconsistent recruitment counts remain qualified. Independent peers reviewed all original mechanisms/models and thirteen core care/five diagnosis records and prompted removal of an airway-to-conjunctiva anatomical mismatch. No dedicated GeneReviews chapter applies to this acquired complex disorder. Remaining abstract-only sources and unmined supplements are identified; caches were generated only using just fetch-reference.

Create: Aspirin-Exacerbated Respiratory Disease · 2026-08-27T16:37:38Z · View source

New Disease entry for AERD/N-ERD, curated against MONDO:0008834 = OMIM 208550 = DOID:0111579. Lump/split call: DISEASE, not GROUPING - one conserved pathograph. Seven pathophysiology nodes span the chronic arm and the acute drug-triggered arm, plus an environmental influences_mechanisms link for NSAID exposure. Evidence: 27 snippets, all verified against the local reference cache; primary sources were preferred over the deep-research report's review-level citations. Two KNOWLEDGE_GAP discussions record the unresolved initiating lesion and the unexplained mechanism of maintenance-aspirin benefit. One Edison falcon deep-research report is included; its reference validation reported 11 of 11 resolved and zero confabulation. Validated with just validate, just validate-terms, just count-verified-snippets, just check-entity-refs and just check-duplicate-keys.

Falcon ▸

Aspirin-Exacerbated Respiratory Disease (AERD): Disease-Characteristics Report

Edison Scientific Literature 17 citations 2026-08-27T16:27:40.312723

Aspirin-Exacerbated Respiratory Disease (AERD): Disease-Characteristics Report

Executive summary

Aspirin-exacerbated respiratory disease (AERD), increasingly termed NSAID-exacerbated respiratory disease (N-ERD), is a chronic, usually adult-onset inflammatory disorder of the unified upper and lower airway. It comprises asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and reproducible respiratory reactions to aspirin or other strong cyclooxygenase-1 (COX-1) inhibitors. It is a complex, multifactorial disease—not an IgE allergy to aspirin and not a Mendelian disorder. Current evidence supports dysregulated arachidonic-acid metabolism superimposed on epithelial and type-2 inflammation, with deficient protective prostaglandin-E signaling and excessive cysteinyl leukotriene and prostaglandin-D2 activity. Mast cells, eosinophils, platelets, basophils, ILC2s, plasma cells, macrophages, and airway epithelial cells form the principal cellular network. (badrani2021cellularinteractionsin pages 1-3, li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2022newconceptsfor pages 1-3)

AERD affects approximately 0.3–0.9% of the general US population, about 7% of adults with asthma, approximately 15% with severe asthma, and 8–26% of CRSwNP populations, depending on ascertainment. Diagnosis is clinical when the triad and repeated unequivocal reactions are present; otherwise, supervised aspirin provocation is the reference standard. No blood, urine, genomic, or omics test can currently replace challenge testing. Management is multidisciplinary and combines guideline-based asthma therapy, topical sinonasal corticosteroids and saline irrigation, leukotriene-pathway therapy, endoscopic sinus surgery when indicated, aspirin desensitization followed by maintenance aspirin in selected patients, and phenotype-directed biologics. (li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2, sehanobish2022newconceptsfor pages 9-10)

The following table summarizes the central evidence.

domain	current understanding/key statistic	evidence type	key source/date/DOI
Definition / prevalence	AERD (also called N-ERD; historically Samter triad) is the adult-onset syndrome of asthma, chronic rhinosinusitis with nasal polyps, and respiratory reactions to COX-1 inhibitors. Estimated prevalence is ~0.3–0.9% in the general US population and ~7% among people with asthma; prevalence is higher in severe asthma, and some cases are likely undiagnosed. (badrani2021cellularinteractionsin pages 1-3, li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2021aspirinactionsin pages 1-2)	Review synthesis of human epidemiology	Li et al., 2019, Medical Sciences, Mar 2019, DOI: 10.3390/medsci7030045; Badrani & Doherty, 2021, DOI: 10.1097/aci.0000000000000712
Mechanism	Core model: COX-1 inhibition lowers protective prostaglandin signaling and is associated with exaggerated cysteinyl leukotriene and PGD2 pathways, epithelial alarmins (IL-33, TSLP), and type-2 cellular circuits involving mast cells, eosinophils, platelets, ILC2s, basophils, and IL-5Rα+ plasma cells. A newer candidate lipid signal, 15-Oxo-ETE, is elevated in AERD nasal polyps. (badrani2021cellularinteractionsin pages 1-3, sehanobish2022newconceptsfor pages 1-3, badrani2021cellularinteractionsin pages 8-9, sehanobish2022newconceptsfor pages 9-10)	Review of human tissue, biomarker, omics, and animal-model data	Sehanobish et al., Nov 2022, Curr Opin Allergy Clin Immunol, DOI: 10.1097/aci.0000000000000795; Badrani & Doherty, 2021, DOI: 10.1097/aci.0000000000000712
Diagnosis	Aspirin/NSAID challenge remains the diagnostic standard. Urinary LTE4 is consistently higher in N-ERD/AERD than aspirin-tolerant asthma and tends to rise further after aspirin challenge, but assay/reporting heterogeneity limits stand-alone clinical use. Meta-analysis included 3,376 subjects (1,354 N-ERD, 1,420 ATA, 602 healthy controls); N-ERD vs ATA SMD 0.80 (95% CI 0.72–0.89). (patel2026anarrativereview pages 2-4, sehanobish2022newconceptsfor pages 9-10)	Systematic review/meta-analysis plus review synthesis	Marquette et al., Nov 2022, Curr Allergy Asthma Rep, DOI: 10.1007/s11882-022-01049-8
Aspirin desensitization / maintenance	Established multimodal therapy, often paired with sinus surgery. Review-level evidence indicates benefit for sinonasal symptoms, reduced polyp recurrence, improved quality of life, and lower corticosteroid burden in selected patients; biomarkers such as baseline uLTE4/eosinophils may influence response or failure risk. (sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2, sehanobish2022newconceptsfor pages 9-10)	Evidence-based review and cohort synthesis	Levy et al., Dec 2016, Int Forum Allergy Rhinol, DOI: 10.1002/alr.21826; Sehanobish et al., 2021, DOI: 10.3389/fimmu.2021.695815
Dupilumab	Open-label 6-month study: 23% (7/30) developed complete aspirin tolerance and another 33% (10/30) tolerated higher doses; total polyp score, asthma control, and smell improved, with biomarker reductions including urinary LTE4 in those with increased tolerance. (schneider2023dupilumabincreasesaspirin pages 13-14)	Human interventional trial	Schneider et al., Dec 2023, Eur Respir J, DOI: 10.1183/13993003.01335-2022
Omalizumab	Randomized crossover placebo-controlled trial in 16 patients: omalizumab lowered aspirin-challenge urinary LTE4 exposure and 62.5% (10/16) achieved oral aspirin tolerance up to cumulative 930 mg in the omalizumab phase. (sehanobish2022newconceptsfor pages 9-10)	Human randomized controlled trial	Hayashi et al., Jun 2020, Am J Respir Crit Care Med, DOI: 10.1164/rccm.201906-1215OC
Experimental: GLP-1R axis	Platelets are increasingly viewed as mechanistic contributors. In a murine AERD-like model, liraglutide inhibited lysine-aspirin-induced airway resistance and reduced platelet activation/recruitment; in human AERD platelets in vitro, liraglutide attenuated thromboxane receptor agonist-induced activation. This is mechanistically promising but not yet standard care. (badrani2021cellularinteractionsin pages 1-3)	Mixed animal + human in vitro translational study	Foer et al., Oct 2023, Journal of Immunology, DOI: 10.4049/jimmunol.2300102
Experimental: tezepelumab signal	In a severe asthma subgroup analysis, patients with aspirin/NSAID sensitivity had the largest reduction in annualized exacerbation rate with tezepelumab versus placebo: 83% (95% CI 66–91). This supports possible utility in AERD-like severe asthma phenotypes, but the evidence is subgroup rather than AERD-specific prospective trial evidence. (schneider2023dupilumabincreasesaspirin pages 14-14)	Post hoc/subgroup analysis of phase 3 asthma trial	Carr et al., May 2024, Advances in Therapy, DOI: 10.1007/s12325-024-02889-8
Model / evidence limitations	AERD is not a monogenic disorder and lacks a single definitive biomarker. Much mechanistic evidence comes from mixed sources—reviews, tissue studies, RNA-seq/single-cell data, in vitro assays, and murine aspirin-challenge models—so causal inference and treatment selection remain imperfect. Reviews also emphasize heterogeneity and variable response to biologics and aspirin therapy. (badrani2021cellularinteractionsin pages 1-3, sehanobish2022newconceptsfor pages 1-3, badrani2021cellularinteractionsin pages 8-9)	Review synthesis across human, omics, in vitro, and animal studies	Badrani & Doherty, 2021, DOI: 10.1097/aci.0000000000000712; Sehanobish et al., Nov 2022, DOI: 10.1097/aci.0000000000000795

Table: This table summarizes the main evidence domains for aspirin-exacerbated respiratory disease, emphasizing current understanding, key quantitative findings, and the level of supporting evidence. It is useful as a compact reference for epidemiology, mechanisms, diagnosis, and established versus emerging therapies.

1. Disease information

Definition and terminology

The classic triad is:

Asthma, commonly adult-onset and eosinophilic;
CRSwNP, generally bilateral and recurrent; and
Acute upper and/or lower respiratory reactions to COX-1-inhibiting NSAIDs.

Reactions may include nasal obstruction, profuse rhinorrhea, conjunctival symptoms, cough, wheeze, bronchospasm, and occasionally laryngospasm, flushing, gastrointestinal symptoms, or hypotension. Although systemic reactions can resemble anaphylaxis, the canonical mechanism is pharmacologic COX-1 inhibition rather than drug-specific IgE. (li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2021aspirinactionsin pages 1-2)

Synonyms: aspirin-exacerbated respiratory disease; NSAID-exacerbated respiratory disease; N-ERD/NERD; Samter triad/Samter syndrome; aspirin triad; aspirin-sensitive asthma; aspirin-intolerant asthma; aspirin-induced asthma. “N-ERD” is mechanistically broader because cross-reactivity extends beyond aspirin to other strong COX-1 inhibitors.

Identifiers and ontology mapping

MeSH: Asthma, Aspirin-Induced is the closest established descriptor.
ICD-10-CM: no single code completely represents the syndrome. Knowledge bases should compose asthma (J45.-), CRSwNP/nasal polyp (J32.-/J33.-), and adverse-effect or allergy-status coding for aspirin/NSAIDs as appropriate. Coding an aspirin “allergy” alone loses the syndrome’s non-IgE mechanism.
ICD-11: use compositional coding for asthma, chronic rhinosinusitis/nasal polyposis, and NSAID hypersensitivity; local browser releases should be checked because a universally used single AERD stem code is not established.
OMIM/Orphanet: no well-established dedicated Mendelian disease entry is appropriate.
MONDO: a stable dedicated identifier could not be verified from the retrieved authoritative literature; therefore it should be recorded as unconfirmed, not inferred.
Suggested disease-level ontology parentage: complex respiratory disease → asthma phenotype + CRSwNP + nonallergic drug hypersensitivity.

The evidence in this report is predominantly aggregated disease-level literature. Primary evidence includes challenge-confirmed clinical cohorts, randomized or open-label intervention studies, surgical cohorts, nasal-polyp and blood specimens, ex-vivo assays, transcriptomics/single-cell analyses, and induced mouse models. It is not derived from an individual patient’s EHR.

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factors

AERD has no single initiating pathogen, toxin, or causal mutation. Disease susceptibility arises from an incompletely resolved interaction among airway epithelial dysfunction, chronic type-2 inflammation, altered eicosanoid metabolism, and pharmacologic exposure to COX-1 inhibitors. Aspirin does not ordinarily create the underlying chronic disease; rather, COX-1 inhibition exposes an already dysregulated lipid-mediator network and precipitates acute reactions. (badrani2021cellularinteractionsin pages 1-3, sehanobish2022newconceptsfor pages 1-3)

Genetic factors

Reported candidate associations involve LTC4S, ALOX5, CYSLTR1/CYSLTR2, PTGER2/PTGER4, HLA-DPB1, TBXA2R, MS4A2, ACE, and genes affecting epithelial integrity and immune-cell interactions. However, associations are population-dependent and often fail replication. For example, a two-stage Mexican Mestizo candidate-gene study found replicated association of MS4A2 rs573790 CC, but this is a susceptibility marker—not an ACMG-pathogenic causal variant and not clinically diagnostic. Accordingly:

no causal gene, OMIM gene–disease relationship, pathogenic variant, inheritance pattern, carrier frequency, or penetrance estimate is established;
routine WES, WGS, gene panels, single-gene testing, CMA, karyotyping, FISH, mitochondrial testing, and repeat-expansion testing are not indicated for AERD itself;
no validated protective allele, founder mutation, anticipation, germline mosaicism, or consanguinity effect is known.

Demographic and environmental modifiers

Typical onset is in the third or fourth decade; women are more frequently affected, with a reported female:male ratio near 3:2, and may have earlier or more severe disease. Strong COX-1 inhibitors are the defining acute trigger. Alcohol commonly provokes upper-airway or bronchial symptoms in affected patients, although it is not required for diagnosis. General asthma modifiers—smoking, air pollution, viral infection, occupational irritants, obesity, and poor adherence—may worsen respiratory control, but convincing evidence that they specifically cause AERD is limited. (li2019aspirinexacerbatedrespiratory pages 1-3)

Protective factors and interaction

Avoiding strong COX-1 inhibitors prevents pharmacologic attacks but does not reliably halt asthma or polyp progression. Selective COX-2 inhibitors are usually better tolerated, but the first dose may warrant supervised administration in highly reactive patients. Leukotriene modifiers attenuate reactions and chronic symptoms. Aspirin desensitization creates a temporary pharmacologic tolerant state, maintained only by continuous aspirin exposure; interruption permits resensitization. There is insufficient evidence for a generally protective diet, exercise regimen, microbiome intervention, vitamin, or low-salicylate diet. Dietary salicylates are not equivalent to pharmacologic COX-1 inhibition, and restrictive diets have weak evidence. (sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2)

3. Phenotypes

Core phenotype inventory

Phenotype	Type, onset/course, frequency	Functional impact	Suggested HPO term
Adult-onset asthma	Symptom/sign; usually begins in early-to-middle adulthood; episodic exacerbations on chronic disease; often moderate–severe	Dyspnea, rescue medication, systemic steroids, ED visits and hospitalization	HP:0002099 Asthma; HP:0002098 Respiratory distress; HP:0030828 Wheezing
Chronic rhinosinusitis	Sign/symptom; chronic, progressive or fluctuating	Facial pressure, discharge, impaired sleep and productivity	HP:0011109 Chronic sinusitis
Bilateral recurrent nasal polyposis	Physical manifestation; high penetrance within classic AERD; recurrent after surgery	Nasal obstruction, repeated surgery, impaired sleep	HP:0100582 Nasal polyposis
Hyposmia/anosmia	Symptom; common and frequently severe	Food enjoyment, safety, social and emotional effects	HP:0004408 Abnormality of smell; HP:0000458 Anosmia
NSAID-induced rhinorrhea/congestion	Acute provoked symptom, usually within minutes to hours	Restricts analgesic choices; may require monitored challenge	HP:0031417 Rhinorrhea; HP:0001742 Nasal obstruction
Bronchospasm/FEV1 fall	Acute clinical/functional sign after COX-1 inhibition	Potentially severe reaction	HP:0025428 Bronchospasm; HP:0002783 Abnormal pulmonary function
Blood/tissue eosinophilia	Laboratory/pathology abnormality; common but variable	Correlates imperfectly with severity and biologic eligibility	HP:0001880 Eosinophilia
Middle-ear inflammation/hearing symptoms	Secondary manifestation; cohort frequency about 18%, with earlier reports exceeding one-quarter	Poor control and hearing-related disability	HP:0000389 Chronic otitis media; HP:0000365 Hearing impairment

The disease is heterogeneous: high-type-2, mixed, and lower-type-2 inflammatory clusters have been reported. Atopy is neither necessary nor sufficient. A tertiary-center questionnaire study found good/very-good patient-reported control in 83% for asthma, 58% for nasal polyposis, and only 33% for chronic middle-ear disease, illustrating that upper-airway and otologic morbidity may dominate quality of life. AERD CRSwNP generally has greater inflammation, worse baseline health-related quality of life, and more revision surgery than aspirin-tolerant CRSwNP. (sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2)

4. Genetic and molecular information

AERD should be represented as multifactorial/polygenic susceptibility with no clinically actionable causal genotype. Reported SNPs are germline association signals; they are not somatic driver variants, do not meet ACMG/AMP pathogenic classification for AERD, and should not be entered as causal alleles. No recurrent aneuploidy, copy-number disorder, translocation, inversion, or chromosomal syndrome is established.

Molecular modifiers include receptor abundance or signaling through PTGER2/EP2, PTGER4/EP4, CYSLTR1, CYSLTR2, OXGR1/GPR99, CRTH2/PTGDR2, IL4R, IL5RA, ST2/IL1RL1, and enzymes PTGS1/COX-1, PTGS2/COX-2, ALOX5/5-LO, LTC4S, HPGDS, but altered expression or activity is more securely established than pathogenic coding variants. Human studies report reduced COX expression/PGE2 production in polyps and deficient PGE2 production by bronchial fibroblasts; relevant primary studies include PMID 12743569 and 21397936. (sehanobish2022newconceptsfor pages 9-10)

Epigenetic and microRNA changes have been explored, but no methylation signature or miRNA panel is validated for diagnosis, prognosis, or treatment selection. No AERD-specific pharmacogenomic guideline from CPIC or PharmGKB is established.

5. Environmental, lifestyle, and infectious information

Defining exposure: aspirin and nonselective NSAIDs that strongly inhibit COX-1.
Alcohol: frequent non-NSAID symptom trigger; mechanism may involve mast-cell/lipid-mediator pathways, but estimates vary.
Smoking/pollution/occupation: plausible asthma and CRS aggravators; evidence specific to AERD onset is insufficient.
Diet: low-salicylate diets remain experimental and potentially burdensome; no routine recommendation is supported.
Exercise: beneficial for general health and asthma when controlled, but not demonstrated to prevent AERD.
Infection: no bacterium, virus, fungus, or parasite causes AERD. Respiratory infections can exacerbate asthma or sinus disease but do not explain COX-1 cross-reactivity.

6. Mechanism and pathophysiology

Integrated causal chain

Upstream chronic state: genetically and environmentally conditioned epithelial barrier/immune dysregulation → chronic sinonasal and bronchial inflammation → reduced protective PGE2 production or EP-receptor responsiveness plus increased 5-LO/LTC4S capacity → constitutively elevated cysteinyl leukotrienes and PGD2. (badrani2021cellularinteractionsin pages 1-3, sehanobish2022newconceptsfor pages 1-3, sehanobish2022newconceptsfor pages 9-10)

Acute trigger: aspirin/nonselective NSAID inhibits COX-1 → further loss of PGE2 restraint on eosinophils, mast cells, and 5-LO activity → abrupt amplification of LTC4/LTD4/LTE4 and PGD2 → CysLT-receptor-mediated vascular permeability, mucus secretion, sensory symptoms, and bronchial smooth-muscle contraction. (patel2026anarrativereview pages 2-4, sehanobish2021aspirinactionsin pages 1-2)

Cellular amplification: CysLTs and epithelial injury promote IL-33 release; IL-33 activates mast cells and ILC2s. TSLP stimulates mast-cell PGD2 production; PGD2 acting through CRTH2 recruits or activates eosinophils, basophils, Th2 cells, and ILC2s. ILC2/Th2-derived IL-4, IL-5, and IL-13 sustain eosinophilia, IgE/plasma-cell responses, goblet-cell metaplasia, mucus, edema, bronchial hyperresponsiveness, and polyp growth. Platelet–leukocyte aggregates contribute LTC4S activity and inflammatory recruitment. (badrani2021cellularinteractionsin pages 1-3, badrani2021cellularinteractionsin pages 8-9)

Tissue outcome: persistent epithelial inflammation, edema, extracellular-matrix remodeling and polyp formation in nasal/paranasal mucosa; bronchial hyperresponsiveness and variable airflow obstruction in lower airways; recurrent acute reactions upon COX-1 inhibition.

Biochemical and omics findings

Lipidomics/metabolomics: elevated baseline and challenge-induced urinary LTE4; elevated PGD2 metabolites; low lipoxin A4; and increased 15-oxo-ETE in AERD nasal polyps. (sehanobish2022newconceptsfor pages 1-3)
Transcriptomics: RNA-seq of nasal epithelium has identified altered leukotriene-metabolism and epithelial-response genes. (badrani2021cellularinteractionsin pages 8-9)
Single-cell profiling: IL-5Rα expression is enriched on IgE/IgG4-expressing polyp plasma cells; activated basophils and IL-5Rα-positive plasma cells associate with severe polyposis. A 2024 study further reported a proliferative signature in nasal-polyp antibody-secreting cells, supporting local adaptive-immune activity rather than proving a causal autoantibody. (sehanobish2022newconceptsfor pages 1-3, badrani2021cellularinteractionsin pages 8-9)
Macrophages: persistent pro-inflammatory activation of alveolar monocyte-derived macrophages is a proposed contributor. (sehanobish2022newconceptsfor pages 1-3)
Spatial transcriptomics/CRISPR screens: no clinically mature AERD-specific result was identified.

Suggested annotations include GO:0006690 eicosanoid metabolic process; GO:0002540 leukotriene production involved in inflammatory response; GO:0006954 inflammatory response; GO:0042098 T-cell proliferation; GO:0032615 interleukin-12 production (use only where experimentally supported); and cell terms CL:0000097 mast cell, CL:0000771 eosinophil, CL:0000233 platelet, CL:0001069 group 2 innate lymphoid cell, CL:0000787 memory B cell, CL:0000786 plasma cell, CL:0000235 macrophage, CL:0002633 respiratory airway epithelial cell.

7. Anatomical structures affected

Primary sites are the nasal cavity, paranasal sinus mucosa, nasal polyps, and bronchial airways. Suggested UBERON mappings include UBERON:0001707 nasal cavity, UBERON:0001825 paranasal sinus, UBERON:0001988 nasal mucosa, UBERON:0002185 bronchus, and UBERON:0002048 lung. Disease is ordinarily bilateral/diffuse rather than unilateral; unilateral polyposis should prompt an alternative diagnosis. Secondary involvement may include the middle ear and Eustachian tube.

Affected tissues comprise pseudostratified respiratory epithelium, polyp stroma, submucosal vasculature, mucus glands, airway smooth muscle, and resident/infiltrating immune compartments. Relevant subcellular sites include plasma membrane receptors, cytosolic arachidonic-acid enzymes, nuclear transcriptional machinery, and secretory granules of mast cells/eosinophils; there is no defining mitochondrial, lysosomal, or protein-aggregation lesion. Increased sphenoid bone thickness has been reported, probably reflecting chronic inflammatory remodeling (PMID 32660262). (sehanobish2022newconceptsfor pages 9-10)

8. Temporal development

A typical sequence is persistent rhinitis/sinus symptoms, development of asthma, recurrent polyps, and recognition of NSAID reactions, although the order varies. Onset is generally insidious during the third–fourth decades rather than congenital or pediatric. The chronic component is lifelong and progressive/fluctuating; acute drug reactions are episodic. Polyps commonly recur after surgery without sustained anti-inflammatory treatment. Up to 40% of patients in some CRSwNP cohorts may develop or have aspirin sensitivity recognized during follow-up. (li2019aspirinexacerbatedrespiratory pages 1-3, levy2016contemporarymanagementof pages 1-2)

There is no formal staging system analogous to cancer staging. Practical severity domains are asthma control/exacerbations, systemic-corticosteroid burden, endoscopic polyp score, CT Lund–Mackay score, smell function, SNOT-22, prior surgery, and drug-reaction severity. Remission is usually treatment-induced and domain-specific; “cure” is uncommon. Important intervention windows include disease recognition before inadvertent NSAID exposure, postoperative control before rapid polyp regrowth, and biologic or aspirin-therapy escalation before repeated systemic steroid use.

9. Inheritance and population epidemiology

AERD prevalence is approximately 0.3–0.9% in the general US population, ~7% among adults with asthma, and ~15% among severe asthma, with estimates of 8–26% among CRSwNP and approximately 10% among nasal-polyp populations. Challenge-based studies generally detect more disease than history alone; roughly 12% may remain undiagnosed in some asthma settings. (badrani2021cellularinteractionsin pages 1-3, li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2)

Incidence per 100,000 person-years is not reliably established. Women predominate at roughly 3:2. AERD occurs globally; apparent geographic or ethnic differences may reflect referral, NSAID use, diagnostic challenge availability, and genetic background. No robust geographic founder variant is known.

Inheritance is multifactorial/polygenic with incomplete and poorly quantified familial aggregation. Mendelian penetrance, carrier status, anticipation, mosaicism, and consanguinity are not applicable.

10. Diagnostics

Clinical criteria and reference testing

A confident clinical diagnosis requires asthma/variable airflow obstruction, objective CRSwNP or chronic eosinophilic sinus disease, and repeated convincing respiratory reactions to at least one—and preferably multiple—COX-1 inhibitors. Where exposure history is absent, ambiguous, or discordant, a supervised graded aspirin challenge is the reference standard. Oral challenge is most widely used; nasal lysine-aspirin and bronchial protocols are available in specialized settings. Challenge requires stable asthma, baseline spirometry, trained staff, and rescue capability. (li2019aspirinexacerbatedrespiratory pages 1-3, sehanobish2022newconceptsfor pages 9-10)

Tests should include:

spirometry with bronchodilator response and serial FEV1 during challenge;
nasal endoscopy for bilateral polyps;
sinus CT for extent and surgical planning—not for aspirin sensitivity itself;
CBC with differential, total IgE, and FeNO for inflammatory phenotyping, not confirmation;
urinary LTE4 as an adjunctive research/specialty biomarker.

A 2022 meta-analysis included 3,376 participants—1,354 N-ERD, 1,420 aspirin-tolerant asthma, and 602 healthy controls. Baseline uLTE4 was higher in N-ERD than aspirin-tolerant asthma (SMD 0.80, 95% CI 0.72–0.89); it rose after aspirin challenge in N-ERD (SMD 0.56, 95% CI 0.26–0.85) but not meaningfully in aspirin-tolerant asthma (SMD 0.12, 95% CI −0.08–0.33). Heterogeneous assays and thresholds prevent stand-alone diagnosis. (patel2026anarrativereview pages 2-4)

Pathology and differential diagnosis

Polyps usually show marked eosinophilic/type-2 inflammation, edema, epithelial abnormalities, mast cells and plasma cells, but histology is not specific. Differential diagnoses include aspirin-tolerant eosinophilic CRSwNP with asthma, IgE-mediated single-NSAID allergy, NSAID-induced urticaria/angioedema without airway disease, allergic fungal rhinosinusitis, eosinophilic granulomatosis with polyangiitis, cystic fibrosis, primary ciliary dyskinesia, immunodeficiency, and unilateral neoplasm.

There is no population, newborn, carrier, prenatal, or genetic screening program. Targeted case-finding among adults with severe asthma plus recurrent bilateral polyps is appropriate.

11. Outcome and prognosis

AERD generally does not have a defined disease-specific reduction in life expectancy, 5-year survival, or mortality rate. Its major burden is morbidity: severe asthma, systemic corticosteroid exposure, repeated sinus surgery, persistent anosmia, sleep disruption, middle-ear disease, restricted analgesic options, emergency care, and impaired work/social functioning. Compared with aspirin-tolerant asthma or CRSwNP, patients have more corticosteroid use, hospitalizations, lower FEV1, severe recurrent polyposis, and poorer quality of life. (sehanobish2021aspirinactionsin pages 1-2, levy2016contemporarymanagementof pages 1-2)

Poor prognostic features include severe or uncontrolled asthma, high polyp burden, prior revision surgery, persistent eosinophilia/type-2 inflammation, high urinary LTE4, inadequate topical therapy, and failure or intolerance of aspirin maintenance. No biomarker has sufficient validation to predict individual progression. Prognosis improves substantially with coordinated allergy/pulmonology/otolaryngology care, although responses to aspirin therapy and biologics remain heterogeneous.

12. Treatment and real-world implementation

Baseline algorithm

Confirm asthma, CRSwNP, and the NSAID-reaction phenotype.
Avoid strong COX-1 inhibitors until evaluated; provide written drug-safety guidance and suitable analgesic alternatives.
Optimize inhaled corticosteroid-containing asthma treatment, bronchodilators, intranasal corticosteroid, saline irrigation, and short systemic-steroid courses only when necessary.
Add a leukotriene receptor antagonist such as montelukast or 5-LO inhibitor zileuton, especially around challenge/desensitization.
Perform endoscopic sinus surgery for obstructive/uncontrolled disease and to improve topical drug access.
For persistent disease, choose aspirin desensitization/maintenance, biologic therapy, or both according to asthma/polyp severity, bleeding and gastrointestinal risk, aspirin need, prior response, cost, pregnancy plans, and patient preference.

Suggested NCIt mappings include corticosteroid therapy, leukotriene-receptor antagonist therapy, monoclonal-antibody therapy, aspirin desensitization, endoscopic sinus surgery, and supportive care; exact NCIt concept IDs should be validated against the current NCIt release rather than inferred.

Aspirin desensitization and aspirin therapy after desensitization

Desensitization followed by uninterrupted daily aspirin can reduce sinonasal symptoms, polyp recurrence, systemic steroid use, asthma morbidity, emergency visits, and repeat surgery in selected patients, especially when performed after adequate sinus surgery. Review-level evidence suggests reduction in polyp recurrence in more than 70% of treated patients, although protocols, doses, and outcome definitions vary. (sehanobish2021aspirinactionsin pages 1-2, sehanobish2022newconceptsfor pages 9-10)

A 2023 Chilean prospective cohort of 12 patients treated with sinus surgery, desensitization, and maintenance aspirin found sustained SNOT-22 improvement (p=0.002), reduced polyp score (p=0.001), only three small recurrences, and a 6.6-point Lund–Mackay reduction (p<0.001) at one year. Adverse effects occurred in 75%, most often abdominal pain (66.7%), but no participant discontinued during follow-up. This small uncontrolled study supports feasibility, not comparative superiority.

Contraindications or cautions include active peptic ulceration, bleeding disorder, anticoagulation conflicts, uncontrolled asthma, pregnancy, inability to adhere, and prior severe aspirin toxicity. Loss of doses can reverse tolerance.

Biologics

None is uniquely AERD-approved; use follows severe-asthma and/or CRSwNP indications.

Dupilumab blocks IL-4Rα and therefore IL-4/IL-13 signaling. In a 2023 open-label study, after six months 23% (7/30) achieved complete aspirin tolerance and 33% (10/30) tolerated higher doses. Total polyp score changed by −2.68±1.84, asthma-control score by +2.34±3.67, and smell score by +11.16±9.54 (all p<0.001). Increased tolerance was associated with lower uLTE4 and reduced eotaxin-1, CCL17, IL-5, IL-17A, and IL-6. The abstract conclusion states: “Dupilumab improves aspirin hypersensitivity in over 50% of patients.” (schneider2023dupilumabincreasesaspirin pages 14-14, schneider2023dupilumabincreasesaspirin pages 13-14)
Omalizumab neutralizes free IgE. In a double-blind randomized crossover trial of 16 challenge-confirmed patients, aspirin-challenge uLTE4 exposure fell from a median 80.8 on placebo to 51.1 during omalizumab (p<0.001); 10/16 (62.5%) tolerated cumulative aspirin doses up to 930 mg. This demonstrates that IgE-pathway modulation can suppress reactions even though AERD is not a conventional aspirin-specific IgE allergy.
Mepolizumab and benralizumab target IL-5 or IL-5Rα and can improve eosinophilic asthma and CRSwNP, but AERD response is variable. A 2023 perioperative series reported that mepolizumab did not reliably prevent polyp regrowth; this cautions against assuming that eosinophil depletion controls every AERD pathway.
Tezepelumab, targeting TSLP, reduced annualized exacerbations by 83% (95% CI 66–91) in the aspirin/NSAID-sensitive subgroup of the 2024 NAVIGATOR severe-asthma analysis. This is hypothesis-supporting subgroup evidence, not an AERD-specific prospective trial.

Expert reviews emphasize that there is no definitive evidence that biologics must always precede aspirin desensitization or vice versa. Dupilumab often provides the broadest simultaneous benefit for smell, polyps, and asthma, whereas aspirin therapy is inexpensive and may be particularly valuable after surgery or when aspirin is required for cardiovascular indications. Choice should be individualized. (sehanobish2022newconceptsfor pages 1-3)

Current experimental approaches and trials

Retrieved AERD-specific ClinicalTrials.gov records include dupilumab mechanism/efficacy studies NCT03595488, NCT04442256, and NCT05031455; thromboxane-receptor antagonist ifetroban safety NCT02216357; low-salicylate diet NCT01540032/NCT01778465; nasal microbiome NCT04375293; genetics/genomics NCT04261582; microRNA NCT01631773; IL-5R signaling in upper-airway cells NCT05672030; sleep after sinonasal surgery NCT03627481; and aspirin therapy/SARS-CoV-2 susceptibility NCT05797597. These records include small mechanistic trials and observational studies and do not establish routine care.

A 2023 translational study found that the GLP-1R agonist liraglutide reduced lysine-aspirin-induced airway resistance and platelet activation/recruitment in an AERD-like mouse model and attenuated thromboxane-agonist activation in platelets from 31 patients with AERD and 11 controls. This supports the platelet–GLP-1R axis as a candidate target but not off-label clinical treatment. (badrani2021cellularinteractionsin pages 1-3)

Gene therapy, cell therapy, RNA therapeutics, CRISPR treatment, and transplantation have no established role.

13. Prevention

Primary prevention: no intervention is known to prevent initial disease development. There is no vaccine or validated genetic/lifestyle prevention program.

Secondary prevention: recognize the combination of adult-onset asthma, recurrent bilateral polyps, anosmia, and NSAID or alcohol reactions; confirm uncertain cases before inadvertent exposure. Maintain a precise medication record distinguishing cross-reactive COX-1 intolerance from single-drug IgE allergy.

Tertiary prevention: avoid unplanned strong COX-1 exposure; use a medical-alert plan; optimize inhaled and topical therapy; control polyps early; use leukotriene modifiers around planned challenge; consider surgery, biologics, or aspirin desensitization to reduce recurrence and steroid toxicity. Patients who have been desensitized require continuous prescribed aspirin and instructions for missed doses. Standard immunizations are appropriate for asthma health but do not prevent AERD.

14. Other species and natural disease

No well-characterized naturally occurring veterinary equivalent of the full human AERD triad was identified in dogs, cats, livestock, or wildlife. Consequently, there is no established breed/VBO association, zoonotic transmission, cross-species natural epidemiology, or veterinary carrier state. Aspirin pharmacology and orthologous eicosanoid genes are conserved, but this does not establish naturally occurring AERD. The condition is noninfectious and nontransmissible.

15. Model organisms and experimental systems

The principal in-vivo system is an induced murine AERD-like model, commonly involving allergic airway inflammation/eosinophilia followed by lysine-aspirin challenge. It can reproduce acute airway-resistance increases, mast-cell activation, platelet recruitment, IL-33 dependence, PGD2/CysLT release, and response to pathway inhibition. Murine work supports a sequence in which LTE4 promotes epithelial IL-33, followed by mast-cell activation and acute bronchoconstriction. (badrani2021cellularinteractionsin pages 1-3)

Genetic knockouts or pathway perturbations involving PGE synthase/EP receptors, leukotriene receptors, IL-33/ST2, mast cells, platelets, or ILC2s are mechanistic models rather than complete disease replicas. Ex-vivo systems include patient platelets, eosinophils, mast cells, nasal epithelial cultures, polyp explants, fibroblasts, and peripheral blood; omics systems include bulk RNA-seq, single-cell RNA-seq, metabolomics, and lipid mediator profiling. (badrani2021cellularinteractionsin pages 8-9, sehanobish2022newconceptsfor pages 9-10)

Limitations are substantial: mice do not spontaneously develop the full adult-onset sequence of asthma, bilateral recurrent polyposis, and human NSAID intolerance; induced sensitization and aspirin dosing differ from clinical disease; and no model captures long-term surgery–polyp recurrence or heterogeneous biologic response. No validated zebrafish, Drosophila, C. elegans, yeast, iPSC, or organoid model currently recapitulates the complete syndrome.

Evidence-quality conclusions and key gaps

The strongest clinical evidence supports challenge-based diagnosis, uLTE4 as an adjunct rather than replacement biomarker, coordinated upper/lower-airway treatment, postoperative aspirin desensitization in selected patients, and use of asthma/CRSwNP-approved biologics. The most important 2023–2024 developments are dupilumab-associated improvement in aspirin tolerance, the tezepelumab signal in NSAID-sensitive severe asthma, GLP-1R/platelet translational findings, and single-cell evidence of proliferative antibody-secreting cells in AERD polyps. These advances refine endotyping but do not yet provide a curative treatment or definitive molecular diagnostic. (sehanobish2022newconceptsfor pages 1-3, schneider2023dupilumabincreasesaspirin pages 14-14, schneider2023dupilumabincreasesaspirin pages 13-14)

Major unresolved questions include why the syndrome begins in adulthood, which epithelial or immune abnormalities are initiating rather than secondary, how to select aspirin therapy versus a specific biologic, whether combination therapy modifies natural history, and which biomarkers predict durable remission. There remain no validated causal variants, protective variants, AERD-specific mortality estimates, population incidence rates, or natural animal disease models.

References

(badrani2021cellularinteractionsin pages 1-3): Jana H. Badrani and Taylor A. Doherty. Cellular interactions in aspirin-exacerbated respiratory disease. Dec 2021. URL: https://doi.org/10.1097/aci.0000000000000712, doi:10.1097/aci.0000000000000712. This article has 17 citations and is from a peer-reviewed journal.
(li2019aspirinexacerbatedrespiratory pages 1-3): Kevin L. Li, Andrew Y. Lee, and Waleed M. Abuzeid. Aspirin exacerbated respiratory disease: epidemiology, pathophysiology, and management. Mar 2019. URL: https://doi.org/10.3390/medsci7030045, doi:10.3390/medsci7030045. This article has 80 citations.
(sehanobish2022newconceptsfor pages 1-3): Esha Sehanobish, Mohammad Asad, and Elina Jerschow. New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease. Current Opinion in Allergy and Clinical Immunology, 22:42-48, Nov 2022. URL: https://doi.org/10.1097/aci.0000000000000795, doi:10.1097/aci.0000000000000795. This article has 10 citations and is from a peer-reviewed journal.
(sehanobish2021aspirinactionsin pages 1-2): Esha Sehanobish, Mohammad Asad, Mali Barbi, Steven A. Porcelli, and Elina Jerschow. Aspirin actions in treatment of nsaid-exacerbated respiratory disease. Frontiers in Immunology, Jun 2021. URL: https://doi.org/10.3389/fimmu.2021.695815, doi:10.3389/fimmu.2021.695815. This article has 16 citations and is from a peer-reviewed journal.
(levy2016contemporarymanagementof pages 1-2): Joshua M. Levy, Luke Rudmik, Anju T. Peters, Sarah K. Wise, Brian W. Rotenberg, and Timothy L. Smith. Contemporary management of chronic rhinosinusitis with nasal polyposis in aspirin‐exacerbated respiratory disease: an evidence‐based review with recommendations. International Forum of Allergy & Rhinology, 6:1273-1283, Dec 2016. URL: https://doi.org/10.1002/alr.21826, doi:10.1002/alr.21826. This article has 75 citations and is from a peer-reviewed journal.
(sehanobish2022newconceptsfor pages 9-10): Esha Sehanobish, Mohammad Asad, and Elina Jerschow. New concepts for the pathogenesis and management of aspirin-exacerbated respiratory disease. Current Opinion in Allergy and Clinical Immunology, 22:42-48, Nov 2022. URL: https://doi.org/10.1097/aci.0000000000000795, doi:10.1097/aci.0000000000000795. This article has 10 citations and is from a peer-reviewed journal.
(badrani2021cellularinteractionsin pages 8-9): Jana H. Badrani and Taylor A. Doherty. Cellular interactions in aspirin-exacerbated respiratory disease. Dec 2021. URL: https://doi.org/10.1097/aci.0000000000000712, doi:10.1097/aci.0000000000000712. This article has 17 citations and is from a peer-reviewed journal.
(patel2026anarrativereview pages 2-4): Preena Ketan Patel, Aagat Sharma Khatiwada, Peter J Andrews, Glenis K Scadding, and Alfonso Luca Pendolino. A narrative review of recent developments in aspirin therapy after desensitization in nsaids-exacerbated respiratory disease. Journal of Inflammation Research, Volume 19:1-23, Aug 2026. URL: https://doi.org/10.2147/jir.s620047, doi:10.2147/jir.s620047. This article has 0 citations and is from a peer-reviewed journal.
(schneider2023dupilumabincreasesaspirin pages 13-14): Sven Schneider, Katharina Poglitsch, Christina Morgenstern, Tamara Quint, Katharina Gangl, Christoph Sinz, Tina Bartosik, Nicholas James Campion, David Tianxiang Liu, Lukas David Landegger, Aldine Tu, Victoria Stanek, Marianne Rocha-Hasler, Christine Bangert, and Julia Eckl-Dorna. Dupilumab increases aspirin tolerance in nsaid-exacerbated respiratory disease. The European Respiratory Journal, 61:2201335, Dec 2023. URL: https://doi.org/10.1183/13993003.01335-2022, doi:10.1183/13993003.01335-2022. This article has 43 citations.
(schneider2023dupilumabincreasesaspirin pages 14-14): Sven Schneider, Katharina Poglitsch, Christina Morgenstern, Tamara Quint, Katharina Gangl, Christoph Sinz, Tina Bartosik, Nicholas James Campion, David Tianxiang Liu, Lukas David Landegger, Aldine Tu, Victoria Stanek, Marianne Rocha-Hasler, Christine Bangert, and Julia Eckl-Dorna. Dupilumab increases aspirin tolerance in nsaid-exacerbated respiratory disease. The European Respiratory Journal, 61:2201335, Dec 2023. URL: https://doi.org/10.1183/13993003.01335-2022, doi:10.1183/13993003.01335-2022. This article has 43 citations.

Artifacts

Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome	Count
References checked	11
Resolved	11
Unresolved (possible confabulation)	0
Unverifiable	0
References weighed for topical relevance	11
On topic	9
Off topic	0

All extracted references resolved successfully.

Ask OpenScientist

OpenScientist Report

Classifications

Inheritance

Mechanistic Hypotheses

Discussions and Knowledge Gaps

Pathophysiology

Pathograph

Phenotypes

Medical Actions

Environmental Factors

Biochemical Markers

Diagnosis

Progression

Prevalence

Clinical Trials

Experimental Models

Animal Models

Source YAML

References & Deep Research

References

Deep Research

Aspirin-Exacerbated Respiratory Disease (AERD): Disease-Characteristics Report

Executive summary

1. Disease information

Definition and terminology

Identifiers and ontology mapping

2. Etiology, risk, protective factors, and gene–environment interaction

Causal factors

Genetic factors

Demographic and environmental modifiers

Protective factors and interaction

3. Phenotypes

Core phenotype inventory

4. Genetic and molecular information

5. Environmental, lifestyle, and infectious information

6. Mechanism and pathophysiology

Integrated causal chain

Biochemical and omics findings

7. Anatomical structures affected

8. Temporal development

9. Inheritance and population epidemiology

10. Diagnostics

Clinical criteria and reference testing

Pathology and differential diagnosis

11. Outcome and prognosis

12. Treatment and real-world implementation

Baseline algorithm

Aspirin desensitization and aspirin therapy after desensitization

Biologics

Current experimental approaches and trials

13. Prevention

14. Other species and natural disease

15. Model organisms and experimental systems

Evidence-quality conclusions and key gaps

Artifacts

Reference Validation